Publication List - Peter Valent

Complete Publication List

1: Vekariya U, Toma M, Nieborowska-Skorska M, Le BV, Caron MC, Kukuyan AM, Sullivan-Reed K, Podszywalow-Bartnicka P, Chitrala KN, Atkins J, Drzewiecka M, Feng W, Chan J, Chatla S, Golovine K, Jelinek J, Sliwinski T, Ghosh J, Matlawska-Wasowska K, Chandramouly G, Nejati R, Wasik M, Sykes SM, Piwocka K, Hadzijusufovic E, Valent P, Pomerantz RT, Morton G, Childers W, Zhao H, Paietta EM, Levine RL, Tallman MS, Fernandez HF, Litzow MR, Gupta GP, Masson JY, Skorski T. DNA polymerase θ protects leukemia cells from metabolically induced DNA damage. Blood. 2023 May 11;141(19):2372-2389. doi: 10.1182/blood.2022018428. PMID: 36580665.

2: Kennedy VE, Perkins C, Reiter A, Jawhar M, Lübke J, Kluin-Nelemans HC, Shomali W, Langford C, Abuel J, Hermine O, Niedoszytko M, Gorska A, Mital A, Bonadonna P, Zanotti R, Tanasi I, Mattsson M, Hagglund H, Triggiani M, Yavuz AS, Panse J, Christen D, Heizmann M, Shoumariyeh K, Müller S, Elena C, Malcovati L, Fiorelli N, Wortmann F, Vucinic V, Brockow K, Fokoloros C, Papageorgiou SG, Breynaert C, Bullens D, Doubek M, Ilerhaus A, Angelova-Fischer I, Solomianyi O, Várkonyi J, Sabato V, Rüfer A, Schug TD, Hermans MAW, Fortina AB, Caroppo F, Bumbea H, Gulen T, Hartmann K, Elberink HO, Schwaab J, Arock M, Valent P, Sperr WR, Gotlib J. Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry. Blood Adv. 2023 May 9;7(9):1713-1724. doi: 10.1182/bloodadvances.2022008292. PMID: 36094848; PMCID: PMC10182174.

3: Willmann M, Peter B, Slavnitsch K, Berger D, Witzeneder N, Stefanzl G, Eisenwort G, Ivanov D, Sadovnik I, Hadzijusufovic E, Greiner G, Bernthaler T, Hoermann G, Dahlhoff M, Rülicke T, Valent P. Engraftment in NSG_SCF mice correlates with the WHO category and prognosis in systemic mastocytosis. Leukemia. 2023 May;37(5):1162-1165. doi: 10.1038/s41375-023-01871-7. Epub 2023 Mar 14. PMID: 36918646; PMCID: PMC10169652.

4: Ivanov D, Milosevic Feenstra JD, Sadovnik I, Herrmann H, Peter B, Willmann M, Greiner G, Slavnitsch K, Hadzijusufovic E, Rülicke T, Dahlhoff M, Hoermann G, Machherndl-Spandl S, Eisenwort G, Fillitz M, Sliwa T, Krauth MT, Bettelheim P, Sperr WR, Koller E, Pfeilstöcker M, Gisslinger H, Keil F, Kralovics R, Valent P. Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR- mutated myeloproliferative neoplasms. Am J Hematol. 2023 May;98(5):770-783. doi: 10.1002/ajh.26889. Epub 2023 Mar 9. PMID: 36814396.

5: Lübke J, Naumann N, Metzgeroth G, Kreil S, Brand T, Horny HP, Sotlar K, Cross NCP, Fabarius A, Valent P, Hofmann WK, Reiter A, Schwaab J. Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis. Ann Hematol. 2023 Apr 4. doi: 10.1007/s00277-023-05180-y. Epub ahead of print. PMID: 37012462.

6: Mancini M, Monaldi C, De Santis S, Papayannidis C, Rondoni M, Sartor C, Bruno S, Pagano L, Criscuolo M, Zanotti R, Bonifacio M, Tosi P, Arock M, Valent P, Cavo M, Soverini S. SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted. Biomark Res. 2023 Mar 10;11(1):29. doi: 10.1186/s40364-023-00468-7. PMID: 36894973; PMCID: PMC9999558.

7: Valent P, Hartmann K, Bonadonna P, Sperr WR, Niedoszytko M, Hermine O, Kluin- Nelemans HC, Sotlar K, Hoermann G, Nedoszytko B, Broesby-Olsen S, Zanotti R, Lange M, Doubek M, Brockow K, Alvarez-Twose I, Varkonyi J, Yavuz S, Nilsson G, Radia D, Grattan C, Schwaab J, Gülen T, Oude Elberink HNG, Hägglund H, Siebenhaar F, Hadzijusufovic E, Sabato V, Mayer J, Reiter A, Orfao A, Horny HP, Triggiani M, Arock M. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives. J Allergy Clin Immunol Pract. 2023 Mar 1:S2213-2198(23)00225-8. doi: 10.1016/j.jaip.2023.02.021. Epub ahead of print. PMID: 36868470.

8: Degenfeld-Schonburg L, Gamperl S, Stefanzl G, Schruef AK, Sadovnik I, Bauer K, Smiljkovic D, Eisenwort G, Peter B, Greiner G, Hadzijusufovic E, Schwaab J, Sperr WR, Hoermann G, Kopanja S, Szépfalusi Z, Hoetzenecker K, Jaksch P, Reiter A, Arock M, Valent P. Antineoplastic efficacy profiles of avapritinib and nintedanib in <i>KIT</i> D816V⁺ systemic mastocytosis: a preclinical study. Am J Cancer Res. 2023 Feb 15;13(2):355-378. PMID: 36895976; PMCID: PMC9989615.

9: Graf I, Greiner G, Marculescu R, Gleixner KV, Herndlhofer S, Stefanzl G, Knoebl P, Jäger U, Hauswirth A, Schwarzinger I, Thalhammer R, Kundi M, Hoermann G, Mitterbauer-Hohendanner G, Valent P, Sperr WR. N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia. Am J Hematol. 2023 Feb;98(2):290-299. doi: 10.1002/ajh.26805. Epub 2023 Jan 1. PMID: 36588398; PMCID: PMC10107495.

10: Lübke J, Schwaab J, Christen D, Elberink HO, Span B, Niedoszytko M, Gorska A, Lange M, Gleixner KV, Hadzijusufovic E, Solomianyi O, Angelova-Fischer I, Zanotti R, Bonifacio M, Bonadonna P, Shoumariyeh K, von Bubnoff N, Müller S, Perkins C, Elena C, Malcovati L, Hagglund H, Mattsson M, Parente R, Varkonyi J, Fortina AB, Caroppo F, Zink A, Brockow K, Breynaert C, Bullens D, Yavuz AS, Doubek M, Sabato V, Schug T, Niederwieser D, Hartmann K, Triggiani M, Gotlib J, Hermine O, Arock M, Kluin-Nelemans HC, Panse J, Sperr WR, Valent P, Reiter A, Jawhar M. Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis. J Allergy Clin Immunol Pract. 2023 Feb;11(2):581-590.e5. doi: 10.1016/j.jaip.2022.10.051. Epub 2022 Nov 17. PMID: 36403897.

11: Valent P, Akin C, Sperr WR, Horny HP, Arock M, Metcalfe DD, Galli SJ. New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy. Annu Rev Pathol. 2023 Jan 24;18:361-386. doi: 10.1146/annurev- pathmechdis-031521-042618. Epub 2022 Oct 21. PMID: 36270293.

12: Konstantinou GN, Riedl MA, Valent P, Podder I, Maurer M. Urticaria and Angioedema: Understanding Complex Pathomechanisms to Facilitate Patient Communication, Disease Management, and Future Treatment. J Allergy Clin Immunol Pract. 2023 Jan;11(1):94-106. doi: 10.1016/j.jaip.2022.11.006. PMID: 36610760.

13: Porwit A, Béné MC, Duetz C, Matarraz S, Oelschlaegel U, Westers TM, Wagner- Ballon O, Kordasti S, Valent P, Preijers F, Alhan C, Bellos F, Bettelheim P, Burbury K, Chapuis N, Cremers E, Della Porta MG, Dunlop A, Eidenschink-Brodersen L, Font P, Fontenay M, Hobo W, Ireland R, Johansson U, Loken MR, Ogata K, Orfao A, Psarra K, Saft L, Subira D, Te Marvelde J, Wells DA, van der Velden VHJ, Kern W, van de Loosdrecht AA. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group. Cytometry B Clin Cytom. 2023 Jan;104(1):27-50. doi: 10.1002/cyto.b.22108. Epub 2022 Dec 20. PMID: 36537621; PMCID: PMC10107708.

14: Valent P, Klion AD, Roufosse F, Simon D, Metzgeroth G, Leiferman KM, Schwaab J, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Hoermann G, Haferlach T, Moriggl R, George TI, Akin C, Bochner BS, Gotlib J, Reiter A, Horny HP, Arock M, Simon HU, Gleich GJ. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes. Allergy. 2023 Jan;78(1):47-59. doi: 10.1111/all.15544. Epub 2022 Oct 19. PMID: 36207764; PMCID: PMC9797433.

15: Graf I, Herndlhofer S, Kundi M, Greiner G, Sperr M, Hadzijusufovic E, Valent P, Sperr WR. Incidence of symptomatic Covid-19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population. Eur J Haematol. 2023 Jan;110(1):67-76. doi: 10.1111/ejh.13875. Epub 2022 Oct 17. PMID: 36193973; PMCID: PMC9874474.

16: Smiljkovic D, Herrmann H, Sadovnik I, Gamperl S, Berger D, Stefanzl G, Eisenwort G, Hoermann G, Kopanja S, Dorofeeva Y, Focke-Tejkl M, Jaksch P, Hoetzenecker K, Szepfalusi Z, Valenta R, Arock M, Valent P. Expression and regulation of Siglec-6 (CD327) on human mast cells and basophils. J Allergy Clin Immunol. 2023 Jan;151(1):202-211. doi: 10.1016/j.jaci.2022.07.018. Epub 2022 Aug 8. PMID: 35953001.

17: Westers TM, Saft L, van der Velden VHJ, Te Marvelde JG, Dunlop A, Ireland R, Valent P, Porwit A, Béné MC, van de Loosdrecht AA. A series of case studies illustrating the role of flow cytometry in the diagnostic work-up of myelodysplastic syndromes. Cytometry B Clin Cytom. 2023 Jan;104(1):87-97. doi: 10.1002/cyto.b.22061. Epub 2022 Feb 18. PMID: 35179296; PMCID: PMC10078764.

18: van de Loosdrecht AA, Kern W, Porwit A, Valent P, Kordasti S, Cremers E, Alhan C, Duetz C, Dunlop A, Hobo W, Preijers F, Wagner-Ballon O, Chapuis N, Fontenay M, Bettelheim P, Eidenschink-Brodersen L, Font P, Johansson U, Loken MR, Te Marvelde JG, Matarraz S, Ogata K, Oelschlaegel U, Orfao A, Psarra K, Subirá D, Wells DA, Béné MC, Della Porta MG, Burbury K, Bellos F, van der Velden VHJ, Westers TM, Saft L, Ireland R. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group. Cytometry B Clin Cytom. 2023 Jan;104(1):77-86. doi: 10.1002/cyto.b.22044. Epub 2021 Dec 13. PMID: 34897979.

19: van der Velden VHJ, Preijers F, Johansson U, Westers TM, Dunlop A, Porwit A, Béné MC, Valent P, Te Marvelde J, Wagner-Ballon O, Oelschlaegel U, Saft L, Kordasti S, Ireland R, Cremers E, Alhan C, Duetz C, Hobo W, Chapuis N, Fontenay M, Bettelheim P, Eidenshink-Brodersen L, Font P, Loken MR, Matarraz S, Ogata K, Orfao A, Psarra K, Subirá D, Wells DA, Della Porta MG, Burbury K, Bellos F, Weiß E, Kern W, van de Loosdrecht A. Flow cytometric analysis of myelodysplasia: Pre- analytical and technical issues-Recommendations from the European LeukemiaNet. Cytometry B Clin Cytom. 2023 Jan;104(1):15-26. doi: 10.1002/cyto.b.22046. Epub 2021 Dec 11. PMID: 34894176; PMCID: PMC10078694.

20: Sadovnik I, Ivanov D, Smiljkovic D, Stefanzl G, Degenfeld-Schonburg L, Herndlhofer S, Eisenwort G, Hauswirth AW, Sliwa T, Keil F, Sperr WR, Valent P. Identification of CD203c as a New Basophil-Specific Flow-Marker in Ph⁺ Chronic Myeloid Leukemia. Cells. 2022 Dec 20;12(1):3. doi: 10.3390/cells12010003. PMID: 36611797; PMCID: PMC9818308.

21: Heinemann T, Kornauth C, Severin Y, Vladimer GI, Pemovska T, Hadzijusufovic E, Agis H, Krauth MT, Sperr WR, Valent P, Jäger U, Simonitsch-Klupp I, Superti- Furga G, Staber PB, Snijder B. Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine. Blood Cancer Discov. 2022 Nov 2;3(6):502-515. doi: 10.1158/2643-3230.BCD-21-0219. PMID: 36125297; PMCID: PMC9894727.

22: Grunt TW, Valent P. Cancer - A devastating disease, but also an eye-opener and window into the deep mysteries of life and its origins. Prog Biophys Mol Biol. 2022 Nov;175:131-139. doi: 10.1016/j.pbiomolbio.2022.09.009. Epub 2022 Oct 2. PMID: 36198374.

23: Zeilinger EL, Oppenauer C, Knefel M, Kantor V, Schneckenreiter C, Lubowitzki S, Krammer K, Popinger C, Kitta A, Kum L, Adamidis F, Unseld M, Masel EK, Füreder T, Zöchbauer-Müller S, Bartsch R, Raderer M, Prager G, Krauth MT, Sperr WR, Porpaczy E, Staber PB, Valent P, Gaiger A. Prevalence of anxiety and depression in people with different types of cancer or haematologic malignancies: a cross-sectional study. Epidemiol Psychiatr Sci. 2022 Oct 17;31:e74. doi: 10.1017/S2045796022000592. PMID: 36245424; PMCID: PMC9583630.

24: Reiter A, Gotlib J, Álvarez-Twose I, Radia D, Lübke J, ScD PB, Wang A, Norregaard C, Dimitrijević S, Sullivan E, Louie-Gao M, Schwaab J, Galinsky I, Perkins C, Sperr W, Sriskandarajah P, Chin A, Sendhil S, ScD MSD, Valent P, DeAngelo D. MPN-435 Overall Survival in Patients With Systemic Mastocytosis With Associated Hematologic Neoplasm Treated With Avapritinib Versus Best Available Therapy. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S337. doi: 10.1016/S2152-2650(22)01459-8. PMID: 36164009.

25: Mughal TI, Pemmaraju N, Bejar R, Gale RP, Bose P, Kiladjian JJ, Prchal J, Royston D, Pollyea D, Valent P, Brümmendorf TH, Skorski T, Patnaik M, Santini V, Fenaux P, Kucine N, Verstovsek S, Mesa R, Barbui T, Saglio G, Van Etten RA. Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. Hematol Oncol. 2022 Oct;40(4):491-504. doi: 10.1002/hon.2987. Epub 2022 Apr 15. PMID: 35368098.

26: Moyo TK, Mendler JH, Itzykson R, Kishtagari A, Solary E, Seegmiller AC, Gerds AT, Ayers GD, Dezern AE, Nazha A, Valent P, van de Loosdrecht AA, Onida F, Pleyer L, Cirici BX, Tibes R, Geissler K, Komrokji RS, Zhang J, Germing U, Steensma DP, Wiseman DH, Pfeilstöecker M, Elena C, Cross NCP, Kiladjian JJ, Luebbert M, Mesa RA, Montalban-Bravo G, Sanz GF, Platzbecker U, Patnaik MM, Padron E, Santini V, Fenaux P, Savona MR; MDS/MPN International Working Group. The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes. BMC Cancer. 2022 Sep 24;22(1):1013. doi: 10.1186/s12885-022-10073-w. PMID: 36153475; PMCID: PMC9509596.

27: Peter B, Eisenwort G, Sadovnik I, Bauer K, Willmann M, Rülicke T, Berger D, Stefanzl G, Greiner G, Hoermann G, Keller A, Wolf D, Čulen M, Winter GE, Hoffmann T, Schiefer AI, Sperr WR, Zuber J, Mayer J, Valent P. BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph⁺ chronic myeloid leukemia. Am J Hematol. 2022 Sep;97(9):1215-1225. doi: 10.1002/ajh.26650. Epub 2022 Jul 18. PMID: 35794848; PMCID: PMC9546315.

28: Zeilinger EL, Nader IW, Wiedermann W, Gutierrez-Colosia MR, Unseld M, Lubowitzki S, Raderer M, Staber PB, Valent P, Gaiger A. Latent structure and measurement invariance of the Hospital Anxiety and Depression Scale in cancer outpatients. Int J Clin Health Psychol. 2022 Sep-Dec;22(3):100315. doi: 10.1016/j.ijchp.2022.100315. Epub 2022 May 26. PMID: 35662789; PMCID: PMC9157192.

29: Gaiger A, Lubowitzki S, Krammer K, Zeilinger EL, Acel A, Cenic O, Schrott A, Unseld M, Rassoulian AP, Skrabs C, Valent P, Gisslinger H, Marosi C, Preusser M, Prager G, Kornek G, Pirker R, Steger GG, Bartsch R, Raderer M, Simonitsch-Klupp I, Thalhammer R, Zielinski C, Jäger U. The cancer survival index-A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies. Cancer Med. 2022 Sep;11(18):3387-3396. doi: 10.1002/cam4.4697. Epub 2022 Mar 22. PMID: 35315594; PMCID: PMC9487871.

30: Reiter A, Gotlib J, Álvarez-Twose I, Radia DH, Lübke J, Bobbili PJ, Wang A, Norregaard C, Dimitrijevic S, Sullivan E, Louie-Gao M, Schwaab J, Galinsky IA, Perkins C, Sperr WR, Sriskandarajah P, Chin A, Sendhil SR, Duh MS, Valent P, DeAngelo DJ. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis. Leukemia. 2022 Aug;36(8):2108-2120. doi: 10.1038/s41375-022-01615-z. Epub 2022 Jul 5. PMID: 35790816; PMCID: PMC9343245.

31: Jennings SV, Finnerty CC, Hobart JS, Martín-Martínez M, Sinclair KA, Slee VM, Agopian J, Akin C, Álvarez-Twose I, Bonadonna P, Bowman AS, Brockow K, Bumbea H, de Haro C, Fok JS, Hartmann K, Hegmann N, Hermine O, Kalisiak M, Katelaris CH, Kurz J, Marcis P, Mayne D, Mendoza D, Moussy A, Mudretzkyj G, Vaia NN, Niedoszytko M, Elberink HO, Orfao A, Radia DH, Rosenmeier S, Ribada E, Schinhofen W, Schwaab J, Siebenhaar F, Triggiani M, Tripodo G, Velazquez R, Wielink Y, Wimazal F, Yigit T, Zubrinich C, Valent P. Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond. J Allergy Clin Immunol Pract. 2022 Aug;10(8):2039-2051. doi: 10.1016/j.jaip.2022.06.018. Epub 2022 Jun 28. PMID: 35777651.

32: Pyatilova P, Akin C, Alvarez-Twose I, Arock M, Bonadonna P, Brockow K, Butterfield JH, Broesby-Olsen S, Carter MC, Castells M, George TI, Gotlib J, Greiner G, Gülen T, Hartmann K, Hermine O, Horny HP, Jawhar M, Lange M, Lyons JJ, Maurer M, Metcalfe DD, Nedoszytko B, Niedoszytko M, Orfao A, Reiter A, Schwaab J, Sotlar K, Sperr WR, Triggiani M, Valent P, Siebenhaar F. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium. J Allergy Clin Immunol Pract. 2022 Aug;10(8):2015-2024. doi: 10.1016/j.jaip.2022.05.037. Epub 2022 Jun 18. PMID: 35724950.

33: Sotlar K, George TI, Kluin P, Reiter A, Schwaab J, Panse J, Brockow K, Hartmann K, Sperr WR, Kristensen T, Nedoszytko B, Carter M, Bonadonna P, Lyons JJ, Kluin-Nelemans HC, Hermine O, Akin C, Broesby-Olsen S, Hoermann G, Triggiani M, Butterfield JH, Jawhar M, Gotlib J, Metcalfe DD, Orfao A, Arock M, Valent P, Horny HP. Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group. J Allergy Clin Immunol Pract. 2022 Aug;10(8):1986-1998.e2. doi: 10.1016/j.jaip.2022.05.036. Epub 2022 Jun 18. PMID: 35724949.

34: Gotlib J, Schwaab J, Shomali W, George TI, Radia DH, Castells M, Carter MC, Hartmann K, Álvarez-Twose I, Brockow K, Bonadonna P, Hermine O, Niedoszytko M, Hoermann G, Sperr WR, Elberink HO, Siebenhaar F, Butterfield JH, Ustun C, Zanotti R, Triggiani M, Schwartz LB, Lyons JJ, Orfao A, Sotlar K, Horny HP, Arock M, Metcalfe DD, Akin C, Lübke J, Valent P, Reiter A. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis. J Allergy Clin Immunol Pract. 2022 Aug;10(8):2025-2038.e1. doi: 10.1016/j.jaip.2022.05.034. Epub 2022 Jun 18. PMID: 35724948.

35: Valent P, Hartmann K, Bonadonna P, Gülen T, Brockow K, Alvarez-Twose I, Hermine O, Niedoszytko M, Carter MC, Hoermann G, Butterfield JH, Lyons JJ, Sperr WR, Greiner G, Sotlar K, Kluin-Nelemans HC, Schwaab J, Lange M, George TI, Siebenhaar F, Broesby-Olsen S, Jawhar M, Nedoszytko B, Castells M, Orfao A, Gotlib J, Reiter A, Horny HP, Triggiani M, Arock M, Metcalfe DD, Akin C. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM Consortium. J Allergy Clin Immunol Pract. 2022 Aug;10(8):1941-1950. doi: 10.1016/j.jaip.2022.05.007. Epub 2022 May 25. PMID: 35623575.

36: Boehm T, Ristl R, Mühlbacher J, Valent P, Wahrmann M, Jilma B. Massive release of T_H2 cytokines induced a cytokine storm during a severe mast cell activation event in a patient with indolent systemic mastocytosis. J Allergy Clin Immunol. 2022 Aug;150(2):406-414.e16. doi: 10.1016/j.jaci.2022.04.023. Epub 2022 Apr 30. PMID: 35504498.

37: Valent P, Hartmann K, Schwaab J, Alvarez-Twose I, Brockow K, Bonadonna P, Hermine O, Niedoszytko M, Carter MC, Hoermann G, Sperr WR, Butterfield JH, Ustun C, Zanotti R, Radia DH, Castells M, Triggiani M, Schwartz LB, Orfao A, George TI, Sotlar K, Gotlib J, Reiter A, Horny HP, Arock M, Akin C, Metcalfe DD. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice. J Allergy Clin Immunol Pract. 2022 Aug;10(8):1999-2012.e6. doi: 10.1016/j.jaip.2022.03.007. Epub 2022 Mar 25. PMID: 35342031.

38: Hoermann G, Sotlar K, Jawhar M, Kristensen T, Bachelot G, Nedoszytko B, Carter MC, Horny HP, Bonadonna P, Sperr WR, Hartmann K, Brockow K, Lyons JJ, Kluin-Nelemans HC, Hermine O, Akin C, Broesby-Olsen S, Triggiani M, Butterfield JH, Schwaab J, Reiter A, Gotlib J, Metcalfe DD, George TI, Orfao A, Valent P, Arock M. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. J Allergy Clin Immunol Pract. 2022 Aug;10(8):1953-1963. doi: 10.1016/j.jaip.2022.03.001. Epub 2022 Mar 11. PMID: 35283331.

39: Geissler K, Jäger E, Barna A, Gurbisz M, Marschon R, Graf T, Nösslinger T, Pfeilstöcker M, Machherndl-Spandl S, Stauder R, Zebisch A, Sill H, Öhler L, Kusec R, Hoermann G, Valent P. Multistep pathogenesis of chronic myelomonocytic leukemia in patients. Eur J Haematol. 2022 Jul;109(1):50-57. doi: 10.1111/ejh.13768. Epub 2022 Mar 23. PMID: 35299281; PMCID: PMC9310570.

40: Zeilinger EL, Lubowitzki S, Unseld M, Schneckenreiter C, Heindl D, Staber PB, Raderer M, Valent P, Zöchbauer-Müller S, Bartsch R, Prager G, Jaeger U, Gaiger A. The impact of COVID-19 on cancer care of outpatients with low socioeconomic status. Int J Cancer. 2022 Jul 1;151(1):77-82. doi: 10.1002/ijc.33960. Epub 2022 Feb 17. PMID: 35128650; PMCID: PMC9087749.

41: Schneeweiss-Gleixner M, Filik Y, Stefanzl G, Berger D, Sadovnik I, Bauer K, Smiljkovic D, Eisenwort G, Witzeneder N, Greiner G, Hoermann G, Schiefer AI, Schwaab J, Jawhar M, Reiter A, Sperr WR, Arock M, Valent P, Gleixner KV. CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in <i>KIT</i> D816V⁺ Neoplastic Mast Cells. Cancers (Basel). 2022 Jun 23;14(13):3070. doi: 10.3390/cancers14133070. PMID: 35804842; PMCID: PMC9264943.

42: Akin C, Arock M, Valent P. Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet? J Allergy Clin Immunol. 2022 Jun;149(6):1912-1918. doi: 10.1016/j.jaci.2022.04.020. Epub 2022 Apr 26. PMID: 35487307.

43: Tsai M, Valent P, Galli SJ. KIT as a master regulator of the mast cell lineage. J Allergy Clin Immunol. 2022 Jun;149(6):1845-1854. doi: 10.1016/j.jaci.2022.04.012. Epub 2022 Apr 22. PMID: 35469840; PMCID: PMC9177781.

44: Arock M, Hoermann G, Sotlar K, Hermine O, Sperr WR, Hartmann K, Brockow K, Akin C, Triggiani M, Broesby-Olsen S, Reiter A, Gotlib J, Horny HP, Orfao A, Metcalfe DD, Valent P. Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022. J Allergy Clin Immunol. 2022 Jun;149(6):1855-1865. doi: 10.1016/j.jaci.2022.04.004. Epub 2022 Apr 14. PMID: 35430191.

45: Valent P, Akin C, Hartmann K, Reiter A, Gotlib J, Sotlar K, Sperr WR, Degenfeld-Schonburg L, Smiljkovic D, Triggiani M, Horny HP, Arock M, Galli SJ, Metcalfe DD. Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders? J Allergy Clin Immunol. 2022 Jun;149(6):1866-1874. doi: 10.1016/j.jaci.2022.04.003. Epub 2022 Apr 12. PMID: 35421448.

46: Lübke J, Schwaab J, Naumann N, Horny HP, Weiß C, Metzgeroth G, Kreil S, Cross NCP, Sotlar K, Fabarius A, Hofmann WK, Valent P, Gotlib J, Jawhar M, Reiter A. Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis. J Clin Oncol. 2022 Jun 1;40(16):1783-1794. doi: 10.1200/JCO.21.01849. Epub 2022 Mar 2. PMID: 35235417.

47: Erdogan F, Radu TB, Orlova A, Qadree AK, de Araujo ED, Israelian J, Valent P, Mustjoki SM, Herling M, Moriggl R, Gunning PT. JAK-STAT core cancer pathway: An integrative cancer interactome analysis. J Cell Mol Med. 2022 Apr;26(7):2049-2062. doi: 10.1111/jcmm.17228. Epub 2022 Mar 1. PMID: 35229974; PMCID: PMC8980946.

48: Milosevic Feenstra JD, Jäger R, Schischlik F, Ivanov D, Eisenwort G, Rumi E, Schuster M, Gisslinger B, Machherndl-Spandl S, Bettelheim P, Krauth MT, Keil F, Bock C, Cazzola M, Gisslinger H, Kralovics R, Valent P. PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms. Am J Hematol. 2022 Apr;97(4):390-400. doi: 10.1002/ajh.26461. Epub 2022 Jan 21. PMID: 35015307; PMCID: PMC9306481.

49: Erdogan F, Qadree AK, Radu TB, Orlova A, de Araujo ED, Israelian J, Valent P, Mustjoki SM, Herling M, Moriggl R, Gunning PT. Structural and mutational analysis of member-specific STAT functions. Biochim Biophys Acta Gen Subj. 2022 Mar;1866(3):130058. doi: 10.1016/j.bbagen.2021.130058. Epub 2021 Nov 11. PMID: 34774983.

50: Elst J, De Puysseleyr LP, Ebo DG, Faber MA, Van Gasse AL, van der Poorten MM, Decuyper II, Bridts CH, Mertens C, Van Houdt M, Hagendorens MM, De Clerck LS, Verlinden A, Vermeulen K, Maes MB, Berneman ZN, Valent P, Sabato V. Overexpression of FcεRI on Bone Marrow Mast Cells, but Not MRGPRX2, in Clonal Mast Cell Disorders With Wasp Venom Anaphylaxis. Front Immunol. 2022 Feb 25;13:835618. doi: 10.3389/fimmu.2022.835618. PMID: 35281031; PMCID: PMC8914951.

51: Kornauth C, Pemovska T, Vladimer GI, Bayer G, Bergmann M, Eder S, Eichner R, Erl M, Esterbauer H, Exner R, Felsleitner-Hauer V, Forte M, Gaiger A, Geissler K, Greinix HT, Gstöttner W, Hacker M, Hartmann BL, Hauswirth AW, Heinemann T, Heintel D, Hoda MA, Hopfinger G, Jaeger U, Kazianka L, Kenner L, Kiesewetter B, Krall N, Krajnik G, Kubicek S, Le T, Lubowitzki S, Mayerhoefer ME, Menschel E, Merkel O, Miura K, Müllauer L, Neumeister P, Noesslinger T, Ocko K, Öhler L, Panny M, Pichler A, Porpaczy E, Prager GW, Raderer M, Ristl R, Ruckser R, Salamon J, Schiefer AI, Schmolke AS, Schwarzinger I, Selzer E, Sillaber C, Skrabs C, Sperr WR, Srndic I, Thalhammer R, Valent P, van der Kouwe E, Vanura K, Vogt S, Waldstein C, Wolf D, Zielinski CC, Zojer N, Simonitsch-Klupp I, Superti- Furga G, Snijder B, Staber PB. Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. Cancer Discov. 2022 Feb;12(2):372-387. doi: 10.1158/2159-8290.CD-21-0538. Epub 2021 Oct 11. PMID: 34635570; PMCID: PMC9762339.

52: Zanotti R, Bonifacio M, Lucchini G, Sperr WR, Scaffidi L, van Anrooij B, Oude Elberink HN, Rossignol J, Hermine O, Gorska A, Lange M, Hadzijusufovic E, Miething C, Müller S, Perkins C, Shomali W, Elena C, Illerhaus A, Jawhar M, Parente R, Caroppo F, Solomianyi O, Zink A, Mattsson M, Yavuz AS, Panse J, Varkonyi J, Doubek M, Sabato V, Breynaert C, Vucinic V, Schug T, Hägglund H, Wortmann F, Brockow K, Angelova-Fischer I, Belloni Fortina A, Triggiani M, Reiter A, Hartmann K, Malcovati L, Gotlib J, Shoumariyeh K, Niedoszytko M, Arock M, Kluin-Nelemans HC, Bonadonna P, Valent P. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. Leukemia. 2022 Feb;36(2):516-524. doi: 10.1038/s41375-021-01406-y. Epub 2021 Sep 20. PMID: 34545185.

53: Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, Carver J, Dent S, Ky B, Lyon AR, López-Fernández T, Fradley MG, Ganatra S, Curigliano G, Mitchell JD, Minotti G, Lang NN, Liu JE, Neilan TG, Nohria A, O'Quinn R, Pusic I, Porter C, Reynolds KL, Ruddy KJ, Thavendiranathan P, Valent P. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022 Jan 31;43(4):280-299. doi: 10.1093/eurheartj/ehab674. PMID: 34904661; PMCID: PMC8803367.

54: Valent P, Hartmann K, Bonadonna P, Niedoszytko M, Triggiani M, Arock M, Brockow K. Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022. Int Arch Allergy Immunol. 2022;183(7):693-705. doi: 10.1159/000524532. Epub 2022 May 23. PMID: 35605594; PMCID: PMC9393812.

55: Filik Y, Bauer K, Hadzijusufovic E, Haider P, Greiner G, Witzeneder N, Hoermann G, Hohensinner PJ, Gleixner KV, Wojta J, Sperr WR, Valent P. PI3-kinase inhibition as a strategy to suppress the leukemic stem cell niche in Ph+ chronic myeloid leukemia. Am J Cancer Res. 2021 Dec 15;11(12):6042-6059. PMID: 35018241; PMCID: PMC8727792.

56: Pemovska T, Bigenzahn JW, Srndic I, Lercher A, Bergthaler A, César-Razquin A, Kartnig F, Kornauth C, Valent P, Staber PB, Superti-Furga G. Metabolic drug survey highlights cancer cell dependencies and vulnerabilities. Nat Commun. 2021 Dec 14;12(1):7190. doi: 10.1038/s41467-021-27329-x. PMID: 34907165; PMCID: PMC8671470.

57: Willmann M, Yuzbasiyan-Gurkan V, Marconato L, Dacasto M, Hadzijusufovic E, Hermine O, Sadovnik I, Gamperl S, Schneeweiss-Gleixner M, Gleixner KV, Böhm T, Peter B, Eisenwort G, Moriggl R, Li Z, Jawhar M, Sotlar K, Jensen-Jarolim E, Sexl V, Horny HP, Galli SJ, Arock M, Vail DM, Kiupel M, Valent P. Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal. Front Vet Sci. 2021 Dec 10;8:755258. doi: 10.3389/fvets.2021.755258. PMID: 34957277; PMCID: PMC8702826.

58: Kollmann S, Grausenburger R, Klampfl T, Prchal-Murphy M, Bastl K, Pisa H, Knab VM, Brandstoetter T, Doma E, Sperr WR, Lagger S, Farlik M, Moriggl R, Valent P, Halbritter F, Kollmann K, Heller G, Maurer B, Sexl V. A STAT5B-CD9 axis determines self-renewal in hematopoietic and leukemic stem cells. Blood. 2021 Dec 9;138(23):2347-2359. doi: 10.1182/blood.2021010980. PMID: 34320169; PMCID: PMC8777465.

59: Bregante J, Schönbichler A, Pölöske D, Degenfeld-Schonburg L, Monzó Contreras G, Hadzijusufovic E, de Araujo ED, Valent P, Moriggl R, Orlova A. Efficacy and Synergy of Small Molecule Inhibitors Targeting <i>FLT3</i>-ITD⁺ Acute Myeloid Leukemia. Cancers (Basel). 2021 Dec 8;13(24):6181. doi: 10.3390/cancers13246181. PMID: 34944800; PMCID: PMC8699584.

60: Berger D, Bauer K, Kornauth C, Gamperl S, Stefanzl G, Smiljkovic D, Sillaber C, Bettelheim P, Knöbl P, Schiefer AI, Greiner G, Thalhammer R, Hoermann G, Schwarzinger I, Staber PB, Sperr WR, Valent P. Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis. Neoplasia. 2021 Dec;23(12):1183-1191. doi: 10.1016/j.neo.2021.09.010. Epub 2021 Oct 31. PMID: 34731787; PMCID: PMC8572856.

61: Boehm T, Ristl R, Joseph S, Petroczi K, Klavins K, Valent P, Jilma B. Metabolome and lipidome derangements during a severe mast cell activation event in a patient with indolent systemic mastocytosis. J Allergy Clin Immunol. 2021 Dec;148(6):1533-1544. doi: 10.1016/j.jaci.2021.03.043. Epub 2021 Apr 20. PMID: 33864889.

62: Valent P, Akin C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O, Niedoszytko M, Schwaab J, Lyons JJ, Carter MC, Elberink HO, Butterfield JH, George TI, Greiner G, Ustun C, Bonadonna P, Sotlar K, Nilsson G, Jawhar M, Siebenhaar F, Broesby-Olsen S, Yavuz S, Zanotti R, Lange M, Nedoszytko B, Hoermann G, Castells M, Radia DH, Muñoz-Gonzalez JI, Sperr WR, Triggiani M, Kluin-Nelemans HC, Galli SJ, Schwartz LB, Reiter A, Orfao A, Gotlib J, Arock M, Horny HP, Metcalfe DD. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. Hemasphere. 2021 Oct 13;5(11):e646. doi: 10.1097/HS9.0000000000000646. PMID: 34901755; PMCID: PMC8659997.

63: Gülen T, Akin C, Bonadonna P, Siebenhaar F, Broesby-Olsen S, Brockow K, Niedoszytko M, Nedoszytko B, Oude Elberink HNG, Butterfield JH, Sperr WR, Alvarez-Twose I, Horny HP, Sotlar K, Schwaab J, Jawhar M, Zanotti R, Nilsson G, Lyons JJ, Carter MC, George TI, Hermine O, Gotlib J, Orfao A, Triggiani M, Reiter A, Hartmann K, Castells M, Arock M, Schwartz LB, Metcalfe DD, Valent P. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. J Allergy Clin Immunol Pract. 2021 Nov;9(11):3918-3928. doi: 10.1016/j.jaip.2021.06.011. Epub 2021 Jun 22. PMID: 34166845.

64: Wardle CLW, Oldhoff JM, Diepstra A, Valent P, Horny HP, Oude Elberink HNG, Kluin PM, Diercks GFH. Case report of a clinically indolent but morphologically high-grade cutaneous mast cell tumor in an adult: Atypical cutaneous mastocytoma or mast cell sarcoma? J Cutan Pathol. 2021 Nov;48(11):1404-1409. doi: 10.1111/cup.14088. Epub 2021 Jul 2. PMID: 34152029; PMCID: PMC8638666.

65: Eisenwort G, Sadovnik I, Keller A, Ivanov D, Peter B, Berger D, Stefanzl G, Bauer K, Slavnitsch K, Greiner G, Gleixner KV, Sperr WR, Willmann M, Sill H, Bettelheim P, Geissler K, Deininger M, Rülicke T, Valent P. Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia. Leukemia. 2021 Nov;35(11):3176-3187. doi: 10.1038/s41375-021-01227-z. Epub 2021 Mar 30. PMID: 33785864; PMCID: PMC7611912.

66: van der Kouwe E, Heller G, Czibere A, Pulikkan JA, Agreiter C, Castilla LH, Delwel R, Di Ruscio A, Ebralidze AK, Forte M, Grebien F, Heyes E, Kazianka L, Klinger J, Kornauth C, Le T, Lind K, Barbosa IAM, Pemovska T, Pichler A, Schmolke AS, Schweicker CM, Sill H, Sperr WR, Spittler A, Surapally S, Trinh BQ, Valent P, Vanura K, Welner RS, Zuber J, Tenen DG, Staber PB. Core-binding factor leukemia hijacks the T-cell-prone PU.1 antisense promoter. Blood. 2021 Oct 14;138(15):1345-1358. doi: 10.1182/blood.2020008971. PMID: 34010414; PMCID: PMC8525333.

67: Maifrede S, Le BV, Nieborowska-Skorska M, Golovine K, Sullivan-Reed K, Dunuwille WMB, Nacson J, Hulse M, Keith K, Madzo J, Caruso LB, Gazze Z, Lian Z, Padella A, Chitrala KN, Bartholdy BA, Matlawska-Wasowska K, Di Marcantonio D, Simonetti G, Greiner G, Sykes SM, Valent P, Paietta EM, Tallman MS, Fernandez HF, Litzow MR, Minden MD, Huang J, Martinelli G, Vassiliou GS, Tempera I, Piwocka K, Johnson N, Challen GA, Skorski T. <i>TET2</i> and <i>DNMT3A</i> Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. Cancer Res. 2021 Oct 1;81(19):5089-5101. doi: 10.1158/0008-5472.CAN-20-3761. Epub 2021 Jul 2. PMID: 34215619; PMCID: PMC8487956.

68: Gleixner KV, Filik Y, Berger D, Schewzik C, Stefanzl G, Sadovnik I, Degenfeld-Schonburg L, Eisenwort G, Schneeweiss-Gleixner M, Byrgazov K, Sperr WR, Mayer J, Lion T, Valent P. Asciminib and ponatinib exert synergistic anti- neoplastic effects on CML cells expressing <i>BCR- ABL1</i>^T315I-compound mutations. Am J Cancer Res. 2021 Sep 15;11(9):4470-4484. PMID: 34659899; PMCID: PMC8493398.

69: Machherndl-Spandl S, Jäger E, Barna A, Gurbisz M, Marschon R, Graf T, Graf E, Geissler C, Hoermann G, Nösslinger T, Pfeilstöcker M, Bettelheim P, Zach O, Weltermann A, Heibl S, Thaler J, Zebisch A, Sill H, Stauder R, Webersinke G, Kusec R, Ulsperger E, Schneeweiss B, Öhler L, Germing U, Valent P, Tüchler H, Geissler K. Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia. Eur J Haematol. 2021 Aug;107(2):265-274. doi: 10.1111/ejh.13647. Epub 2021 Jun 1. PMID: 33998054; PMCID: PMC8480146.

70: Elst J, Ebo DG, Faber MA, Van Gasse AL, Decuyper II, van der Poorten MM, Bridts CH, De Puysseleyr LP, Mertens C, Hagendorens MM, De Clerck LS, Walschot M, Verlinden A, Berger D, Valent P, Sabato V. Culturing cells with mast cell phenotype and function: Comparison of peripheral blood and bone marrow as a source. J Immunol Methods. 2021 Aug;495:113061. doi: 10.1016/j.jim.2021.113061. Epub 2021 Apr 30. PMID: 33933470.

71: Naumann N, Lübke J, Shomali W, Reiter L, Horny HP, Jawhar M, Dangelo V, Fabarius A, Metzgeroth G, Kreil S, Sotlar K, Oni C, Harrison C, Hofmann WK, Cross NCP, Valent P, Radia D, Gotlib J, Reiter A, Schwaab J. Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations. Br J Haematol. 2021 Jul;194(2):344-354. doi: 10.1111/bjh.17567. Epub 2021 Jun 1. PMID: 34060083.

72: Aberer E, Sperr WR, Bretterklieber A, Avian A, Hadzijusufovic E, Kluin- Nelemans HC, Oude Elberink H, van Anrooij B, Niedoszytko M, Lange M, Górska A, Elena C, Brazzelli V, Belloni Fortina A, Caroppo F, Hartmann K, Illerhaus A, Reiter A, Jawhar M, Bonadonna P, Zanotti R, Triggiani M, Parente R, Gotlib J, Doubek M, von Bubnoff N, Fuchs D, Sabato V, Brockow K, Jäkel N, Panse J, Valent P. Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis. J Invest Dermatol. 2021 Jul;141(7):1719-1727. doi: 10.1016/j.jid.2020.12.030. Epub 2021 Feb 11. PMID: 33581142.

73: Valent P, Degenfeld-Schonburg L, Sadovnik I, Horny HP, Arock M, Simon HU, Reiter A, Bochner BS. Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity. Semin Immunopathol. 2021 Jun;43(3):423-438. doi: 10.1007/s00281-021-00863-y. Epub 2021 May 30. PMID: 34052871; PMCID: PMC8164832.

74: Bonadonna P, Brockow K, Niedoszytko M, Elberink HO, Akin C, Nedoszytko B, Butterfield JH, Alvarez-Twose I, Sotlar K, Schwaab J, Jawhar M, Castells M, Sperr WR, Hermine O, Gotlib J, Zanotti R, Reiter A, Broesby-Olsen S, Bindslev- Jensen C, Schwartz LB, Horny HP, Radia D, Triggiani M, Sabato V, Carter MC, Siebenhaar F, Orfao A, Grattan C, Metcalfe DD, Arock M, Gulen T, Hartmann K, Valent P. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). J Allergy Clin Immunol Pract. 2021 Jun;9(6):2139-2144. doi: 10.1016/j.jaip.2021.03.041. Epub 2021 Apr 5. PMID: 33831618; PMCID: PMC8019658.

75: Obrová K, Grumaz S, Remely M, Czurda S, Krickl I, Herndlhofer S, Gleixner KV, Sperr WR, Größlinger L, Frank T, Andrade N, Egger-Matiqi T, Peters C, Engstler G, Dworzak M, Attarbaschi A, van Grotel M, van den Heuvel-Eibrink MM, Moiseev IS, Rogacheva Y, Zubarovskaya L, Zubarovskaya N, Pichler H, Lawitschka A, Koller E, Keil F, Valent P, Sohn K, Lion T. Presence of viremia during febrile neutropenic episodes in patients undergoing chemotherapy for malignant neoplasms. Am J Hematol. 2021 Jun 1;96(6):719-726. doi: 10.1002/ajh.26177. Epub 2021 May 3. PMID: 33784434.

76: Gotlib J, George TI, Carter MC, Austen KF, Bochner B, Dwyer DF, Lyons JJ, Hamilton MJ, Butterfield J, Bonadonna P, Weiler C, Galli SJ, Schwartz LB, Elberink HO, Maitland A, Theoharides T, Ustun C, Horny HP, Orfao A, Deininger M, Radia D, Jawhar M, Kluin-Nelemans H, Metcalfe DD, Arock M, Sperr WR, Valent P, Castells M, Akin C. Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference. J Allergy Clin Immunol. 2021 Jun;147(6):2043-2052. doi: 10.1016/j.jaci.2021.03.008. Epub 2021 Mar 11. PMID: 33745886; PMCID: PMC9521380.

77: Panagiota V, Meggendorfer M, Kubasch AS, Gabdoulline R, Krönke J, Mies A, Shahswar R, Kandziora C, Klement P, Schiller J, Göhring G, Haferlach C, Ganster C, Shirneshan K, Gutermuth A, Thiede C, Germing U, Schroeder T, Kobbe G, Klesse S, Koenecke C, Schlegelberger B, Kröger N, Haase D, Döhner K, Sperr WR, Valent P, Ganser A, Thol F, Haferlach T, Platzbecker U, Heuser M. Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. Am J Hematol. 2021 Jun 1;96(6):E207-E210. doi: 10.1002/ajh.26162. Epub 2021 Apr 7. PMID: 33725366.

78: Renz H, Bachert C, Berek C, Hamelmann E, Levi-Schaffer F, Raap U, Simon HU, Ploetz S, Taube C, Valent P, Voehringer D, Werfel T, Zhang N, Ring J. Physiology and pathology of eosinophils: Recent developments: Summary of the Focus Workshop Organized by DGAKI. Scand J Immunol. 2021 Jun;93(6):e13032. doi: 10.1111/sji.13032. Epub 2021 Mar 11. PMID: 33624312.

79: Han SY, Mrózek K, Voutsinas J, Wu Q, Morgan EA, Vestergaard H, Ohgami R, Kluin PM, Kristensen TK, Pullarkat S, Møller MB, Schiefer AI, Baughn LB, Kim Y, Czuchlewski D, Hilberink JR, Horny HP, George TI, Dolan M, Ku NK, Arana Yi C, Pullarkat V, Kohlschmidt J, Salhotra A, Soma L, Bloomfield CD, Chen D, Sperr WR, Marcucci G, Cho C, Akin C, Gotlib J, Broesby-Olsen S, Larson M, Linden MA, Deeg HJ, Hoermann G, Perales MA, Hornick JL, Litzow MR, Nakamura R, Weisdorf D, Borthakur G, Huls G, Valent P, Ustun C, Yeung CCS. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Adv. 2021 May 25;5(10):2481-2489. doi: 10.1182/bloodadvances.2020003605. PMID: 34003250; PMCID: PMC8152510.

80: Carr RM, Vorobyev D, Lasho T, Marks DL, Tolosa EJ, Vedder A, Almada LL, Yurcheko A, Padioleau I, Alver B, Coltro G, Binder M, Safgren SL, Horn I, You X, Solary E, Balasis ME, Berger K, Hiebert J, Witzig T, Buradkar A, Graf T, Valent P, Mangaonkar AA, Robertson KD, Howard MT, Kaufmann SH, Pin C, Fernandez-Zapico ME, Geissler K, Droin N, Padron E, Zhang J, Nikolaev S, Patnaik MM. RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nat Commun. 2021 May 18;12(1):2901. doi: 10.1038/s41467-021-23186-w. PMID: 34006870; PMCID: PMC8131698.

81: Niedoszytko M, Valent P, Nedoszytko B. Mastocytosis, MCAS, and Related Disorders-Diagnosis, Classification, and Therapy. Int J Mol Sci. 2021 May 10;22(9):5024. doi: 10.3390/ijms22095024. PMID: 34068468; PMCID: PMC8125991.

82: Giannetti MP, Weller E, Alvarez-Twose I, Torrado I, Bonadonna P, Zanotti R, Dwyer DF, Foer D, Akin C, Hartmann K, Rama TA, Sperr WR, Valent P, Teodosio C, Orfao A, Castells M. COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms. J Allergy Clin Immunol Pract. 2021 May;9(5):2083-2086. doi: 10.1016/j.jaip.2021.02.023. Epub 2021 Feb 23. PMID: 33631409; PMCID: PMC7899934.

83: Geissler K, Jäger E, Barna A, Graf T, Graf E, Öhler L, Hoermann G, Valent P. Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival. Eur J Haematol. 2021 May;106(5):627-633. doi: 10.1111/ejh.13577. Epub 2021 Mar 8. PMID: 33432601; PMCID: PMC8554855.

84: Toledo MAS, Gatz M, Sontag S, Gleixner KV, Eisenwort G, Feldberg K, Hamouda AEI, Kluge F, Guareschi R, Rossetti G, Sechi AS, Dufva OMJ, Mustjoki SM, Maurer A, Schüler HM, Goetzke R, Braunschweig T, Kaiser A, Panse J, Jawhar M, Reiter A, Hilberg F, Ettmayer P, Wagner W, Koschmieder S, Brümmendorf TH, Valent P, Chatain N, Zenke M. Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis. Blood. 2021 Apr 15;137(15):2070-2084. doi: 10.1182/blood.2019004509. PMID: 33512435.

85: Fuchs D, Kilbertus A, Kofler K, von Bubnoff N, Shoumariyeh K, Zanotti R, Bonadonna P, Scaffidi L, Doubek M, Elberink HO, Span LFR, Hermine O, Elena C, Benvenuti P, Yavuz AS, Brockow K, Zink A, Aberer E, Gorska A, Romantowski J, Hadzijusufovic E, Fortina AB, Caroppo F, Perkins C, Illerhaus A, Panse J, Vucinic V, Jawhar M, Sabato V, Triggiani M, Parente R, Bergström A, Breynaert C, Gotlib J, Reiter A, Hartmann K, Niedoszytko M, Arock M, Kluin-Nelemans HC, Sperr WR, Greul R, Valent P. Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin. J Allergy Clin Immunol Pract. 2021 Apr;9(4):1705-1712.e4. doi: 10.1016/j.jaip.2020.12.022. Epub 2020 Dec 23. PMID: 33346151.

86: Gotlib J, Kluin-Nelemans HC, Akin C, Hartmann K, Valent P, Reiter A. Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin. Expert Opin Biol Ther. 2021 Apr;21(4):487-498. doi: 10.1080/14712598.2021.1837109. Epub 2021 Jan 15. PMID: 33063554.

87: Reszka E, Jabłońska E, Wieczorek E, Valent P, Arock M, Nilsson G, Nedoszytko B, Niedoszytko M. Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis. Int J Mol Sci. 2021 Mar 15;22(6):2964. doi: 10.3390/ijms22062964. PMID: 33803981; PMCID: PMC7999363.

88: Brockow K, Plata-Nazar K, Lange M, Nedoszytko B, Niedoszytko M, Valent P. Mediator-Related Symptoms and Anaphylaxis in Children with Mastocytosis. Int J Mol Sci. 2021 Mar 7;22(5):2684. doi: 10.3390/ijms22052684. PMID: 33799959; PMCID: PMC7962052.

89: Lange M, Hartmann K, Carter MC, Siebenhaar F, Alvarez-Twose I, Torrado I, Brockow K, Renke J, Irga-Jaworska N, Plata-Nazar K, Ługowska-Umer H, Czarny J, Belloni Fortina A, Caroppo F, Nowicki RJ, Nedoszytko B, Niedoszytko M, Valent P. Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021. Int J Mol Sci. 2021 Mar 4;22(5):2586. doi: 10.3390/ijms22052586. PMID: 33806685; PMCID: PMC7961542.

90: Schneeweiss-Gleixner M, Greiner G, Herndlhofer S, Schellnegger J, Krauth MT, Gleixner KV, Wimazal F, Steinhauser C, Kundi M, Thalhammer R, Schwarzinger I, Hoermann G, Esterbauer H, Födinger M, Valent P, Sperr WR. Impact of <i>HFE</i> gene variants on iron overload, overall survival and leukemia-free survival in myelodysplastic syndromes. Am J Cancer Res. 2021 Mar 1;11(3):955-967. PMID: 33791166; PMCID: PMC7994158.

91: Valent P, Orfao A, Kubicek S, Staber P, Haferlach T, Deininger M, Kollmann K, Lion T, Virgolini I, Winter G, Hantschel O, Kenner L, Zuber J, Grebien F, Moriggl R, Hoermann G, Hermine O, Andreeff M, Bock C, Mughal T, Constantinescu SN, Kralovics R, Sexl V, Skoda R, Superti-Furga G, Jäger U. Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. Hemasphere. 2021 Feb 17;5(3):e536. doi: 10.1097/HS9.0000000000000536. PMID: 33623882; PMCID: PMC7892291.

92: Muñoz-González JI, Álvarez-Twose I, Jara-Acevedo M, Zanotti R, Perkins C, Jawhar M, Sperr WR, Shoumariyeh K, Schwaab J, Greiner G, Henriques A, Caldas C, Fernández-Giménez C, Sánchez-Muñoz L, Mayado A, Pérez-Pons A, Schmitt-Graeff A, Duyster J, Tanasi I, Olivieri F, Mora-Casterá E, Luna I, Senent L, Bañas MH, Nuñez-García A, Jurado-Chacón M, Martín-Sánchez G, Colado E, Xicoy B, Gener- Ricós G, Gotlib J, Bonadonna P, Reiter A, Valent P, García-Montero AC, Orfao A. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. Lancet Haematol. 2021 Mar;8(3):e194-e204. doi: 10.1016/S2352-3026(20)30400-2. Epub 2021 Jan 25. PMID: 33508247.

93: Kuendgen A, Nomdedeu M, Tuechler H, Garcia-Manero G, Komrokji RS, Sekeres MA, Della Porta MG, Cazzola M, DeZern AE, Roboz GJ, Steensma DP, Van de Loosdrecht AA, Schlenk RF, Grau J, Calvo X, Blum S, Pereira A, Valent P, Costa D, Giagounidis A, Xicoy B, Döhner H, Platzbecker U, Pedro C, Lübbert M, Oiartzabal I, Díez-Campelo M, Cedena MT, Machherndl-Spandl S, López-Pavía M, Baldus CD, Martinez-de-Sola M, Stauder R, Merchan B, List A, Ganster C, Schroeder T, Voso MT, Pfeilstöcker M, Sill H, Hildebrandt B, Esteve J, Nomdedeu B, Cobo F, Haas R, Sole F, Germing U, Greenberg PL, Haase D, Sanz G. Therapy- related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Leukemia. 2021 Mar;35(3):835-849. doi: 10.1038/s41375-020-0917-7. Epub 2020 Jun 29. PMID: 32595214; PMCID: PMC7932916.

94: Sprinzl B, Greiner G, Uyanik G, Arock M, Haferlach T, Sperr WR, Valent P, Hoermann G. Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond. Int J Mol Sci. 2021 Feb 28;22(5):2458. doi: 10.3390/ijms22052458. PMID: 33671092; PMCID: PMC7957558.

95: Bauer K, Berghoff AS, Preusser M, Heller G, Zielinski CC, Valent P, Grunt TW. Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer. Am J Cancer Res. 2021 Feb 1;11(2):530-545. PMID: 33575085; PMCID: PMC7868748.

96: Romantowski J, Górska A, Niedoszytko M, Gulen T, Gruchała-Niedoszytko M, Nedoszytko B, Lange M, Brockow K, Arock M, Akin C, Valent P. A Challenge for Allergologist: Application of Allergy Diagnostic Methods in Mast Cell Disorders. Int J Mol Sci. 2021 Feb 1;22(3):1454. doi: 10.3390/ijms22031454. PMID: 33535634; PMCID: PMC7867197.

97: Pleyer L, Leisch M, Kourakli A, Padron E, Maciejewski JP, Xicoy Cirici B, Kaivers J, Ungerstedt J, Heibl S, Patiou P, Hunter AM, Mora E, Geissler K, Dimou M, Jimenez Lorenzo MJ, Melchardt T, Egle A, Viniou AN, Patel BJ, Arnan M, Valent P, Roubakis C, Bernal Del Castillo T, Galanopoulos A, Calabuig Muñoz M, Bonadies N, Medina de Almeida A, Cermak J, Jerez A, Montoro MJ, Cortés A, Avendaño Pita A, Lopez Andrade B, Hellstroem-Lindberg E, Germing U, Sekeres MA, List AF, Symeonidis A, Sanz GF, Larcher-Senn J, Greil R. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. Lancet Haematol. 2021 Feb;8(2):e135-e148. doi: 10.1016/S2352-3026(20)30374-4. PMID: 33513373.

98: Ustun C, Morgan EA, Ritz EM, Vestergaard H, Pullarkat S, Kluin PM, Ohgami R, Baughn LB, Kim Y, Ku NK, Czuchlewski D, Boe Møller M, Schiefer AI, Mrózek K, Horny HP, George TI, Kielsgaard Kristensen T, Beck T, Nathan S, Arana Yi C, Yeung C, Pullarkat V, Gotlib J, Akin C, Kohlschmidt J, Salhotra A, Soma L, Chen D, Han SY, Cho C, Sperr W, Broesby-Olsen S, Linden MA, Dolan M, Hoermann G, Hornick JL, Bloomfield C, Nakamura R, Joachim Deeg H, Litzow MR, Borthakur G, Weisdorf D, Huls G, Perales MA, Valent P, Marcucci G. Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. Int J Lab Hematol. 2021 Feb;43(1):e19-e25. doi: 10.1111/ijlh.13338. Epub 2020 Sep 14. PMID: 32926565; PMCID: PMC8434847.

99: Greiner G, Sprinzl B, Górska A, Ratzinger F, Gurbisz M, Witzeneder N, Schmetterer KG, Gisslinger B, Uyanik G, Hadzijusufovic E, Esterbauer H, Gleixner KV, Krauth MT, Pfeilstöcker M, Keil F, Gisslinger H, Nedoszytko B, Niedoszytko M, Sperr WR, Valent P, Hoermann G. Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. Blood. 2021 Jan 14;137(2):238-247. doi: 10.1182/blood.2020006157. PMID: 32777817; PMCID: PMC7116780.

100: Ruiz MS, Sánchez MB, Bonecker S, Furtado C, Koile D, Yankilevich P, Cranco S, Custidiano MDR, Freitas J, Moiraghi B, Pérez MA, Pavlovsky C, Varela AI, Ventriglia V, Sánchez Ávalos JC, Larripa I, Zalcberg I, Mordoh J, Valent P, Bianchini M. miRNome profiling of LSC-enriched CD34⁺CD38^-CD26⁺ fraction in Ph⁺ CML- CP samples from Argentinean patients: a potential new pharmacogenomic tool. Front Pharmacol. 2021 Jan 11;11:612573. doi: 10.3389/fphar.2020.612573. PMID: 33569005; PMCID: PMC7869017.

101: Nedoszytko B, Arock M, Lyons JJ, Bachelot G, Schwartz LB, Reiter A, Jawhar M, Schwaab J, Lange M, Greiner G, Hoermann G, Niedoszytko M, Metcalfe DD, Valent P. Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis. Int J Mol Sci. 2021 Jan 2;22(1):411. doi: 10.3390/ijms22010411. PMID: 33401724; PMCID: PMC7795405.

102: Kluin-Nelemans HC, Jawhar M, Reiter A, van Anrooij B, Gotlib J, Hartmann K, Illerhaus A, Oude Elberink HNG, Gorska A, Niedoszytko M, Lange M, Scaffidi L, Zanotti R, Bonadonna P, Perkins C, Elena C, Malcovati L, Shoumariyeh K, von Bubnoff N, Müller S, Triggiani M, Parente R, Schwaab J, Kundi M, Fortina AB, Caroppo F, Brockow K, Zink A, Fuchs D, Angelova-Fischer I, Yavuz AS, Doubek M, Mattsson M, Hagglund H, Panse J, Simonowski A, Sabato V, Schug T, Jentzsch M, Breynaert C, Várkonyi J, Kennedy V, Hermine O, Rossignol J, Arock M, Valent P, Sperr WR. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. Theranostics. 2021 Jan 1;11(1):292-303. doi: 10.7150/thno.51872. PMID: 33391475; PMCID: PMC7681091.

103: Gamperl S, Stefanzl G, Willmann M, Valent P, Hadzijusufovic E. In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells. Vet Med Sci. 2021 Jan;7(1):57-68. doi: 10.1002/vms3.336. Epub 2020 Sep 13. PMID: 32924324; PMCID: PMC7840218.

104: Valent P, Akin C, Nedoszytko B, Bonadonna P, Hartmann K, Niedoszytko M, Brockow K, Siebenhaar F, Triggiani M, Arock M, Romantowski J, Górska A, Schwartz LB, Metcalfe DD. Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. Int J Mol Sci. 2020 Nov 27;21(23):9030. doi: 10.3390/ijms21239030. PMID: 33261124; PMCID: PMC7731385.

105: Valent P, Bauer K, Sadovnik I, Smiljkovic D, Ivanov D, Herrmann H, Filik Y, Eisenwort G, Sperr WR, Rabitsch W. Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues. Stem Cells Transl Med. 2020 Nov;9(11):1331-1343. doi: 10.1002/sctm.20-0147. Epub 2020 Jul 13. PMID: 32657052; PMCID: PMC7581453.

106: Herrmann H, Sadovnik I, Eisenwort G, Rülicke T, Blatt K, Herndlhofer S, Willmann M, Stefanzl G, Baumgartner S, Greiner G, Schulenburg A, Mueller N, Rabitsch W, Bilban M, Hoermann G, Streubel B, Vallera DA, Sperr WR, Valent P. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML. Blood Adv. 2020 Oct 27;4(20):5118-5132. doi: 10.1182/bloodadvances.2020001742. PMID: 33085758; PMCID: PMC7594398.

107: Le BV, Podszywalow-Bartnicka P, Maifrede S, Sullivan-Reed K, Nieborowska- Skorska M, Golovine K, Yao JC, Nejati R, Cai KQ, Caruso LB, Swatler J, Dabrowski M, Lian Z, Valent P, Paietta EM, Levine RL, Fernandez HF, Tallman MS, Litzow MR, Huang J, Challen GA, Link D, Tempera I, Wasik MA, Piwocka K, Skorski T. TGFβR- SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment. Cell Rep. 2020 Oct 6;33(1):108221. doi: 10.1016/j.celrep.2020.108221. PMID: 33027668; PMCID: PMC7578922.

108: Füreder W, Sperr WR, Heibl S, Zebisch A, Pfeilstöcker M, Stefanzl G, Jäger E, Greiner G, Schwarzinger I, Kundi M, Keil F, Hoermann G, Bettelheim P, Valent P. Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network. Ann Hematol. 2020 Oct;99(10):2303-2313. doi: 10.1007/s00277-020-04214-z. Epub 2020 Aug 27. PMID: 32856141.

109: Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R, Malcovati L, Levine MF, Arango JE, Zhou Y, Solé F, Cargo CA, Haase D, Creignou M, Germing U, Zhang Y, Gundem G, Sarian A, van de Loosdrecht AA, Jädersten M, Tobiasson M, Kosmider O, Follo MY, Thol F, Pinheiro RF, Santini V, Kotsianidis I, Boultwood J, Santos FPS, Schanz J, Kasahara S, Ishikawa T, Tsurumi H, Takaori-Kondo A, Kiguchi T, Polprasert C, Bennett JM, Klimek VM, Savona MR, Belickova M, Ganster C, Palomo L, Sanz G, Ades L, Della Porta MG, Elias HK, Smith AG, Werner Y, Patel M, Viale A, Vanness K, Neuberg DS, Stevenson KE, Menghrajani K, Bolton KL, Fenaux P, Pellagatti A, Platzbecker U, Heuser M, Valent P, Chiba S, Miyazaki Y, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Atsuta Y, Gattermann N, Ebert BL, Bejar R, Greenberg PL, Cazzola M, Hellström-Lindberg E, Ogawa S, Papaemmanuil E. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020 Oct;26(10):1549-1556. doi: 10.1038/s41591-020-1008-z. Epub 2020 Aug 3. Erratum in: Nat Med. 2021 Mar;27(3):562. Erratum in: Nat Med. 2021 May;27(5):927. PMID: 32747829; PMCID: PMC8381722.

110: Schwaab J, Cabral do O Hartmann N, Naumann N, Jawhar M, Weiß C, Metzgeroth G, Schmid A, Lübke J, Reiter L, Fabarius A, Cross NCP, Sotlar K, Valent P, Kluin-Nelemans HC, Hofmann WK, Horny HP, Panse J, Reiter A. Importance of Adequate Diagnostic Workup for Correct Diagnosis of Advanced Systemic Mastocytosis. J Allergy Clin Immunol Pract. 2020 Oct;8(9):3121-3127.e1. doi: 10.1016/j.jaip.2020.05.005. Epub 2020 May 15. PMID: 32422371.

111: Smiljkovic D, Kiss R, Lupinek C, Hoermann G, Greiner G, Witzeneder N, Krajnik G, Trautinger F, Vrtala S, Mittermann I, Kundi M, Jilma B, Valenta R, Sperr WR, Valent P. Microarray-Based Detection of Allergen-Reactive IgE in Patients with Mastocytosis. J Allergy Clin Immunol Pract. 2020 Sep;8(8):2761-2768.e16. doi: 10.1016/j.jaip.2020.04.030. Epub 2020 Apr 26. PMID: 32348913; PMCID: PMC7116130.

112: Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O, Sotlar K, Sperr WR, Escribano L, George TI, Kluin-Nelemans HC, Ustun C, Triggiani M, Brockow K, Gotlib J, Orfao A, Kovanen PT, Hadzijusufovic E, Sadovnik I, Horny HP, Arock M, Schwartz LB, Austen KF, Metcalfe DD, Galli SJ. Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. Theranostics. 2020 Aug 29;10(23):10743-10768. doi: 10.7150/thno.46719. PMID: 32929378; PMCID: PMC7482799.

113: Geissler K, Jäger E, Barna A, Gurbisz M, Graf T, Graf E, Nösslinger T, Pfeilstöcker M, Machherndl-Spandl S, Stauder R, Zebisch A, Sill H, Öhler L, Kusec R, Hörmann G, Valent P. Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia. Int J Mol Sci. 2020 Aug 22;21(17):6057. doi: 10.3390/ijms21176057. PMID: 32842710; PMCID: PMC7504428.

114: Hoermann G, Greiner G, Griesmacher A, Valent P. Clonal Hematopoiesis of Indeterminate Potential: A Multidisciplinary Challenge in Personalized Hematology. J Pers Med. 2020 Aug 20;10(3):94. doi: 10.3390/jpm10030094. PMID: 32825226; PMCID: PMC7564336.

115: Fagnan A, Bagger FO, Piqué-Borràs MR, Ignacimouttou C, Caulier A, Lopez CK, Robert E, Uzan B, Gelsi-Boyer V, Aid Z, Thirant C, Moll U, Tauchmann S, Kurtovic-Kozaric A, Maciejewski J, Dierks C, Spinelli O, Salmoiraghi S, Pabst T, Shimoda K, Deleuze V, Lapillonne H, Sweeney C, De Mas V, Leite B, Kadri Z, Malinge S, de Botton S, Micol JB, Kile B, Carmichael CL, Iacobucci I, Mullighan CG, Carroll M, Valent P, Bernard OA, Delabesse E, Vyas P, Birnbaum D, Anguita E, Garçon L, Soler E, Schwaller J, Mercher T. Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. Blood. 2020 Aug 6;136(6):698-714. doi: 10.1182/blood.2019003062. PMID: 32350520; PMCID: PMC8215330.

116: Füreder W, Valent P. Switching From High-Dose Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report. Hemasphere. 2020 Aug 4;4(4):e455. doi: 10.1097/HS9.0000000000000455. PMID: 32803134; PMCID: PMC7410035.

117: Valent P, Akin C, Bonadonna P, Brockow K, Niedoszytko M, Nedoszytko B, Butterfield JH, Alvarez-Twose I, Sotlar K, Schwaab J, Jawhar M, Reiter A, Castells M, Sperr WR, Kluin-Nelemans HC, Hermine O, Gotlib J, Zanotti R, Broesby-Olsen S, Horny HP, Triggiani M, Siebenhaar F, Orfao A, Metcalfe DD, Arock M, Hartmann K. Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. J Allergy Clin Immunol. 2020 Aug;146(2):300-306. doi: 10.1016/j.jaci.2020.06.009. Epub 2020 Jun 17. PMID: 32561389; PMCID: PMC7297685.

118: Petzer AL, Sperr WR, Buxhofer-Ausch V, Sliwa T, Schmidt S, Greil R, Wölfler A, Pichler P, Dormann C, Burgstaller S, Tinchon C, Lang A, Goebel F, Uthman S, Muenchmeier N, Valent P. A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting : R-EFECT study. Wien Klin Wochenschr. 2020 Aug;132(15-16):415-422. doi: 10.1007/s00508-020-01690-1. Epub 2020 Jun 12. PMID: 32533444; PMCID: PMC7445202.

119: Hartmann K, Gotlib J, Akin C, Hermine O, Awan FT, Hexner E, Mauro MJ, Menssen HD, Redhu S, Knoll S, Sotlar K, George TI, Horny HP, Valent P, Reiter A, Kluin-Nelemans HC. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. J Allergy Clin Immunol. 2020 Aug;146(2):356-366.e4. doi: 10.1016/j.jaci.2020.03.044. Epub 2020 May 11. PMID: 32437738.

120: Trizuljak J, Sperr WR, Nekvindová L, Elberink HO, Gleixner KV, Gorska A, Lange M, Hartmann K, Illerhaus A, Bonifacio M, Perkins C, Elena C, Malcovati L, Fortina AB, Shoumariyeh K, Jawhar M, Zanotti R, Bonadonna P, Caroppo F, Zink A, Triggiani M, Parente R, von Bubnoff N, Yavuz AS, Hägglund H, Mattsson M, Panse J, Jäkel N, Kilbertus A, Hermine O, Arock M, Fuchs D, Sabato V, Brockow K, Bretterklieber A, Niedoszytko M, van Anrooij B, Reiter A, Gotlib J, Kluin- Nelemans HC, Mayer J, Doubek M, Valent P. Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. Allergy. 2020 Aug;75(8):1927-1938. doi: 10.1111/all.14248. Epub 2020 Mar 16. PMID: 32108361; PMCID: PMC7115854.

121: Landolina N, Zaffran I, Smiljkovic D, Serrano-Candelas E, Schmiedel D, Friedman S, Arock M, Hartmann K, Pikarsky E, Mandelboim O, Martin M, Valent P, Levi-Schaffer F. Activation of Siglec-7 results in inhibition of in vitro and in vivo growth of human mast cell leukemia cells. Pharmacol Res. 2020 Aug;158:104682. doi: 10.1016/j.phrs.2020.104682. Epub 2020 Feb 5. PMID: 32035162.

122: Nedoszytko B, Sobalska-Kwapis M, Strapagiel D, Lange M, Górska A, Elberink JNGO, van Doormaal J, Słomka M, Kalinowski L, Gruchała-Niedoszytko M, Nowicki RJ, Valent P, Niedoszytko M. Results from a Genome-Wide Association Study (GWAS) in Mastocytosis Reveal New Gene Polymorphisms Associated with WHO Subgroups. Int J Mol Sci. 2020 Jul 31;21(15):5506. doi: 10.3390/ijms21155506. PMID: 32752121; PMCID: PMC7432708.

123: Greiner G, Ratzinger F, Gurbisz M, Witzeneder N, Taghizadeh H, Mustafa SGK, Mitterbauer-Hohendanner G, Esterbauer H, Mannhalter C, Sperr WR, Valent P, Hoermann G. Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia. Clin Chem Lab Med. 2020 Jul 28;58(8):1214-1222. doi: 10.1515/cclm-2019-1172. PMID: 32084002; PMCID: PMC7115836.

124: Schmoellerl J, Barbosa IAM, Eder T, Brandstoetter T, Schmidt L, Maurer B, Troester S, Pham HTT, Sagarajit M, Ebner J, Manhart G, Aslan E, Terlecki- Zaniewicz S, Van der Veen C, Hoermann G, Duployez N, Petit A, Lapillonne H, Puissant A, Itzykson R, Moriggl R, Heuser M, Meisel R, Valent P, Sexl V, Zuber J, Grebien F. CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. Blood. 2020 Jul 23;136(4):387-400. doi: 10.1182/blood.2019003267. PMID: 32344427; PMCID: PMC7115844.

125: Heibl S, Gisslinger B, Jäger E, Barna A, Gurbisz M, Stegemann M, Bettelheim P, Machherndl-Spandl S, Pfeilstöcker M, Nösslinger T, Uyanik G, Hoermann G, Stauder R, Thaler J, Kusec R, Valent P, Gisslinger H, Geissler K. Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype. Cancers (Basel). 2020 Jul 14;12(7):1891. doi: 10.3390/cancers12071891. PMID: 32674283; PMCID: PMC7409251.

126: Hubmann R, Schnabl S, Araghi M, Schmidl C, Rendeiro AF, Hilgarth M, Demirtas D, Ali F, Staber PB, Valent P, Zielinski C, Jäger U, Shehata M. Targeting Nuclear NOTCH2 by Gliotoxin Recovers a Tumor-Suppressor NOTCH3 Activity in CLL. Cells. 2020 Jun 18;9(6):1484. doi: 10.3390/cells9061484. PMID: 32570839; PMCID: PMC7348714.

127: Valent P. Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management. Best Pract Res Clin Haematol. 2020 Jun;33(2):101137. doi: 10.1016/j.beha.2019.101137. Epub 2019 Dec 15. PMID: 32460976.

128: Arock M, Sotlar K, Gotlib J, Sperr WR, Hartmann K, Schwartz LB, Akin C, Horny HP, Valent P. New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019. Leuk Lymphoma. 2020 May;61(5):1075-1083. doi: 10.1080/10428194.2019.1703974. Epub 2019 Dec 26. PMID: 31876203; PMCID: PMC7115828.

129: Geissler K, Jäger E, Barna A, Gurbisz M, Graf T, Graf E, Nösslinger T, Pfeilstöcker M, Tüchler H, Sliwa T, Keil F, Geissler C, Heibl S, Thaler J, Machherndl-Spandl S, Zach O, Weltermann A, Bettelheim P, Stauder R, Zebisch A, Sill H, Schwarzinger I, Schneeweiss B, Öhler L, Ulsperger E, Kusec R, Germing U, Sperr WR, Knöbl P, Jäger U, Hörmann G, Valent P. Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 Patients. Int J Mol Sci. 2020 Apr 24;21(8):3025. doi: 10.3390/ijms21083025. PMID: 32344757; PMCID: PMC7215883.

130: Hadzijusufovic E, Keller A, Berger D, Greiner G, Wingelhofer B, Witzeneder N, Ivanov D, Pecnard E, Nivarthi H, Schur FKM, Filik Y, Kornauth C, Neubauer HA, Müllauer L, Tin G, Park J, de Araujo ED, Gunning PT, Hoermann G, Gouilleux F, Kralovics R, Moriggl R, Valent P. STAT5 is Expressed in CD34⁺/CD38^- Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms. Cancers (Basel). 2020 Apr 21;12(4):1021. doi: 10.3390/cancers12041021. PMID: 32326377; PMCID: PMC7225958.

131: Riffel P, Schwaab J, Lutz C, Naumann N, Metzgeroth G, Fabarius A, Schoenberg SO, Hofmann WK, Valent P, Reiter A, Jawhar M. An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis. J Cancer Res Clin Oncol. 2020 Apr;146(4):945-951. doi: 10.1007/s00432-019-03119-3. Epub 2020 Jan 24. PMID: 31980928; PMCID: PMC7085471.

132: Kluin-Nelemans HC, Reiter A, Illerhaus A, van Anrooij B, Hartmann K, Span LFR, Gorska A, Niedoszytko M, Lange M, Scaffidi L, Zanotti R, Bonadonna P, Perkins C, Elena C, Malcovati L, Shoumariyeh K, von Bubnoff N, Parente R, Triggiani M, Schwaab J, Jawhar M, Caroppo F, Fortina AB, Brockow K, Zink A, Fuchs D, Kilbertus A, Yavuz AS, Doubek M, Mattsson M, Hagglund H, Panse J, Sabato V, Aberer E, Niederwieser D, Breynaert C, Várkonyi J, Kennedy V, Lortholary O, Jakob T, Hermine O, Rossignol J, Arock M, Gotlib J, Valent P, Sperr WR. Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. Leukemia. 2020 Apr;34(4):1090-1101. doi: 10.1038/s41375-019-0632-4. Epub 2019 Nov 18. PMID: 31740811; PMCID: PMC7115841.

133: Valent P, Sadovnik I, Eisenwort G, Herrmann H, Bauer K, Mueller N, Sperr WR, Wicklein D, Schumacher U. Redistribution, homing and organ-invasion of neoplastic stem cells in myeloid neoplasms. Semin Cancer Biol. 2020 Feb;60:191-201. doi: 10.1016/j.semcancer.2019.07.025. Epub 2019 Aug 10. PMID: 31408723; PMCID: PMC7115853.

134: Maurer B, Nivarthi H, Wingelhofer B, Pham HTT, Schlederer M, Suske T, Grausenburger R, Schiefer AI, Prchal-Murphy M, Chen D, Winkler S, Merkel O, Kornauth C, Hofbauer M, Hochgatterer B, Hoermann G, Hoelbl-Kovacic A, Prochazkova J, Lobello C, Cumaraswamy AA, Latzka J, Kitzwögerer M, Chott A, Janikova A, Pospíšilova Š, Loizou JI, Kubicek S, Valent P, Kolbe T, Grebien F, Kenner L, Gunning PT, Kralovics R, Herling M, Müller M, Rülicke T, Sexl V, Moriggl R. High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. Haematologica. 2020 Jan 31;105(2):435-447. doi: 10.3324/haematol.2019.216986. PMID: 31123029; PMCID: PMC7012494.

135: Greiner G, Gurbisz M, Ratzinger F, Witzeneder N, Class SV, Eisenwort G, Simonitsch-Klupp I, Esterbauer H, Mayerhofer M, Müllauer L, Sperr WR, Valent P, Hoermann G. Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis. Haematologica. 2020 Jan 31;105(2):366-374. doi: 10.3324/haematol.2019.217950. PMID: 31018976; PMCID: PMC7012478.

136: Valent P. KIT D816V and the cytokine storm in mastocytosis: production and role of interleukin-6. Haematologica. 2020 Jan;105(1):5-6. doi: 10.3324/haematol.2019.234864. PMID: 31894094; PMCID: PMC6939527.

137: Schneeweiss-Gleixner M, Byrgazov K, Stefanzl G, Berger D, Eisenwort G, Lucini CB, Herndlhofer S, Preuner S, Obrova K, Pusic P, Witzeneder N, Greiner G, Hoermann G, Sperr WR, Lion T, Deininger M, Valent P, Gleixner KV. CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR- ABL1^T315I+ clones in TKI-resistant CML. EBioMedicine. 2019 Dec;50:111-121. doi: 10.1016/j.ebiom.2019.11.004. Epub 2019 Nov 21. PMID: 31761618; PMCID: PMC6921367.

138: Sperr WR, Kundi M, Alvarez-Twose I, van Anrooij B, Oude Elberink JNG, Gorska A, Niedoszytko M, Gleixner KV, Hadzijusufovic E, Zanotti R, Bonadonna P, Bonifacio M, Perkins C, Illerhaus A, Elena C, Merante S, Shoumariyeh K, von Bubnoff N, Parente R, Jawhar M, Belloni Fortina A, Caroppo F, Brockow K, Zink A, Fuchs D, Kilbertus AJ, Yavuz AS, Doubek M, Hägglund H, Panse J, Sabato V, Bretterklieber A, Niederwieser D, Breynaert C, Hartmann K, Triggiani M, Nedoszytko B, Reiter A, Orfao A, Hermine O, Gotlib J, Arock M, Kluin-Nelemans HC, Valent P. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematol. 2019 Dec;6(12):e638-e649. doi: 10.1016/S2352-3026(19)30166-8. Epub 2019 Oct 31. PMID: 31676322; PMCID: PMC7115823.

139: Gamperl S, Stefanzl G, Peter B, Smiljkovic D, Bauer K, Willmann M, Valent P, Hadzijusufovic E. Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells. Vet Comp Oncol. 2019 Dec;17(4):553-561. doi: 10.1111/vco.12520. Epub 2019 Aug 13. PMID: 31286638; PMCID: PMC6900099.

140: Huang HJ, Curin M, Banerjee S, Chen KW, Garmatiuk T, Resch-Marat Y, Carvalho-Queiroz C, Blatt K, Gafvelin G, Grönlund H, Valent P, Campana R, Focke- Tejkl M, Valenta R, Vrtala S. A hypoallergenic peptide mix containing T cell epitopes of the clinically relevant house dust mite allergens. Allergy. 2019 Dec;74(12):2461-2478. doi: 10.1111/all.13956. Epub 2019 Oct 3. PMID: 31228873; PMCID: PMC7078969.

141: Jawhar M, Schwaab J, Álvarez-Twose I, Shoumariyeh K, Naumann N, Lübke J, Perkins C, Muñoz-González JI, Meggendorfer M, Kennedy V, Metzgeroth G, Fabarius A, Pfeifer D, Sotlar K, Horny HP, von Bubnoff N, Haferlach T, Cross NCP, Hofmann WK, Sperr WR, García-Montero AC, Valent P, Gotlib J, Orfao A, Reiter A. MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. J Clin Oncol. 2019 Nov 1;37(31):2846-2856. doi: 10.1200/JCO.19.00640. Epub 2019 Sep 11. PMID: 31509472; PMCID: PMC6823885.

142: Eisenwort G, Sadovnik I, Schwaab J, Jawhar M, Keller A, Stefanzl G, Berger D, Blatt K, Hoermann G, Bilban M, Willmann M, Winding C, Sperr WR, Arock M, Rülicke T, Reiter A, Valent P. Identification of a leukemia-initiating stem cell in human mast cell leukemia. Leukemia. 2019 Nov;33(11):2673-2684. doi: 10.1038/s41375-019-0460-6. Epub 2019 Apr 5. PMID: 30953030; PMCID: PMC6839966.

143: Menzl I, Zhang T, Berger-Becvar A, Grausenburger R, Heller G, Prchal-Murphy M, Edlinger L, Knab VM, Uras IZ, Grundschober E, Bauer K, Roth M, Skucha A, Liu Y, Hatcher JM, Liang Y, Kwiatkowski NP, Fux D, Hoelbl-Kovacic A, Kubicek S, Melo JV, Valent P, Weichhart T, Grebien F, Zuber J, Gray NS, Sexl V. A kinase- independent role for CDK8 in BCR-ABL1⁺ leukemia. Nat Commun. 2019 Oct 18;10(1):4741. doi: 10.1038/s41467-019-12656-x. PMID: 31628323; PMCID: PMC6802219.

144: Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA, Haase D, Haferlach T, Elena C, Pleyer L, Kern W, Pemovska T, Vladimer GI, Schanz J, Keller A, Lübbert M, Lion T, Sotlar K, Reiter A, De Witte T, Pfeilstöcker M, Geissler K, Padron E, Deininger M, Orfao A, Horny HP, Greenberg PL, Arber DA, Malcovati L, Bennett JM. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica. 2019 Oct;104(10):1935-1949. doi: 10.3324/haematol.2019.222059. Epub 2019 May 2. PMID: 31048353; PMCID: PMC6886439.

145: Geissler K, Jäger E, Barna A, Gurbisz M, Marschon R, Graf T, Graf E, Borjan B, Jilch R, Geissler C, Hoermann G, Esterbauer H, Schwarzinger I, Nösslinger T, Pfeilstöcker M, Tüchler H, Reisner R, Sliwa T, Keil F, Bettelheim P, Machherndl- Spandl S, Doleschal B, Zach O, Weltermann A, Heibl S, Thaler J, Zebisch A, Sill H, Stauder R, Webersinke G, Petzer A, Kusec R, Ulsperger E, Schneeweiss B, Berger J, Öhler L, Germing U, Sperr WR, Knöbl P, Jäger U, Valent P. The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) : A representative and useful real-life data source for further biomedical research. Wien Klin Wochenschr. 2019 Sep;131(17-18):410-418. doi: 10.1007/s00508-019-1526-1. Epub 2019 Jul 18. PMID: 31321531; PMCID: PMC6748886.

146: Valent P, Sadovnik I, Eisenwort G, Bauer K, Herrmann H, Gleixner KV, Schulenburg A, Rabitsch W, Sperr WR, Wolf D. Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML. Int J Mol Sci. 2019 Aug 29;20(17):4233. doi: 10.3390/ijms20174233. PMID: 31470642; PMCID: PMC6747233.

147: Mughal TI, Pemmaraju N, Radich JP, Deininger MW, Kucine N, Kiladjian JJ, Bose P, Gotlib J, Valent P, Chen CC, Barbui T, Rampal R, Verstovsek S, Koschmieder S, Saglio G, Van Etten RA. Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. Hematol Oncol. 2019 Aug;37(3):240-252. doi: 10.1002/hon.2622. Epub 2019 Jun 20. PMID: 31013548.

148: Schmidt L, Heyes E, Scheiblecker L, Eder T, Volpe G, Frampton J, Nerlov C, Valent P, Grembecka J, Grebien F. CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex. Leukemia. 2019 Jul;33(7):1608-1619. doi: 10.1038/s41375-019-0382-3. Epub 2019 Jan 24. PMID: 30679799; PMCID: PMC6612510.

149: Kollmann S, Grundschober E, Maurer B, Warsch W, Grausenburger R, Edlinger L, Huuhtanen J, Lagger S, Hennighausen L, Valent P, Decker T, Strobl B, Mueller M, Mustjoki S, Hoelbl-Kovacic A, Sexl V. Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia. Leukemia. 2019 Jul;33(7):1583-1597. doi: 10.1038/s41375-018-0369-5. Epub 2019 Jan 24. PMID: 30679796; PMCID: PMC6755975.

150: Valent P, Akin C, Gleixner KV, Sperr WR, Reiter A, Arock M, Triggiani M. Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches. Int J Mol Sci. 2019 Jun 18;20(12):2976. doi: 10.3390/ijms20122976. PMID: 31216696; PMCID: PMC6627900.

151: Jawhar M, Döhner K, Kreil S, Schwaab J, Shoumariyeh K, Meggendorfer M, Span LLF, Fuhrmann S, Naumann N, Horny HP, Sotlar K, Kubuschok B, von Bubnoff N, Spiekermann K, Heuser M, Metzgeroth G, Fabarius A, Klein S, Hofmann WK, Kluin- Nelemans HC, Haferlach T, Döhner H, Cross NCP, Sperr WR, Valent P, Reiter A. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. Leukemia. 2019 May;33(5):1124-1134. doi: 10.1038/s41375-018-0346-z. Epub 2019 Jan 11. PMID: 30635631; PMCID: PMC6756067.

152: Uras IZ, Maurer B, Nivarthi H, Jodl P, Kollmann K, Prchal-Murphy M, Milosevic Feenstra JD, Zojer M, Lagger S, Grausenburger R, Grabner B, Holly R, Kavirayani A, Bock C, Gisslinger H, Valent P, Kralovics R, Sexl V. CDK6 coordinates <i>JAK2</i>^V617F mutant MPN via NF-κB and apoptotic networks. Blood. 2019 Apr 11;133(15):1677-1690. doi: 10.1182/blood-2018-08-872648. Epub 2019 Jan 11. PMID: 30635286; PMCID: PMC6543514.

153: Valent P, Akin C. Doctor, I Think I Am Suffering from MCAS: Differential Diagnosis and Separating Facts from Fiction. J Allergy Clin Immunol Pract. 2019 Apr;7(4):1109-1114. doi: 10.1016/j.jaip.2018.11.045. PMID: 30961836.

154: Valent P, Akin C, Bonadonna P, Hartmann K, Brockow K, Niedoszytko M, Nedoszytko B, Siebenhaar F, Sperr WR, Oude Elberink JNG, Butterfield JH, Alvarez-Twose I, Sotlar K, Reiter A, Kluin-Nelemans HC, Hermine O, Gotlib J, Broesby-Olsen S, Orfao A, Horny HP, Triggiani M, Arock M, Schwartz LB, Metcalfe DD. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. J Allergy Clin Immunol Pract. 2019 Apr;7(4):1125-1133.e1. doi: 10.1016/j.jaip.2019.01.006. Epub 2019 Feb 5. PMID: 30737190; PMCID: PMC6643056.

155: Nieborowska-Skorska M, Maifrede S, Ye M, Toma M, Hewlett E, Gordon J, Le BV, Sliwinski T, Zhao H, Piwocka K, Valent P, Tulin AV, Childers W, Skorski T. Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia. Leuk Lymphoma. 2019 Apr;60(4):1098-1101. doi: 10.1080/10428194.2018.1520988. Epub 2018 Oct 2. PMID: 30277116; PMCID: PMC6445778.

156: Russell N, Jennings S, Jennings B, Slee V, Sterling L, Castells M, Valent P, Akin C. The Mastocytosis Society Survey on Mast Cell Disorders: Part 2-Patient Clinical Experiences and Beyond. J Allergy Clin Immunol Pract. 2019 Apr;7(4):1157-1165.e6. doi: 10.1016/j.jaip.2018.07.032. Epub 2018 Aug 8. PMID: 30098409.

157: Najafi N, Hofer G, Gattinger P, Smiljkovic D, Blatt K, Selb R, Stoecklinger A, Keller W, Valent P, Niederberger V, Thalhamer J, Valenta R, Flicker S. Fusion proteins consisting of Bet v 1 and Phl p 5 form IgE-reactive aggregates with reduced allergenic activity. Sci Rep. 2019 Mar 8;9(1):4006. doi: 10.1038/s41598-019-39798-8. PMID: 30850635; PMCID: PMC6408504.

158: Gleixner KV, Sadovnik I, Schneeweiss M, Eisenwort G, Byrgazov K, Stefanzl G, Berger D, Herrmann H, Hadzijusufovic E, Lion T, Valent P. A kinase profile- adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1^T315I in Ph+ CML. Leuk Res. 2019 Mar;78:36-44. doi: 10.1016/j.leukres.2018.12.013. Epub 2018 Dec 28. PMID: 30711891; PMCID: PMC6834439.

159: Boehm T, Reiter B, Ristl R, Petroczi K, Sperr W, Stimpfl T, Valent P, Jilma B. Massive release of the histamine-degrading enzyme diamine oxidase during severe anaphylaxis in mastocytosis patients. Allergy. 2019 Mar;74(3):583-593. doi: 10.1111/all.13663. Epub 2019 Jan 1. PMID: 30418682; PMCID: PMC6590243.

160: Willmann M, Hadzijusufovic E, Hermine O, Dacasto M, Marconato L, Bauer K, Peter B, Gamperl S, Eisenwort G, Jensen-Jarolim E, Müller M, Arock M, Vail DM, Valent P. Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms. Vet Comp Oncol. 2019 Mar;17(1):1-10. doi: 10.1111/vco.12440. Epub 2018 Sep 24. PMID: 30136349; PMCID: PMC6378619.

161: Valent P, Kern W, Hoermann G, Milosevic Feenstra JD, Sotlar K, Pfeilstöcker M, Germing U, Sperr WR, Reiter A, Wolf D, Arock M, Haferlach T, Horny HP. Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML. Int J Mol Sci. 2019 Feb 12;20(3):789. doi: 10.3390/ijms20030789. PMID: 30759825; PMCID: PMC6387423.

162: Neukirchen-Strapatsas J, Tuechler H, Porta MD, Fenaux P, Guerci A, Haas R, Rossi M, Sapena R, Sperr WR, Strupp C, Stamatoullas A, Valent P, Germing U, Bennett JM. Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes. Leuk Res. 2019 Feb;77:8-13. doi: 10.1016/j.leukres.2018.12.012. Epub 2018 Dec 28. PMID: 30605856.

163: Valent P, Bonadonna P, Hartmann K, Broesby-Olsen S, Brockow K, Butterfield JH, Triggiani M, Lyons JJ, Oude Elberink JNG, Arock M, Metcalfe DD, Akin C. Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome. Int Arch Allergy Immunol. 2019;180(1):44-51. doi: 10.1159/000501079. Epub 2019 Jun 28. PMID: 31256161; PMCID: PMC7115850.

164: Valent P, Oude Elberink JNG, Gorska A, Lange M, Zanotti R, van Anrooij B, Bonifacio M, Bonadonna P, Gleixner KV, Hadzijusufovic E, Perkins C, Hartmann K, Illerhaus A, Merante S, Elena C, Shoumariyeh K, von Bubnoff N, Parente R, Triggiani M, Schwaab J, Jawhar M, Caroppo F, Fortina AB, Brockow K, David Fuchs, Greul R, Yavuz AS, Doubek M, Mattsson M, Hagglund H, Panse J, Sabato V, Aberer E, Al-Ali HK, Morren MA, Varkonyi J, Zink A, Niedoszytko M, Niederwieser D, Malcovati L, Reiter A, Kennedy V, Gotlib J, Lortholary O, Hermine O, Arock M, Kluin-Nelemans H, Sperr WR; Study Group of the European Competence Network on Mastocytosis (ECNM). The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. J Allergy Clin Immunol Pract. 2019 Jan;7(1):81-87. doi: 10.1016/j.jaip.2018.09.024. Epub 2018 Nov 8. PMID: 30416055; PMCID: PMC7115815.

165: Valent P. ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications. Pathobiology. 2019;86(1):30-38. doi: 10.1159/000489042. Epub 2018 Jun 1. PMID: 29860246; PMCID: PMC7115849.

166: Uras IZ, Maurer B, Nebenfuehr S, Zojer M, Valent P, Sexl V. Therapeutic Vulnerabilities in <i>FLT3</i>-Mutant AML Unmasked by Palbociclib. Int J Mol Sci. 2018 Dec 11;19(12):3987. doi: 10.3390/ijms19123987. PMID: 30544932; PMCID: PMC6321303.

167: Schanz J, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance. Genes Chromosomes Cancer. 2018 Nov;57(11):547-556. doi: 10.1002/gcc.22667. Epub 2018 Sep 24. PMID: 30248204.

168: Merante S, Ferretti VV, Elena C, Brazzelli V, Zanotti R, Neri I, Magliacane D, Belloni Fortina A, Ingeborg F, Pastorello EA, Pieri L, Papayannidis C, Mauro M, Grifoni F, Minelli R, Guggiari E, Difonzo E, Bocchia M, Caroppo F, Di Nuzzo S, Elli EM, Rondoni M, Ciccocioppo R, Di Stefano M, Bossi G, Boveri E, Bonadonna P, Giona F, Valent P, Triggiani M. The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry. Future Oncol. 2018 Nov;14(26):2713-2723. doi: 10.2217/fon-2018-0291. Epub 2018 Sep 12. PMID: 30207489.

169: Mueller N, Wicklein D, Eisenwort G, Jawhar M, Berger D, Stefanzl G, Greiner G, Boehm A, Kornauth C, Muellauer L, Sehner S, Hoermann G, Sperr WR, Staber PB, Jaeger U, Zuber J, Arock M, Schumacher U, Reiter A, Valent P. CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis. Blood. 2018 Nov 1;132(18):1936-1950. doi: 10.1182/blood-2018-02-833582. Epub 2018 Jul 17. PMID: 30018080; PMCID: PMC6382065.

170: Arock M, Wedeh G, Hoermann G, Bibi S, Akin C, Peter B, Gleixner KV, Hartmann K, Butterfield JH, Metcalfe DD, Valent P. Preclinical human models and emerging therapeutics for advanced systemic mastocytosis. Haematologica. 2018 Nov;103(11):1760-1771. doi: 10.3324/haematol.2018.195867. Epub 2018 Jul 5. PMID: 29976735; PMCID: PMC6278969.

171: Miyazaki Y, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Santini V, Lübbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SMM, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL. Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. Leuk Res. 2018 Oct;73:51-57. doi: 10.1016/j.leukres.2018.08.022. Epub 2018 Sep 6. PMID: 30219650.

172: Valent P, Büsche G, Theurl I, Uras IZ, Germing U, Stauder R, Sotlar K, Füreder W, Bettelheim P, Pfeilstöcker M, Oberbauer R, Sperr WR, Geissler K, Schwaller J, Moriggl R, Béné MC, Jäger U, Horny HP, Hermine O. Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts. Haematologica. 2018 Oct;103(10):1593-1603. doi: 10.3324/haematol.2018.192518. Epub 2018 Aug 3. PMID: 30076180; PMCID: PMC6165792.

173: Valent P, Horny HP, Arock M. The underestimated role of basophils in Ph⁺ chronic myeloid leukaemia. Eur J Clin Invest. 2018 Oct;48(10):e13000. doi: 10.1111/eci.13000. Epub 2018 Aug 6. PMID: 30019447; PMCID: PMC6175372.

174: Ustun C, Morgan E, Moodie EEM, Pullarkat S, Yeung C, Broesby-Olsen S, Ohgami R, Kim Y, Sperr W, Vestergaard H, Chen D, Kluin PM, Dolan M, Mrózek K, Czuchlewski D, Horny HP, George TI, Kristensen TK, Ku NK, Yi CA, Møller MB, Marcucci G, Baughn L, Schiefer AI, Hilberink JR, Pullarkat V, Shanley R, Kohlschmidt J, Coulombe J, Salhotra A, Soma L, Cho C, Linden MA, Akin C, Gotlib J, Hoermann G, Hornick J, Nakamura R, Deeg J, Bloomfield CD, Weisdorf D, Litzow MR, Valent P, Huls G, Perales MA, Borthakur G. Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit). Cancer Med. 2018 Sep;7(9):4447-4455. doi: 10.1002/cam4.1733. Epub 2018 Aug 16. PMID: 30117318; PMCID: PMC6144246.

175: Kaivers J, Lauseker M, Hildebrandt B, Fenaux P, Pfeilstöcker M, Valent P, Platzbecker U, Latagliata R, Oliva EN, Xicoy B, Götze K, Ganster C, Haase D, Bug G, Kündgen A, Gattermann N, Haas R, Germing U. The IPSS-R has prognostic impact in untreated patients with MDS del(5q). Leuk Res. 2018 Sep;72:27-33. doi: 10.1016/j.leukres.2018.07.019. Epub 2018 Jul 23. PMID: 30075323.

176: Valent P, Hadzijusufovic E, Grunt T, Karlic H, Peter B, Herrmann H, Eisenwort G, Hoermann G, Schulenburg A, Willmann M, Hubmann R, Shehata M, Selzer E, Gleixner KV, Rülicke T, Sperr WR, Marian B, Pfeilstöcker M, Pehamberger H, Keil F, Jäger U, Zielinski C. Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives. Wien Klin Wochenschr. 2018 Sep;130(17-18):517-529. doi: 10.1007/s00508-018-1355-7. Epub 2018 Jul 13. PMID: 30006759; PMCID: PMC6132878.

177: Valent P, Akin C, Bonadonna P, Hartmann K, Broesby-Olsen S, Brockow K, Butterfield JH, Reiter A, Gotlib J, Castells M, Milner JD, Carter MC, Komarow H, Radia D, Pardanani A, Sotlar K, Triggiani M, Horny HP, Arock M, Schwartz LB, Metcalfe DD. Mast cell activation syndrome: Importance of consensus criteria and call for research. J Allergy Clin Immunol. 2018 Sep;142(3):1008-1010. doi: 10.1016/j.jaci.2018.06.004. Epub 2018 Jun 19. PMID: 29928922; PMCID: PMC7115848.

178: Porpaczy E, Tripolt S, Hoelbl-Kovacic A, Gisslinger B, Bago-Horvath Z, Casanova-Hevia E, Clappier E, Decker T, Fajmann S, Fux DA, Greiner G, Gueltekin S, Heller G, Herkner H, Hoermann G, Kiladjian JJ, Kolbe T, Kornauth C, Krauth MT, Kralovics R, Muellauer L, Mueller M, Prchal-Murphy M, Putz EM, Raffoux E, Schiefer AI, Schmetterer K, Schneckenleithner C, Simonitsch-Klupp I, Skrabs C, Sperr WR, Staber PB, Strobl B, Valent P, Jaeger U, Gisslinger H, Sexl V. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood. 2018 Aug 16;132(7):694-706. doi: 10.1182/blood-2017-10-810739. Epub 2018 Jun 14. Erratum in: Blood. 2019 Feb 14;133(7):768. PMID: 29907599; PMCID: PMC7115916.

179: Wingelhofer B, Neubauer HA, Valent P, Han X, Constantinescu SN, Gunning PT, Müller M, Moriggl R. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. Leukemia. 2018 Aug;32(8):1713-1726. doi: 10.1038/s41375-018-0117-x. Epub 2018 Mar 27. PMID: 29728695; PMCID: PMC6087715.

180: Füreder W, Sperr WR, Gleixner K, Thalhammer R, Schwarzinger I, Hoermann G, Kornauth C, Grünberger B, Valent P. Major response of PNH to an AML chemotherapy protocol. Ann Hematol. 2018 Aug;97(8):1487-1488. doi: 10.1007/s00277-018-3307-8. Epub 2018 Mar 22. PMID: 29568989.

181: Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, Jelinek J, Piwocka K, Sliwinski T, Stoklosa T, Ploski R, Fischer T, Sykes SM, Koschmieder S, Bullinger L, Valent P, Wasik MA, Huang J, Skorski T. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. Blood. 2018 Jul 5;132(1):67-77. doi: 10.1182/blood-2018-02-834895. Epub 2018 May 21. PMID: 29784639; PMCID: PMC6034642.

182: Gadermaier E, Marth K, Lupinek C, Campana R, Hofer G, Blatt K, Smiljkovic D, Roder U, Focke-Tejkl M, Vrtala S, Keller W, Valent P, Valenta R, Flicker S. Isolation of a high-affinity Bet v 1-specific IgG-derived ScFv from a subject vaccinated with hypoallergenic Bet v 1 fragments. Allergy. 2018 Jul;73(7):1425-1435. doi: 10.1111/all.13394. Epub 2018 Feb 20. PMID: 29315611; PMCID: PMC6032869.

183: Sullivan-Reed K, Bolton-Gillespie E, Dasgupta Y, Langer S, Siciliano M, Nieborowska-Skorska M, Hanamshet K, Belyaeva EA, Bernhardy AJ, Lee J, Moore M, Zhao H, Valent P, Matlawska-Wasowska K, Müschen M, Bhatia S, Bhatia R, Johnson N, Wasik MA, Mazin AV, Skorski T. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. Cell Rep. 2018 Jun 12;23(11):3127-3136. doi: 10.1016/j.celrep.2018.05.034. PMID: 29898385; PMCID: PMC6082171.

184: Blatt K, Menzl I, Eisenwort G, Cerny-Reiterer S, Herrmann H, Herndlhofer S, Stefanzl G, Sadovnik I, Berger D, Keller A, Hauswirth A, Hoermann G, Willmann M, Rülicke T, Sill H, Sperr WR, Mannhalter C, Melo JV, Jäger U, Sexl V, Valent P. Phenotyping and Target Expression Profiling of CD34⁺/CD38^- and CD34⁺/CD38⁺ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia. Neoplasia. 2018 Jun;20(6):632-642. doi: 10.1016/j.neo.2018.04.004. Epub 2018 May 15. PMID: 29772458; PMCID: PMC5994777.

185: Bauer K, Berger D, Zielinski CC, Valent P, Grunt TW. Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells. Oncotarget. 2018 May 29;9(41):26491-26506. doi: 10.18632/oncotarget.25474. PMID: 29899872; PMCID: PMC5995173.

186: Skucha A, Ebner J, Schmöllerl J, Roth M, Eder T, César-Razquin A, Stukalov A, Vittori S, Muhar M, Lu B, Aichinger M, Jude J, Müller AC, Győrffy B, Vakoc CR, Valent P, Bennett KL, Zuber J, Superti-Furga G, Grebien F. MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. Nat Commun. 2018 May 18;9(1):1983. doi: 10.1038/s41467-018-04329-y. PMID: 29777171; PMCID: PMC5959866.

187: Wingelhofer B, Maurer B, Heyes EC, Cumaraswamy AA, Berger-Becvar A, de Araujo ED, Orlova A, Freund P, Ruge F, Park J, Tin G, Ahmar S, Lardeau CH, Sadovnik I, Bajusz D, Keserű GM, Grebien F, Kubicek S, Valent P, Gunning PT, Moriggl R. Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia. 2018 May;32(5):1135-1146. doi: 10.1038/s41375-017-0005-9. Epub 2018 Feb 2. PMID: 29472718; PMCID: PMC5940656.

188: Schneeweiss M, Peter B, Bibi S, Eisenwort G, Smiljkovic D, Blatt K, Jawhar M, Berger D, Stefanzl G, Herndlhofer S, Greiner G, Hoermann G, Hadzijusufovic E, Gleixner KV, Bettelheim P, Geissler K, Sperr WR, Reiter A, Arock M, Valent P. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. Haematologica. 2018 May;103(5):799-809. doi: 10.3324/haematol.2017.179895. Epub 2018 Feb 8. PMID: 29439183; PMCID: PMC5927976.

189: Naumann N, Jawhar M, Schwaab J, Kluger S, Lübke J, Metzgeroth G, Popp HD, Khaled N, Horny HP, Sotlar K, Valent P, Haferlach C, Göhring G, Schlegelberger B, Meggendorfer M, Hofmann WK, Cross NCP, Reiter A, Fabarius A. Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis. Genes Chromosomes Cancer. 2018 May;57(5):252-259. doi: 10.1002/gcc.22526. Epub 2018 Feb 19. PMID: 29341334.

190: Eckl-Dorna J, Fröschl R, Lupinek C, Kiss R, Gattinger P, Marth K, Campana R, Mittermann I, Blatt K, Valent P, Selb R, Mayer A, Gangl K, Steiner I, Gamper J, Perkmann T, Zieglmayer P, Gevaert P, Valenta R, Niederberger V. Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels-A pilot study. Allergy. 2018 May;73(5):1003-1012. doi: 10.1111/all.13343. Epub 2017 Dec 12. PMID: 29083477; PMCID: PMC5969304.

191: Burgstaller S, Stauder R, Kuehr T, Lang A, Machherndl-Spandl S, Mayrbaeurl B, Noesslinger T, Petzer A, Valent P, Greil R, Thaler J. A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1. Leuk Lymphoma. 2018 May;59(5):1121-1126. doi: 10.1080/10428194.2017.1369070. Epub 2017 Aug 30. PMID: 28853315.

192: Peter B, Bibi S, Eisenwort G, Wingelhofer B, Berger D, Stefanzl G, Blatt K, Herrmann H, Hadzijusufovic E, Hoermann G, Hoffmann T, Schwaab J, Jawhar M, Willmann M, Sperr WR, Zuber J, Sotlar K, Horny HP, Moriggl R, Reiter A, Arock M, Valent P. Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells. Leukemia. 2018 Apr;32(4):1016-1022. doi: 10.1038/leu.2017.338. Epub 2017 Nov 29. PMID: 29249817; PMCID: PMC6037300.

193: Demyanets S, Jaeger E, Pablik E, Greiner G, Herndlhofer S, Valent P, Schwarzinger I. The JAK2 blocker TG101209 is a potent inhibitor of clonogenic progenitor cell growth in patients with chronic myeloid leukaemia. Br J Haematol. 2018 Apr;181(1):137-139. doi: 10.1111/bjh.14508. Epub 2017 Feb 21. PMID: 28220937.

194: Greiner G, Gurbisz M, Ratzinger F, Witzeneder N, Simonitsch-Klupp I, Mitterbauer-Hohendanner G, Mayerhofer M, Müllauer L, Sperr WR, Valent P, Hoermann G. Digital PCR: A Sensitive and Precise Method for <i>KIT</i> D816V Quantification in Mastocytosis. Clin Chem. 2018 Mar;64(3):547-555. doi: 10.1373/clinchem.2017.277897. Epub 2017 Dec 13. PMID: 29237714; PMCID: PMC7115889.

195: Keller A, Wingelhofer B, Peter B, Bauer K, Berger D, Gamperl S, Reifinger M, Cerny-Reiterer S, Moriggl R, Willmann M, Valent P, Hadzijusufovic E. The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma. Vet Comp Oncol. 2018 Mar;16(1):55-68. doi: 10.1111/vco.12311. Epub 2017 Apr 11. Erratum in: Vet Comp Oncol. 2019 Sep;17(3):446-447. PMID: 28397975; PMCID: PMC5824979.

196: Hatch EW, Geeze MB, Martin C, Salama ME, Hartmann K, Eisenwort G, Blatt K, Valent P, Gotlib J, Lee JH, Chen L, Ward HH, Lidke DS, George TI. Variability of PD-L1 expression in mastocytosis. Blood Adv. 2018 Feb 13;2(3):189-199. doi: 10.1182/bloodadvances.2017011551. PMID: 29378725; PMCID: PMC5812326.

197: Valent P, Stauder R, Theurl I, Geissler K, Sliwa T, Sperr WR, Bettelheim P, Sill H, Pfeilstöcker M. Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform. Expert Rev Hematol. 2018 Feb;11(2):109-116. doi: 10.1080/17474086.2018.1420473. Epub 2018 Jan 2. PMID: 29292655.

198: Stauder R, Valent P, Theurl I. Anemia at older age: etiologies, clinical implications, and management. Blood. 2018 Feb 1;131(5):505-514. doi: 10.1182/blood-2017-07-746446. Epub 2017 Nov 15. PMID: 29141943.

199: Pham HTT, Maurer B, Prchal-Murphy M, Grausenburger R, Grundschober E, Javaheri T, Nivarthi H, Boersma A, Kolbe T, Elabd M, Halbritter F, Pencik J, Kazemi Z, Grebien F, Hengstschläger M, Kenner L, Kubicek S, Farlik M, Bock C, Valent P, Müller M, Rülicke T, Sexl V, Moriggl R. STAT5BN642H is a driver mutation for T cell neoplasia. J Clin Invest. 2018 Jan 2;128(1):387-401. doi: 10.1172/JCI94509. Epub 2017 Dec 4. PMID: 29200404; PMCID: PMC5749501.

200: Valenta R, Karaulov A, Niederberger V, Gattinger P, van Hage M, Flicker S, Linhart B, Campana R, Focke-Tejkl M, Curin M, Eckl-Dorna J, Lupinek C, Resch- Marat Y, Vrtala S, Mittermann I, Garib V, Khaitov M, Valent P, Pickl WF. Molecular Aspects of Allergens and Allergy. Adv Immunol. 2018;138:195-256. doi: 10.1016/bs.ai.2018.03.002. Epub 2018 Apr 26. PMID: 29731005.

201: Orlova A, Wingelhofer B, Neubauer HA, Maurer B, Berger-Becvar A, Keserű GM, Gunning PT, Valent P, Moriggl R. Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas. Expert Opin Ther Targets. 2018 Jan;22(1):45-57. doi: 10.1080/14728222.2018.1406924. Epub 2017 Nov 24. PMID: 29148847; PMCID: PMC5743003.

202: Willmann M, Sadovnik I, Eisenwort G, Entner M, Bernthaler T, Stefanzl G, Hadzijusufovic E, Berger D, Herrmann H, Hoermann G, Valent P, Rülicke T. Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph⁺ chronic myeloid leukemia. Exp Hematol. 2018 Jan;57:50-59.e6. doi: 10.1016/j.exphem.2017.09.012. Epub 2017 Oct 12. PMID: 29031704; PMCID: PMC7115814.

203: Byrgazov K, Lucini CB, Valent P, Hantschel O, Lion T. BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib. Haematologica. 2018 Jan;103(1):e10-e12. doi: 10.3324/haematol.2017.176347. Epub 2017 Oct 5. PMID: 28983061; PMCID: PMC5777206.

204: Martinelli G, Mancini M, De Benedittis C, Rondoni M, Papayannidis C, Manfrini M, Meggendorfer M, Calogero R, Guadagnuolo V, Fontana MC, Bavaro L, Padella A, Zago E, Pagano L, Zanotti R, Scaffidi L, Specchia G, Albano F, Merante S, Elena C, Savini P, Gangemi D, Tosi P, Ciceri F, Poletti G, Riccioni L, Morigi F, Delledonne M, Haferlach T, Cavo M, Valent P, Soverini S. SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis. Leukemia. 2018 Jan;32(1):139-148. doi: 10.1038/leu.2017.183. Epub 2017 Jun 16. PMID: 28663576; PMCID: PMC5770597.

205: Boidol B, Kornauth C, van der Kouwe E, Prutsch N, Kazianka L, Gültekin S, Hoermann G, Mayerhoefer ME, Hopfinger G, Hauswirth A, Panny M, Aretin MB, Hilgarth B, Sperr WR, Valent P, Simonitsch-Klupp I, Moriggl R, Merkel O, Kenner L, Jäger U, Kubicek S, Staber PB. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. Blood. 2017 Dec 7;130(23):2499-2503. doi: 10.1182/blood-2017-05-785683. Epub 2017 Sep 27. PMID: 28972014.

206: Valent P, Akin C, Arock M, Bock C, George TI, Galli SJ, Gotlib J, Haferlach T, Hoermann G, Hermine O, Jäger U, Kenner L, Kreipe H, Majeti R, Metcalfe DD, Orfao A, Reiter A, Sperr WR, Staber PB, Sotlar K, Schiffer C, Superti-Furga G, Horny HP. Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. EBioMedicine. 2017 Dec;26:17-24. doi: 10.1016/j.ebiom.2017.11.024. Epub 2017 Nov 26. PMID: 29203377; PMCID: PMC5832623.

207: Snijder B, Vladimer GI, Krall N, Miura K, Schmolke AS, Kornauth C, Lopez de la Fuente O, Choi HS, van der Kouwe E, Gültekin S, Kazianka L, Bigenzahn JW, Hoermann G, Prutsch N, Merkel O, Ringler A, Sabler M, Jeryczynski G, Mayerhoefer ME, Simonitsch-Klupp I, Ocko K, Felberbauer F, Müllauer L, Prager GW, Korkmaz B, Kenner L, Sperr WR, Kralovics R, Gisslinger H, Valent P, Kubicek S, Jäger U, Staber PB, Superti-Furga G. Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open- label, pilot study. Lancet Haematol. 2017 Dec;4(12):e595-e606. doi: 10.1016/S2352-3026(17)30208-9. Epub 2017 Nov 15. PMID: 29153976; PMCID: PMC5719985.

208: Bauer K, Hadzijusufovic E, Cerny-Reiterer S, Hoermann G, Reifinger M, Pirker A, Valent P, Willmann M. IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells. Vet Comp Oncol. 2017 Dec;15(4):1240-1256. doi: 10.1111/vco.12260. Epub 2016 Aug 9. PMID: 27507155; PMCID: PMC5798577.

209: Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F, Eisenwort G, Schgoer W, Herndlhofer S, Kaun C, Theurl M, Sperr WR, Rix U, Sadovnik I, Jilma B, Schernthaner GH, Wojta J, Wolf D, Superti-Furga G, Kirchmair R, Valent P. Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. Leukemia. 2017 Nov;31(11):2388-2397. doi: 10.1038/leu.2017.245. Epub 2017 Jul 31. PMID: 28757617; PMCID: PMC5669463.

210: Smiljkovic D, Blatt K, Stefanzl G, Dorofeeva Y, Skrabs C, Focke-Tejkl M, Sperr WR, Jaeger U, Valenta R, Valent P. BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils. Allergy. 2017 Nov;72(11):1666-1676. doi: 10.1111/all.13166. Epub 2017 Apr 20. PMID: 28328081; PMCID: PMC5655929.

211: Valent P, Akin C, Hartmann K, George TI, Sotlar K, Peter B, Gleixner KV, Blatt K, Sperr WR, Manley PW, Hermine O, Kluin-Nelemans HC, Arock M, Horny HP, Reiter A, Gotlib J. Midostaurin: a magic bullet that blocks mast cell expansion and activation. Ann Oncol. 2017 Oct 1;28(10):2367-2376. doi: 10.1093/annonc/mdx290. PMID: 28945834; PMCID: PMC7115852.

212: Sperr WR, Herndlhofer S, Gleixner K, Girschikofsky M, Weltermann A, Machherndl-Spandl S, Sliwa T, Poehnl R, Buxhofer-Ausch V, Strecker K, Hoermann G, Knoebl P, Jaeger U, Geissler K, Kundi M, Valent P. Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years. Am J Hematol. 2017 Oct;92(10):E567-E574. doi: 10.1002/ajh.24847. Epub 2017 Aug 17. PMID: 28699225; PMCID: PMC7115890.

213: Freund P, Kerenyi MA, Hager M, Wagner T, Wingelhofer B, Pham HTT, Elabd M, Han X, Valent P, Gouilleux F, Sexl V, Krämer OH, Groner B, Moriggl R. O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies. Leukemia. 2017 Oct;31(10):2132-2142. doi: 10.1038/leu.2017.4. Epub 2017 Jan 11. PMID: 28074064; PMCID: PMC5629373.

214: Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L, van de Loosdrecht AA, Haferlach T, Westers TM, Wells DA, Giagounidis A, Loken M, Orfao A, Lübbert M, Ganser A, Hofmann WK, Ogata K, Schanz J, Béné MC, Hoermann G, Sperr WR, Sotlar K, Bettelheim P, Stauder R, Pfeilstöcker M, Horny HP, Germing U, Greenberg P, Bennett JM. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017 Jul 5;8(43):73483-73500. doi: 10.18632/oncotarget.19008. PMID: 29088721; PMCID: PMC5650276.

215: Stefanzl G, Berger D, Cerny-Reiterer S, Blatt K, Eisenwort G, Sperr WR, Hoermann G, Lind K, Hauswirth AW, Bettelheim P, Sill H, Melo JV, Jäger U, Valent P. The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells. Oncotarget. 2017 Jun 28;8(40):67709-67722. doi: 10.18632/oncotarget.18810. PMID: 28978065; PMCID: PMC5620205.

216: Hoebaus C, Yussuf SM, Valent P, Schernthaner GH. Peripheral arterial disease outcomes and association with suPAR: A bridge to myeloid precursors or mast cells or both? Atherosclerosis. 2017 Sep;264:77-78. doi: 10.1016/j.atherosclerosis.2017.07.007. Epub 2017 Jul 8. PMID: 28724499.

217: Gleixner KV, Schneeweiss M, Eisenwort G, Berger D, Herrmann H, Blatt K, Greiner G, Byrgazov K, Hoermann G, Konopleva M, Waliul I, Cumaraswamy AA, Gunning PT, Maeda H, Moriggl R, Deininger M, Lion T, Andreeff M, Valent P. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. Haematologica. 2017 Sep;102(9):1519-1529. doi: 10.3324/haematol.2016.163436. Epub 2017 Jun 8. PMID: 28596283; PMCID: PMC5685220.

218: Valent P, Hadzijusufovic E, Hoermann G, Füreder W, Schernthaner GH, Sperr WR, Kirchmair R, Wolf D. Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leuk Res. 2017 Aug;59:47-54. doi: 10.1016/j.leukres.2017.05.008. Epub 2017 May 12. PMID: 28549238; PMCID: PMC7115818.

219: Jawhar M, Schwaab J, Naumann N, Horny HP, Sotlar K, Haferlach T, Metzgeroth G, Fabarius A, Valent P, Hofmann WK, Cross NCP, Meggendorfer M, Reiter A. Response and progression on midostaurin in advanced systemic mastocytosis: <i>KIT</i> D816V and other molecular markers. Blood. 2017 Jul 13;130(2):137-145. doi: 10.1182/blood-2017-01-764423. Epub 2017 Apr 19. PMID: 28424161.

220: Hubmann R, Sieghart W, Schnabl S, Araghi M, Hilgarth M, Reiter M, Demirtas D, Valent P, Zielinski C, Jäger U, Shehata M. Gliotoxin Targets Nuclear NOTCH2 in Human Solid Tumor Derived Cell Lines <i>In Vitro</i> and Inhibits Melanoma Growth in Xenograft Mouse Model. Front Pharmacol. 2017 Jul 7;8:319. doi: 10.3389/fphar.2017.00319. PMID: 28736522; PMCID: PMC5500618.

221: Sadovnik I, Herrmann H, Eisenwort G, Blatt K, Hoermann G, Mueller N, Sperr WR, Valent P. Expression of CD25 on leukemic stem cells in BCR-ABL1⁺ CML: Potential diagnostic value and functional implications. Exp Hematol. 2017 Jul;51:17-24. doi: 10.1016/j.exphem.2017.04.003. Epub 2017 Apr 27. PMID: 28457753; PMCID: PMC6044418.

222: Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer- Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JC, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T. Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. J Clin Invest. 2017 Jun 1;127(6):2392-2406. doi: 10.1172/JCI90825. Epub 2017 May 8. PMID: 28481221; PMCID: PMC5451241.

223: Jawhar M, Schwaab J, Meggendorfer M, Naumann N, Horny HP, Sotlar K, Haferlach T, Schmitt K, Fabarius A, Valent P, Hofmann WK, Cross NCP, Metzgeroth G, Reiter A. The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. Haematologica. 2017 Jun;102(6):1035-1043. doi: 10.3324/haematol.2017.163964. Epub 2017 Mar 2. PMID: 28255023; PMCID: PMC5451335.

224: Füreder W, Cerny-Reiterer S, Sperr WR, Müllauer L, Jäger E, Schwarzinger I, Geissler K, Valent P. Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm. Wien Klin Wochenschr. 2017 Jun;129(11-12):404-410. doi: 10.1007/s00508-016-1091-9. Epub 2016 Oct 14. PMID: 27743175; PMCID: PMC5486731.

225: Boehm T, Pils S, Gludovacz E, Szoelloesi H, Petroczi K, Majdic O, Quaroni A, Borth N, Valent P, Jilma B. Quantification of human diamine oxidase. Clin Biochem. 2017 May;50(7-8):444-451. doi: 10.1016/j.clinbiochem.2016.12.011. Epub 2016 Dec 29. PMID: 28041932.

226: Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, Pinto R, Maurillo L, Wetzel J, Musto P, Van De Loosdrecht AA, Costa MJ, Esteves S, Burgstaller S, Stauder R, Autzinger EM, Lang A, Krippl P, Geissler D, Falantes JF, Pedro C, Bargay J, Deben G, Garrido A, Bonanad S, Diez-Campelo M, Thepot S, Ades L, Sperr WR, Valent P, Fenaux P, Sekeres MA, Greil R, Pleyer L. Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. Int J Mol Sci. 2017 Apr 14;18(4):837. doi: 10.3390/ijms18040837. PMID: 28420120; PMCID: PMC5412421.

227: Valent P, Herndlhofer S, Schneeweiß M, Boidol B, Ringler A, Kubicek S, Gleixner KV, Hoermann G, Hadzijusufovic E, Müllauer L, Sperr WR, Superti-Furga G, Mannhalter C. TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML. Oncotarget. 2017 Apr 4;8(14):23061-23072. doi: 10.18632/oncotarget.15481. PMID: 28416739; PMCID: PMC5410285.

228: Valent P, Sotlar K, Blatt K, Hartmann K, Reiter A, Sadovnik I, Sperr WR, Bettelheim P, Akin C, Bauer K, George TI, Hadzijusufovic E, Wolf D, Gotlib J, Mahon FX, Metcalfe DD, Horny HP, Arock M. Proposed diagnostic criteria and classification of basophilic leukemias and related disorders. Leukemia. 2017 Apr;31(4):788-797. doi: 10.1038/leu.2017.15. Epub 2017 Jan 16. PMID: 28090091; PMCID: PMC7115817.

229: Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017 Mar 16;129(11):1420-1427. doi: 10.1182/blood-2016-09-731893. Epub 2016 Dec 28. PMID: 28031180; PMCID: PMC5356454.

230: Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O, Sotlar K, Sperr WR, Escribano L, George TI, Kluin-Nelemans HC, Ustun C, Triggiani M, Brockow K, Gotlib J, Orfao A, Schwartz LB, Broesby-Olsen S, Bindslev-Jensen C, Kovanen PT, Galli SJ, Austen KF, Arber DA, Horny HP, Arock M, Metcalfe DD. Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer Res. 2017 Mar 15;77(6):1261-1270. doi: 10.1158/0008-5472.CAN-16-2234. Epub 2017 Mar 2. PMID: 28254862; PMCID: PMC5354959.

231: Lupinek C, Derfler K, Lee S, Prikoszovich T, Movadat O, Wollmann E, Cornelius C, Weber M, Fröschl R, Selb R, Blatt K, Smiljkovic D, Schoder V, Cervenka R, Plaichner T, Stegfellner G, Huber H, Henning R, Kozik-Jaromin J, Perkmann T, Niederberger V, Petkov V, Valent P, Gauly A, Leinenbach HP, Uhlenbusch-Koerwer I, Valenta R. Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy. EBioMedicine. 2017 Mar;17:119-133. doi: 10.1016/j.ebiom.2017.02.007. Epub 2017 Feb 12. PMID: 28254561; PMCID: PMC5360571.

232: Hogg SJ, Vervoort SJ, Deswal S, Ott CJ, Li J, Cluse LA, Beavis PA, Darcy PK, Martin BP, Spencer A, Traunbauer AK, Sadovnik I, Bauer K, Valent P, Bradner JE, Zuber J, Shortt J, Johnstone RW. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. Cell Rep. 2017 Feb 28;18(9):2162-2174. doi: 10.1016/j.celrep.2017.02.011. PMID: 28249162; PMCID: PMC5340981.

233: Wagner R, Stübiger G, Veigel D, Wuczkowski M, Lanzerstorfer P, Weghuber J, Karteris E, Nowikovsky K, Wilfinger-Lutz N, Singer CF, Colomer R, Benhamú B, López-Rodríguez ML, Valent P, Grunt TW. Multi-level suppression of receptor- PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells. Oncotarget. 2017 Feb 14;8(7):11600-11613. doi: 10.18632/oncotarget.14591. PMID: 28086243; PMCID: PMC5355289.

234: Greiner G, Witzeneder N, Berger A, Schmetterer K, Eisenwort G, Schiefer AI, Roos S, Popow-Kraupp T, Müllauer L, Zuber J, Sexl V, Kenner L, Sperr WR, Valent P, Mayerhofer M, Hoermann G. CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis. Blood. 2017 Jan 19;129(3):371-382. doi: 10.1182/blood-2016-09-739003. Epub 2016 Nov 16. PMID: 27856463; PMCID: PMC7115851.

235: Sopper S, Mustjoki S, White D, Hughes T, Valent P, Burchert A, Gjertsen BT, Gastl G, Baldauf M, Trajanoski Z, Giles F, Hochhaus A, Ernst T, Schenk T, Janssen JJ, Ossenkoppele GJ, Porkka K, Wolf D. Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. J Clin Oncol. 2017 Jan 10;35(2):175-184. doi: 10.1200/JCO.2016.67.0893. Epub 2016 Nov 7. PMID: 28056193.

236: Byrgazov K, Kastner R, Gorna M, Hoermann G, Koenig M, Lucini CB, Ulreich R, Benesch M, Strenger V, Lackner H, Schwinger W, Sovinz P, Haas OA, van den Heuvel-Eibrink M, Niemeyer CM, Hantschel O, Valent P, Superti-Furga G, Urban C, Dworzak MN, Lion T. NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors. Leukemia. 2017 Jan;31(1):237-240. doi: 10.1038/leu.2016.250. Epub 2015 Aug 30. PMID: 27573554; PMCID: PMC5220134.

237: Gschwandtner M, Paulitschke V, Mildner M, Brunner PM, Hacker S, Eisenwort G, Sperr WR, Valent P, Gerner C, Tschachler E. Proteome analysis identifies L1CAM/CD171 and DPP4/CD26 as novel markers of human skin mast cells. Allergy. 2017 Jan;72(1):85-97. doi: 10.1111/all.12919. Epub 2016 May 25. PMID: 27091730.

238: Geissler K, Jäger E, Barna A, Sliwa T, Knöbl P, Schwarzinger I, Gisslinger H, Valent P. Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation? Haematologica. 2016 Dec;101(12):e492. doi: 10.3324/haematol.2016.156448. PMID: 27903714; PMCID: PMC5479601.

239: Johnsen HE, Bøgsted M, Schmitz A, Bødker JS, El-Galaly TC, Johansen P, Valent P, Zojer N, Van Valckenborgh E, Vanderkerken K, van Duin M, Sonneveld P, Perez-Andres M, Orfao A, Dybkær K. The myeloma stem cell concept, revisited: from phenomenology to operational terms. Haematologica. 2016 Dec;101(12):1451-1459. doi: 10.3324/haematol.2015.138826. Epub 2016 Nov 10. PMID: 27903712; PMCID: PMC5479618.

240: Sperr WR, Zach O, Pöll I, Herndlhofer S, Knoebl P, Weltermann A, Streubel B, Jaeger U, Kundi M, Valent P. Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post- induction consolidation therapy. Am J Hematol. 2016 Dec;91(12):1239-1245. doi: 10.1002/ajh.24560. Epub 2016 Nov 8. PMID: 27643573.

241: Jawhar M, Schwaab J, Hausmann D, Clemens J, Naumann N, Henzler T, Horny HP, Sotlar K, Schoenberg SO, Cross NC, Fabarius A, Hofmann WK, Valent P, Metzgeroth G, Reiter A. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. Leukemia. 2016 Dec;30(12):2342-2350. doi: 10.1038/leu.2016.190. Epub 2016 Jul 15. PMID: 27416984.

242: Geissler K, Jäger E, Barna A, Sliwa T, Knöbl P, Schwarzinger I, Gisslinger H, Valent P. In vitro and in vivo effects of JAK2 inhibition in chronic myelomonocytic leukemia. Eur J Haematol. 2016 Dec;97(6):562-567. doi: 10.1111/ejh.12773. Epub 2016 Jun 15. PMID: 27157043.

243: Byrgazov K, Lucini CB, Berkowitsch B, Koenig M, Haas OA, Hoermann G, Valent P, Lion T. Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors. Oncotarget. 2016 Nov 22;7(47):78083-78094. doi: 10.18632/oncotarget.12943. PMID: 27801667; PMCID: PMC5363645.

244: Geissler K, Jäger E, Barna A, Alendar T, Ljubuncic E, Sliwa T, Valent P. Chronic myelomonocytic leukemia patients with RAS pathway mutations show high in vitro myeloid colony formation in the absence of exogenous growth factors. Leukemia. 2016 Nov;30(11):2280-2281. doi: 10.1038/leu.2016.235. Epub 2016 Aug 18. PMID: 27585952; PMCID: PMC5097063.

245: Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D. Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood. 2016 Oct 20;128(16):2096-2097. doi: 10.1182/blood-2016-07-728766. Epub 2016 Aug 17. PMID: 27535995; PMCID: PMC5341483.

246: Blatt K, Herrmann H, Stefanzl G, Sperr WR, Valent P. Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma. Oncotarget. 2016 Oct 4;7(40):65627-65642. doi: 10.18632/oncotarget.11593. PMID: 27582537; PMCID: PMC5323180.

247: Ustun C, Arock M, Kluin-Nelemans HC, Reiter A, Sperr WR, George T, Horny HP, Hartmann K, Sotlar K, Damaj G, Hermine O, Verstovsek S, Metcalfe DD, Gotlib J, Akin C, Valent P. Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. Haematologica. 2016 Oct;101(10):1133-1143. doi: 10.3324/haematol.2016.146563. PMID: 27694501.

248: Zieglmayer P, Focke-Tejkl M, Schmutz R, Lemell P, Zieglmayer R, Weber M, Kiss R, Blatt K, Valent P, Stolz F, Huber H, Neubauer A, Knoll A, Horak F, Henning R, Valenta R. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. EBioMedicine. 2016 Sep;11:43-57. doi: 10.1016/j.ebiom.2016.08.022. Epub 2016 Aug 20. PMID: 27650868; PMCID: PMC5049999.

249: Heller G, Topakian T, Altenberger C, Cerny-Reiterer S, Herndlhofer S, Ziegler B, Datlinger P, Byrgazov K, Bock C, Mannhalter C, Hörmann G, Sperr WR, Lion T, Zielinski CC, Valent P, Zöchbauer-Müller S. Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia. Leukemia. 2016 Sep;30(9):1861-8. doi: 10.1038/leu.2016.143. Epub 2016 May 23. PMID: 27211271; PMCID: PMC5240019.

250: Resch Y, Blatt K, Malkus U, Fercher C, Swoboda I, Focke-Tejkl M, Chen KW, Seiberler S, Mittermann I, Lupinek C, Rodriguez-Dominguez A, Zieglmayer P, Zieglmayer R, Keller W, Krzyzanek V, Valent P, Valenta R, Vrtala S. Molecular, Structural and Immunological Characterization of Der p 18, a Chitinase-Like House Dust Mite Allergen. PLoS One. 2016 Aug 22;11(8):e0160641. doi: 10.1371/journal.pone.0160641. PMID: 27548813; PMCID: PMC4993390.

251: Pfeilstöcker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Levis A, Luebbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SM, Miyazaki Y, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL. Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016 Aug 18;128(7):902-10. doi: 10.1182/blood-2016-02-700054. Epub 2016 Jun 22. PMID: 27335276; PMCID: PMC5161006.

252: Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, Nakamura R, Kluin- Nelemans HC, Verstovsek S, Gajewski J, Perales MA, George T, Shore T, Sperr W, Saber W, Kota V, Yavuz AS, Pullarkat V, Rogosheske J, Hogan W, Van Besien K, Hagglund H, Damaj G, Arock M, Horny HP, Metcalfe DD, Deeg HJ, Devine S, Weisdorf D, Akin C, Valent P. Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. Biol Blood Marrow Transplant. 2016 Aug;22(8):1348-1356. doi: 10.1016/j.bbmt.2016.04.018. Epub 2016 Apr 27. PMID: 27131865.

253: Wohlfarth P, Carlström A, Staudinger T, Clauss S, Hermann A, Rabitsch W, Bojic A, Skrabs C, Porpaczy E, Schiefer AI, Valent P, Knöbl P, Agis H, Hauswirth A, Jäger U, Kundi M, Sperr WR, Schellongowski P; Arbeitsgruppe für hämato- onkologische Intensivmedizin der Österreichischen Gesellschaft für Internistische und Allgemeine Intensivmedizin und Notfallmedizin (ÖGIAIN). Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2016 Aug;57(8):1831-8. doi: 10.3109/10428194.2015.1106537. Epub 2016 Jan 13. PMID: 26758791.

254: Cuapio A, Post M, Cerny-Reiterer S, Gleixner KV, Stefanzl G, Basilio J, Herndlhofer S, Sperr WR, Brons NH, Casanova E, Zimmer J, Valent P, Hofer E. Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation. Oncotarget. 2016 Jul 19;7(29):46466-46481. doi: 10.18632/oncotarget.10191. PMID: 27341131; PMCID: PMC5216810.

255: Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, Awan FT, Hexner E, Mauro MJ, Sternberg DW, Villeneuve M, Huntsman Labed A, Stanek EJ, Hartmann K, Horny HP, Valent P, Reiter A. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. N Engl J Med. 2016 Jun 30;374(26):2530-41. doi: 10.1056/NEJMoa1513098. PMID: 27355533.

256: Pleyer L, Valent P, Greil R. Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality? Int J Mol Sci. 2016 Jun 27;17(7):1009. doi: 10.3390/ijms17071009. PMID: 27355944; PMCID: PMC4964385.

257: Broesby-Olsen S, Dybedal I, Gülen T, Kristensen TK, Møller MB, Ackermann L, Sääf M, Karlsson MA, Agertoft L, Brixen K, Hermann P, Stylianou E, Mortz CG, Torfing T, Havelund T, Sander B, Bergström A, Bendix M, Garvey LH, Bjerrum OW, Valent P, Bindslev-Jensen C, Nilsson G, Vestergaard H, Hägglund H. Multidisciplinary Management of Mastocytosis: Nordic Expert Group Consensus. Acta Derm Venereol. 2016 Jun 15;96(5):602-12. doi: 10.2340/00015555-2325. PMID: 26694951.

258: Uras IZ, Walter GJ, Scheicher R, Bellutti F, Prchal-Murphy M, Tigan AS, Valent P, Heidel FH, Kubicek S, Scholl C, Fröhling S, Sexl V. Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood. 2016 Jun 9;127(23):2890-902. doi: 10.1182/blood-2015-11-683581. Epub 2016 Apr 20. PMID: 27099147; PMCID: PMC4920675.

259: Ustun C, Smith A, Cayci Z, Courville EL, Corbacioglu S, Akin C, Horny HP, Valent P, Devine S, Weisdorf DJ. Allogeneic hematopoietic cell transplantation in systemic mastocytosis: is there a high risk for veno-occlusive disease? Eur J Haematol. 2016 Jun;96(6):655-7. doi: 10.1111/ejh.12720. Epub 2016 Jan 22. PMID: 26679533.

260: Culen M, Borsky M, Nemethova V, Razga F, Smejkal J, Jurcek T, Dvorakova D, Zackova D, Weinbergerova B, Semerad L, Sadovnik I, Eisenwort G, Herrmann H, Valent P, Mayer J, Racil Z. Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects. Oncotarget. 2016 May 31;7(22):33016-24. doi: 10.18632/oncotarget.9108. PMID: 27145281; PMCID: PMC5078071.

261: Jawhar M, Schwaab J, Horny HP, Sotlar K, Naumann N, Fabarius A, Valent P, Cross NC, Hofmann WK, Metzgeroth G, Reiter A. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. Eur J Clin Invest. 2016 May;46(5):392-7. doi: 10.1111/eci.12607. Epub 2016 Mar 21. PMID: 26914980.

262: Koschmieder S, Mughal TI, Hasselbalch HC, Barosi G, Valent P, Kiladjian JJ, Jeryczynski G, Gisslinger H, Jutzi JS, Pahl HL, Hehlmann R, Maria Vannucchi A, Cervantes F, Silver RT, Barbui T. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia. 2016 May;30(5):1018-24. doi: 10.1038/leu.2016.12. Epub 2016 Feb 8. PMID: 26854026.

263: Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood. 2016 Apr 28;127(17):2131-43. doi: 10.1182/blood-2015-11-681171. Epub 2016 Feb 10. PMID: 26864341; PMCID: PMC4850868.

264: Sadovnik I, Hoelbl-Kovacic A, Herrmann H, Eisenwort G, Cerny-Reiterer S, Warsch W, Hoermann G, Greiner G, Blatt K, Peter B, Stefanzl G, Berger D, Bilban M, Herndlhofer S, Sill H, Sperr WR, Streubel B, Mannhalter C, Holyoake TL, Sexl V, Valent P. Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML. Clin Cancer Res. 2016 Apr 15;22(8):2051-61. doi: 10.1158/1078-0432.CCR-15-0767. Epub 2015 Nov 25. PMID: 26607600; PMCID: PMC4817228.

265: Kulpa J, Skrabs C, Simanek R, Valent P, Panzer S, Lechner K, Sillaber C, Jäger U. Probability of remaining in unsustained complete remission after steroid therapy withdrawal in patients with primary warm-antibody reactive autoimmune hemolytic anemia. Wien Klin Wochenschr. 2016 Apr;128(7-8):234-7. doi: 10.1007/s00508-015-0863-y. Epub 2015 Sep 24. PMID: 26404740.

266: Campana R, Moritz K, Marth K, Neubauer A, Huber H, Henning R, Blatt K, Hoermann G, Brodie TM, Kaider A, Valent P, Sallusto F, Wöhrl S, Valenta R. Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments. J Allergy Clin Immunol. 2016 Feb;137(2):601-609.e8. doi: 10.1016/j.jaci.2015.08.042. Epub 2015 Oct 28. PMID: 26518092; PMCID: PMC4748398.

267: Peter B, Winter GE, Blatt K, Bennett KL, Stefanzl G, Rix U, Eisenwort G, Hadzijusufovic E, Gridling M, Dutreix C, Hoermann G, Schwaab J, Radia D, Roesel J, Manley PW, Reiter A, Superti-Furga G, Valent P. Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth. Leukemia. 2016 Feb;30(2):464-72. doi: 10.1038/leu.2015.242. Epub 2015 Sep 9. PMID: 26349526; PMCID: PMC4896384.

268: Jayavelu AK, Müller JP, Bauer R, Böhmer SA, Lässig J, Cerny-Reiterer S, Sperr WR, Valent P, Maurer B, Moriggl R, Schröder K, Shah AM, Fischer M, Scholl S, Barth J, Oellerich T, Berg T, Serve H, Frey S, Fischer T, Heidel FH, Böhmer FD. NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells. Leukemia. 2016 Feb;30(2):473-83. doi: 10.1038/leu.2015.234. Epub 2015 Aug 26. PMID: 26308771.

269: Valent P, Groner B, Schumacher U, Superti-Furga G, Busslinger M, Kralovics R, Zielinski C, Penninger JM, Kerjaschki D, Stingl G, Smolen JS, Valenta R, Lassmann H, Kovar H, Jäger U, Kornek G, Müller M, Sörgel F. Paul Ehrlich (1854-1915) and His Contributions to the Foundation and Birth of Translational Medicine. J Innate Immun. 2016;8(2):111-20. doi: 10.1159/000443526. Epub 2016 Feb 5. PMID: 26845587; PMCID: PMC6738855.

270: Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, Matito A, Broesby-Olsen S, Siebenhaar F, Lange M, Niedoszytko M, Castells M, Oude Elberink JNG, Bonadonna P, Zanotti R, Hornick JL, Torrelo A, Grabbe J, Rabenhorst A, Nedoszytko B, Butterfield JH, Gotlib J, Reiter A, Radia D, Hermine O, Sotlar K, George TI, Kristensen TK, Kluin-Nelemans HC, Yavuz S, Hägglund H, Sperr WR, Schwartz LB, Triggiani M, Maurer M, Nilsson G, Horny HP, Arock M, Orfao A, Metcalfe DD, Akin C, Valent P. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016 Jan;137(1):35-45. doi: 10.1016/j.jaci.2015.08.034. Epub 2015 Oct 21. PMID: 26476479.

271: Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K, Horny HP, Metzgeroth G, Kluger S, Naumann N, Haferlach C, Haferlach T, Valent P, Hofmann WK, Fabarius A, Cross NC, Reiter A. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. Leukemia. 2016 Jan;30(1):136-43. doi: 10.1038/leu.2015.284. Epub 2015 Oct 14. PMID: 26464169.

272: Malli T, Buxhofer-Ausch V, Rammer M, Erdel M, Kranewitter W, Rumpold H, Marschon R, Deutschbauer S, Simonitsch-Klupp I, Valent P, Muellner-Ammer K, Sebesta C, Birkner T, Webersinke G. Functional characterization, localization, and inhibitor sensitivity of the TPR-FGFR1 fusion in 8p11 myeloproliferative syndrome. Genes Chromosomes Cancer. 2016 Jan;55(1):60-8. doi: 10.1002/gcc.22311. Epub 2015 Sep 22. PMID: 26391436.

273: Gadermaier E, James LK, Shamji MH, Blatt K, Fauland K, Zieglmayer P, Garmatiuk T, Focke-Tejkl M, Villalba M, Beavil R, Keller W, Valent P, Durham SR, Gould HJ, Flicker S, Valenta R. Epitope specificity determines cross-protection of a SIT-induced IgG4 antibody. Allergy. 2016 Jan;71(1):36-46. doi: 10.1111/all.12710. Epub 2015 Sep 30. PMID: 26221749; PMCID: PMC4716291.

274: Blatt K, Cerny-Reiterer S, Schwaab J, Sotlar K, Eisenwort G, Stefanzl G, Hoermann G, Mayerhofer M, Schneeweiss M, Knapp S, Rülicke T, Hadzijusufovic E, Bauer K, Smiljkovic D, Willmann M, Reiter A, Horny HP, Valent P. Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis. Blood. 2015 Dec 24;126(26):2832-41. doi: 10.1182/blood-2015-03-637728. Epub 2015 Oct 20. Erratum in: Blood. 2018 Mar 22;131(12 ):1390. PMID: 26486787; PMCID: PMC4692143.

275: Braulke F, Müller-Thomas C, Götze K, Platzbecker U, Germing U, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Hildebrandt B, Aul C, Stauder R, Valent P, Fonatsch C, Bacher U, Trümper L, Haase D, Schanz J. Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group. Genes Chromosomes Cancer. 2015 Dec;54(12):809-17. doi: 10.1002/gcc.22292. Epub 2015 Sep 10. PMID: 26355708.

276: Wiechers T, Rabenhorst A, Schick T, Preussner LM, Förster A, Valent P, Horny HP, Sotlar K, Hartmann K. Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis. J Allergy Clin Immunol. 2015 Dec;136(6):1581-1590.e3. doi: 10.1016/j.jaci.2015.05.034. Epub 2015 Jul 4. PMID: 26152315.

277: Wedeh G, Cerny-Reiterer S, Eisenwort G, Herrmann H, Blatt K, Hadzijusufovic E, Sadovnik I, Müllauer L, Schwaab J, Hoffmann T, Bradner JE, Radia D, Sperr WR, Hoermann G, Reiter A, Horny HP, Zuber J, Arock M, Valent P. Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia. Leukemia. 2015 Nov;29(11):2230-7. doi: 10.1038/leu.2015.138. Epub 2015 Jun 9. PMID: 26055303; PMCID: PMC4610040.

278: Rathert P, Roth M, Neumann T, Muerdter F, Roe JS, Muhar M, Deswal S, Cerny- Reiterer S, Peter B, Jude J, Hoffmann T, Boryń ŁM, Axelsson E, Schweifer N, Tontsch-Grunt U, Dow LE, Gianni D, Pearson M, Valent P, Stark A, Kraut N, Vakoc CR, Zuber J. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature. 2015 Sep 24;525(7570):543-547. doi: 10.1038/nature14898. Epub 2015 Sep 14. PMID: 26367798; PMCID: PMC4921058.

279: Niklas N, Hafenscher J, Barna A, Wiesinger K, Pröll J, Dreiseitl S, Preuner-Stix S, Valent P, Lion T, Gabriel C. cFinder: definition and quantification of multiple haplotypes in a mixed sample. BMC Res Notes. 2015 Sep 7;8:422. doi: 10.1186/s13104-015-1382-7. PMID: 26346608; PMCID: PMC4562109.

280: Heuser M, Meggendorfer M, Cruz MM, Fabisch J, Klesse S, Köhler L, Göhring G, Ganster C, Shirneshan K, Gutermuth A, Cerny-Reiterer S, Krönke J, Panagiota V, Haferlach C, Koenecke C, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Ehrlich S, Stamer K, Döhner K, Valent P, Schlegelberger B, Kroeger N, Ganser A, Haase D, Haferlach T, Thol F. Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q. Leukemia. 2015 Sep;29(9):1942-5. doi: 10.1038/leu.2015.49. Epub 2015 Feb 24. PMID: 25792355.

281: Koneczny I, Schulenburg A, Hudec X, Knöfler M, Holzmann K, Piazza G, Reynolds R, Valent P, Marian B. Autocrine fibroblast growth factor 18 signaling mediates Wnt-dependent stimulation of CD44-positive human colorectal adenoma cells. Mol Carcinog. 2015 Sep;54(9):789-799. doi: 10.1002/mc.22146. Epub 2014 Mar 12. PMID: 24619956; PMCID: PMC4162857.

282: Madritsch C, Eckl-Dorna J, Blatt K, Ellinger I, Kundi M, Niederberger V, Valent P, Valenta R, Flicker S. Antibody conjugates bispecific for intercellular adhesion molecule 1 and allergen prevent migration of allergens through respiratory epithelial cell layers. J Allergy Clin Immunol. 2015 Aug;136(2):490-3.e11. doi: 10.1016/j.jaci.2015.01.006. Epub 2015 Mar 11. PMID: 25769914; PMCID: PMC4530582.

283: Theoharides TC, Valent P, Akin C. Mast Cells, Mastocytosis, and Related Disorders. N Engl J Med. 2015 Jul 9;373(2):163-72. doi: 10.1056/NEJMra1409760. PMID: 26154789.

284: Della Porta MG, Tuechler H, Malcovati L, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL, Cazzola M. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia. 2015 Jul;29(7):1502-13. doi: 10.1038/leu.2015.55. Epub 2015 Feb 27. PMID: 25721895.

285: Arock M, Akin C, Hermine O, Valent P. Current treatment options in patients with mastocytosis: status in 2015 and future perspectives. Eur J Haematol. 2015 Jun;94(6):474-90. doi: 10.1111/ejh.12544. Epub 2015 Mar 26. PMID: 25753531.

286: Arock M, Sotlar K, Akin C, Broesby-Olsen S, Hoermann G, Escribano L, Kristensen TK, Kluin-Nelemans HC, Hermine O, Dubreuil P, Sperr WR, Hartmann K, Gotlib J, Cross NC, Haferlach T, Garcia-Montero A, Orfao A, Schwaab J, Triggiani M, Horny HP, Metcalfe DD, Reiter A, Valent P. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia. 2015 Jun;29(6):1223-32. doi: 10.1038/leu.2015.24. Epub 2015 Feb 4. PMID: 25650093; PMCID: PMC4522520.

287: Jawhar M, Schwaab J, Schnittger S, Sotlar K, Horny HP, Metzgeroth G, Müller N, Schneider S, Naumann N, Walz C, Haferlach T, Valent P, Hofmann WK, Cross NC, Fabarius A, Reiter A. Molecular profiling of myeloid progenitor cells in multi- mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event. Leukemia. 2015 May;29(5):1115-22. doi: 10.1038/leu.2015.4. Epub 2015 Jan 8. PMID: 25567135.

288: Focke-Tejkl M, Weber M, Niespodziana K, Neubauer A, Huber H, Henning R, Stegfellner G, Maderegger B, Hauer M, Stolz F, Niederberger V, Marth K, Eckl- Dorna J, Weiss R, Thalhamer J, Blatt K, Valent P, Valenta R. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. J Allergy Clin Immunol. 2015 May;135(5):1207-7.e1-11. doi: 10.1016/j.jaci.2014.09.012. Epub 2014 Nov 13. PMID: 25441634; PMCID: PMC4418753.

289: Veigel D, Wagner R, Stübiger G, Wuczkowski M, Filipits M, Horvat R, Benhamú B, López-Rodríguez ML, Leisser A, Valent P, Grusch M, Hegardt FG, García J, Serra D, Auersperg N, Colomer R, Grunt TW. Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells. Int J Cancer. 2015 May 1;136(9):2078-90. doi: 10.1002/ijc.29261. Epub 2014 Nov 3. PMID: 25302649.

290: Linhart B, Focke-Tejkl M, Weber M, Narayanan M, Neubauer A, Mayrhofer H, Blatt K, Lupinek C, Valent P, Valenta R. Molecular evolution of hypoallergenic hybrid proteins for vaccination against grass pollen allergy. J Immunol. 2015 Apr 15;194(8):4008-18. doi: 10.4049/jimmunol.1400402. Epub 2015 Mar 18. PMID: 25786690; PMCID: PMC4415977.

291: Karmacharya P, Donato AA, Aryal MR, Pathak R, Goonewardene M, Valent P. All systems red. Am J Hematol. 2015 Apr;90(4):356-60. doi: 10.1002/ajh.23869. Epub 2014 Oct 25. PMID: 25294166.

292: Schulenburg A, Blatt K, Cerny-Reiterer S, Sadovnik I, Herrmann H, Marian B, Grunt TW, Zielinski CC, Valent P. Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? J Hematol Oncol. 2015 Feb 25;8:16. doi: 10.1186/s13045-015-0113-9. PMID: 25886184; PMCID: PMC4345016.

293: Cerny-Reiterer S, Rabenhorst A, Stefanzl G, Herndlhofer S, Hoermann G, Müllauer L, Baumgartner S, Beham-Schmid C, Sperr WR, Mannhalter C, Sill H, Linkesch W, Arock M, Hartmann K, Valent P. Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia. Oncotarget. 2015 Feb 20;6(5):3071-84. doi: 10.18632/oncotarget.3074. PMID: 25605011; PMCID: PMC4413638.

294: Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre P. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood. 2015 Feb 5;125(6):901-6. doi: 10.1182/blood-2014-09-594432. Epub 2014 Dec 18. PMID: 25525119.

295: Braulke F, Platzbecker U, Müller-Thomas C, Götze K, Germing U, Brümmendorf TH, Nolte F, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Mallo M, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Shirneshan K, Aul C, Stauder R, Sperr WR, Valent P, Fonatsch C, Trümper L, Haase D, Schanz J. Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group. Haematologica. 2015 Feb;100(2):205-13. doi: 10.3324/haematol.2014.110452. Epub 2014 Oct 24. PMID: 25344522; PMCID: PMC4803133.

296: Valent P, Berger J, Cerny-Reiterer S, Peter B, Eisenwort G, Hoermann G, Müllauer L, Mannhalter C, Steurer M, Bettelheim P, Horny HP, Arock M. Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. Ann Hematol. 2015 Feb;94(2):223-31. doi: 10.1007/s00277-014-2207-9. Epub 2014 Sep 11. PMID: 25209843; PMCID: PMC4896380.

297: Grunt TW, Hebar A, Laffer S, Wagner R, Peter B, Herrmann H, Graf A, Bilban M, Posch M, Hoermann G, Mayerhofer M, Eisenwort G, Zielinski CC, Selzer E, Valent P. Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells. Am J Cancer Res. 2015 Jan 15;5(2):560-74. PMID: 25973297; PMCID: PMC4396035.

298: Valent P. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology. Hematology Am Soc Hematol Educ Program. 2015;2015:98-105. doi: 10.1182/asheducation-2015.1.98. PMID: 26637707.

299: Hoermann G, Greiner G, Valent P. Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms. Mediators Inflamm. 2015;2015:869242. doi: 10.1155/2015/869242. Epub 2015 Oct 12. PMID: 26543328; PMCID: PMC4620237.

300: Sperr WR, Pfeiffer T, Hoermann G, Herndlhofer S, Sillaber C, Mannhalter C, Kundi M, Valent P. Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML. Am J Cancer Res. 2014 Dec 15;5(1):354-62. PMID: 25628944; PMCID: PMC4300686.

301: Obut F, Randall N, Young JA, Valent P, Ustun C. Dasatinib-induced immunosuppression and recurrent respiratory tract infections. Leuk Lymphoma. 2015;56(8):2484-5. doi: 10.3109/10428194.2014.994179. Epub 2015 Jan 21. PMID: 25495173.

302: Valent P, Sotlar K, Sperr WR, Reiter A, Arock M, Horny HP. Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features. Leuk Res. 2015 Jan;39(1):1-5. doi: 10.1016/j.leukres.2014.09.010. Epub 2014 Sep 30. PMID: 25443885; PMCID: PMC4896385.

303: Burgstaller S, Bettelheim P, Krieger O, Machherndl-Spandl S, Nösslinger T, Pleyer L, Sill H, Sperr WR, Stauder R, Valent P, Pfeilstöcker M. 10th anniversary of the Austrian MDS Platform: aims and ongoing projects. Wien Klin Wochenschr. 2015 Jan;127(1-2):12-5. doi: 10.1007/s00508-014-0627-0. Epub 2014 Nov 25. PMID: 25421367.

304: Radonjic-Hoesli S, Valent P, Klion AD, Wechsler ME, Simon HU. Novel targeted therapies for eosinophil-associated diseases and allergy. Annu Rev Pharmacol Toxicol. 2015;55:633-56. doi: 10.1146/annurev-pharmtox-010814-124407. Epub 2014 Oct 17. PMID: 25340931; PMCID: PMC4924608.

305: Banerjee S, Resch Y, Chen KW, Swoboda I, Focke-Tejkl M, Blatt K, Novak N, Wickman M, van Hage M, Ferrara R, Mari A, Purohit A, Pauli G, Sibanda EN, Ndlovu P, Thomas WR, Krzyzanek V, Tacke S, Malkus U, Valent P, Valenta R, Vrtala S. Der p 11 is a major allergen for house dust mite-allergic patients suffering from atopic dermatitis. J Invest Dermatol. 2015 Jan;135(1):102-109. doi: 10.1038/jid.2014.271. Epub 2014 Aug 7. PMID: 24999597; PMCID: PMC4636057.

306: Valent P, Cerny-Reiterer S, Hoermann G, Sperr WR, Müllauer L, Mannhalter C, Pehamberger H. Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT. Am J Blood Res. 2014 Dec 15;4(2):93-100. PMID: 25755909; PMCID: PMC4351647.

307: Valent P, Sadovnik I, Ráčil Z, Herrmann H, Blatt K, Cerny-Reiterer S, Eisenwort G, Lion T, Holyoake T, Mayer J. DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia. Eur J Clin Invest. 2014 Dec;44(12):1239-45. doi: 10.1111/eci.12368. PMID: 25371066.

308: Sabato V, Van De Vijver E, Hagendorens M, Vrelust I, Reyniers E, Fransen E, Bridts C, De Clerck L, Mortier G, Valent P, Ebo D. Familial hypertryptasemia with associated mast cell activation syndrome. J Allergy Clin Immunol. 2014 Dec;134(6):1448-1450.e3. doi: 10.1016/j.jaci.2014.06.007. Epub 2014 Jul 30. PMID: 25086867.

309: Berger A, Sexl V, Valent P, Moriggl R. Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia. Oncotarget. 2014 Oct 30;5(20):9564-76. doi: 10.18632/oncotarget.2465. PMID: 25333255; PMCID: PMC4259420.

310: Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S, Shanley R, Hogan WJ, Perales MA, Shore T, Baurmann H, Stuart R, Gruhn B, Doubek M, Hsu JW, Tholouli E, Gromke T, Godley LA, Pagano L, Gilman A, Wagner EM, Shwayder T, Bornhäuser M, Papadopoulos EB, Böhm A, Vercellotti G, Van Lint MT, Schmid C, Rabitsch W, Pullarkat V, Legrand F, Yakoub-Agha I, Saber W, Barrett J, Hermine O, Hagglund H, Sperr WR, Popat U, Alyea EP, Devine S, Deeg HJ, Weisdorf D, Akin C, Valent P. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014 Oct 10;32(29):3264-74. doi: 10.1200/JCO.2014.55.2018. Epub 2014 Aug 25. PMID: 25154823; PMCID: PMC4876356.

311: Valent P, Sperr WR, Sotlar K, Reiter A, Akin C, Gotlib J, Horny HP, Arock M. The serum tryptase test: an emerging robust biomarker in clinical hematology. Expert Rev Hematol. 2014 Oct;7(5):683-90. doi: 10.1586/17474086.2014.955008. Epub 2014 Aug 28. PMID: 25169217; PMCID: PMC4603354.

312: Valent P, Escribano L, Broesby-Olsen S, Hartmann K, Grattan C, Brockow K, Niedoszytko M, Nedoszytko B, Oude Elberink JN, Kristensen T, Butterfield JH, Triggiani M, Alvarez-Twose I, Reiter A, Sperr WR, Sotlar K, Yavuz S, Kluin- Nelemans HC, Hermine O, Radia D, van Doormaal JJ, Gotlib J, Orfao A, Siebenhaar F, Schwartz LB, Castells M, Maurer M, Horny HP, Akin C, Metcalfe DD, Arock M; European Competence Network on Mastocytosis. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy. 2014 Oct;69(10):1267-74. doi: 10.1111/all.12436. Epub 2014 May 19. PMID: 24836395.

313: Porwit A, van de Loosdrecht AA, Bettelheim P, Brodersen LE, Burbury K, Cremers E, Della Porta MG, Ireland R, Johansson U, Matarraz S, Ogata K, Orfao A, Preijers F, Psarra K, Subirá D, Valent P, van der Velden VH, Wells D, Westers TM, Kern W, Béné MC. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia. 2014 Sep;28(9):1793-8. doi: 10.1038/leu.2014.191. Epub 2014 Jun 12. PMID: 24919805.

314: Valent P, Sotlar K, Sperr WR, Escribano L, Yavuz S, Reiter A, George TI, Kluin-Nelemans HC, Hermine O, Butterfield JH, Hägglund H, Ustun C, Hornick JL, Triggiani M, Radia D, Akin C, Hartmann K, Gotlib J, Schwartz LB, Verstovsek S, Orfao A, Metcalfe DD, Arock M, Horny HP. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol. 2014 Sep;25(9):1691-1700. doi: 10.1093/annonc/mdu047. Epub 2014 Mar 27. PMID: 24675021; PMCID: PMC4155468.

315: Valent P. Targeting the JAK2-STAT5 pathway in CML. Blood. 2014 Aug 28;124(9):1386-8. doi: 10.1182/blood-2014-07-585943. PMID: 25170113; PMCID: PMC4148757.

316: Horny HP, Sotlar K, Reiter A, Valent P. Myelomastocytic leukemia: histopathological features, diagnostic criteria and differential diagnosis. Expert Rev Hematol. 2014 Aug;7(4):431-7. doi: 10.1586/17474086.2014.942280. PMID: 25025369.

317: Rabitsch W, Böhm A, Bojic M, Schellongowski P, Wöhrer S, Sliwa T, Keil F, Worel N, Greinix H, Hauswirth A, Kalhs P, Jaeger U, Valent P, Sperr WR. Clofarabine/cyclophosphamide for debulking before stem cell transplantation. Eur J Clin Invest. 2014 Aug;44(8):775-83. doi: 10.1111/eci.12294. PMID: 24942362.

318: Hoermann G, Blatt K, Greiner G, Putz EM, Berger A, Herrmann H, Cerny- Reiterer S, Gleixner KV, Walz C, Hoetzenecker K, Müllauer L, Reiter A, Sotlar K, Sexl V, Valent P, Mayerhofer M. CD52 is a molecular target in advanced systemic mastocytosis. FASEB J. 2014 Aug;28(8):3540-51. doi: 10.1096/fj.14-250894. Epub 2014 Apr 23. PMID: 24760752.

319: Saleh R, Wedeh G, Herrmann H, Bibi S, Cerny-Reiterer S, Sadovnik I, Blatt K, Hadzijusufovic E, Jeanningros S, Blanc C, Legarff-Tavernier M, Chapiro E, Nguyen-Khac F, Subra F, Bonnemye P, Dubreuil P, Desplat V, Merle-Béral H, Willmann M, Rülicke T, Valent P, Arock M. A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection. Blood. 2014 Jul 3;124(1):111-20. doi: 10.1182/blood-2013-10-534685. Epub 2014 Mar 27. PMID: 24677542.

320: Blatt K, Herrmann H, Hoermann G, Willmann M, Cerny-Reiterer S, Sadovnik I, Herndlhofer S, Streubel B, Rabitsch W, Sperr WR, Mayerhofer M, Rülicke T, Valent P. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML. Clin Cancer Res. 2014 Jul 1;20(13):3589-602. doi: 10.1158/1078-0432.CCR-13-2811. Epub 2014 May 5. PMID: 24799522.

321: Valent P. Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders. Clin Exp Allergy. 2014 Jul;44(7):914-20. doi: 10.1111/cea.12318. PMID: 24702655; PMCID: PMC4603355.

322: Bammer C, Sperr WR, Kemmler G, Wimazal F, Nösslinger T, Schönmetzler A, Krieger O, Pfeilstöcker M, Valent P, Stauder R. Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes. J Geriatr Oncol. 2014 Jul;5(3):299-306. doi: 10.1016/j.jgo.2014.02.002. Epub 2014 Mar 11. PMID: 24636334.

323: Herrmann H, Sadovnik I, Cerny-Reiterer S, Rülicke T, Stefanzl G, Willmann M, Hoermann G, Bilban M, Blatt K, Herndlhofer S, Mayerhofer M, Streubel B, Sperr WR, Holyoake TL, Mannhalter C, Valent P. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood. 2014 Jun 19;123(25):3951-62. doi: 10.1182/blood-2013-10-536078. Epub 2014 Apr 28. PMID: 24778155.

324: Arthold C, Skrabs C, Mitterbauer-Hohendanner G, Thalhammer R, Simonitsch- Klupp I, Panzer S, Valent P, Lechner K, Jäger U, Sillaber C. Cold antibody autoimmune hemolytic anemia and lymphoproliferative disorders: a retrospective study of 20 patients including clinical, hematological, and molecular findings. Wien Klin Wochenschr. 2014 Jun;126(11-12):376-82. doi: 10.1007/s00508-014-0547-z. Epub 2014 May 20. PMID: 24842748.

325: Hoermann G, Gleixner KV, Dinu GE, Kundi M, Greiner G, Wimazal F, Hadzijusufovic E, Mitterbauer G, Mannhalter C, Valent P, Sperr WR. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. Allergy. 2014 Jun;69(6):810-3. doi: 10.1111/all.12409. Epub 2014 Apr 17. PMID: 24750133; PMCID: PMC4896381.

326: Curin M, Weber M, Thalhamer T, Swoboda I, Focke-Tejkl M, Blatt K, Valent P, Marth K, Garmatiuk T, Grönlund H, Thalhamer J, Spitzauer S, Valenta R. Hypoallergenic derivatives of Fel d 1 obtained by rational reassembly for allergy vaccination and tolerance induction. Clin Exp Allergy. 2014 Jun;44(6):882-94. doi: 10.1111/cea.12294. PMID: 24552249; PMCID: PMC4678659.

327: Banerjee S, Weber M, Blatt K, Swoboda I, Focke-Tejkl M, Valent P, Valenta R, Vrtala S. Conversion of Der p 23, a new major house dust mite allergen, into a hypoallergenic vaccine. J Immunol. 2014 May 15;192(10):4867-75. doi: 10.4049/jimmunol.1400064. Epub 2014 Apr 14. PMID: 24733847; PMCID: PMC4582415.

328: Horny HP, Sotlar K, Valent P. Mastocytosis: immunophenotypical features of the transformed mast cells are unique among hematopoietic cells. Immunol Allergy Clin North Am. 2014 May;34(2):315-21. doi: 10.1016/j.iac.2014.01.005. PMID: 24745676; PMCID: PMC5798580.

329: Akin C, Valent P. Diagnostic criteria and classification of mastocytosis in 2014. Immunol Allergy Clin North Am. 2014 May;34(2):207-18. doi: 10.1016/j.iac.2014.02.003. PMID: 24745670.

330: Pleyer L, Germing U, Sperr WR, Linkesch W, Burgstaller S, Stauder R, Girschikofsky M, Schreder M, Pfeilstocker M, Lang A, Sliwa T, Geissler D, Schlick K, Placher-Sorko G, Theiler G, Thaler J, Mitrovic M, Neureiter D, Valent P, Greil R. Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leuk Res. 2014 Apr;38(4):475-83. doi: 10.1016/j.leukres.2014.01.006. Epub 2014 Jan 18. PMID: 24522248.

331: Sadovnik I, Lierman E, Peter B, Herrmann H, Suppan V, Stefanzl G, Haas O, Lion T, Pickl W, Cools J, Vandenberghe P, Valent P. Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA. Exp Hematol. 2014 Apr;42(4):282-293.e4. doi: 10.1016/j.exphem.2013.12.007. Epub 2014 Jan 6. PMID: 24407160; PMCID: PMC4338611.

332: Karlic H, Herrmann H, Varga F, Thaler R, Reitermaier R, Spitzer S, Ghanim V, Blatt K, Sperr WR, Valent P, Pfeilstöcker M. The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia. Crit Rev Oncol Hematol. 2014 Apr;90(1):1-16. doi: 10.1016/j.critrevonc.2013.10.003. Epub 2013 Oct 12. PMID: 24183913.

333: Cerny-Reiterer S, Meyer RA, Herrmann H, Peter B, Gleixner KV, Stefanzl G, Hadzijusufovic E, Pickl WF, Sperr WR, Melo JV, Maeda H, Jäger U, Valent P. Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia. Oncotarget. 2014 Mar 15;5(5):1198-211. doi: 10.18632/oncotarget.1805. PMID: 24681707; PMCID: PMC4012724.

334: Bibi S, Arslanhan MD, Langenfeld F, Jeanningros S, Cerny-Reiterer S, Hadzijusufovic E, Tchertanov L, Moriggl R, Valent P, Arock M. Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy. Haematologica. 2014 Mar;99(3):417-29. doi: 10.3324/haematol.2013.098442. PMID: 24598853; PMCID: PMC3943304.

335: Kastner R, Zopf A, Preuner S, Pröll J, Niklas N, Foskett P, Valent P, Lion T, Gabriel C. Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing. Eur J Cancer. 2014 Mar;50(4):793-800. doi: 10.1016/j.ejca.2013.11.030. Epub 2013 Dec 20. PMID: 24365090; PMCID: PMC4961242.

336: Focke-Tejkl M, Campana R, Reininger R, Lupinek C, Blatt K, Valent P, Pavkov-Keller T, Keller W, Valenta R. Dissection of the IgE and T-cell recognition of the major group 5 grass pollen allergen Phl p 5. J Allergy Clin Immunol. 2014 Mar;133(3):836-45.e11. doi: 10.1016/j.jaci.2013.08.038. Epub 2013 Oct 31. PMID: 24182774; PMCID: PMC6624141.

337: Füreder W, Paulitsch-Buckingham A, Rabitsch W, Jäger E, Schwarzinger I, Sperr WR, Valent P. Evaluation of treatment responses and colony-forming progenitor cells in 50 patients with aplastic anemia after immunosuppressive therapy or hematopoietic stem cell transplantation: a single-center experience. Wien Klin Wochenschr. 2014 Feb;126(3-4):119-25. doi: 10.1007/s00508-013-0484-2. Epub 2014 Jan 18. PMID: 24442858.

338: Gadermaier E, Flicker S, Blatt K, Valent P, Valenta R. Possible therapeutic potential of a recombinant group 2 grass pollen allergen-specific antibody fragment. Allergy. 2014 Feb;69(2):261-4. doi: 10.1111/all.12315. Epub 2013 Nov 20. PMID: 24251384; PMCID: PMC4123173.

339: Mirkina I, Hadzijusufovic E, Krepler C, Mikula M, Mechtcheriakova D, Strommer S, Stella A, Jensen-Jarolim E, Höller C, Wacheck V, Pehamberger H, Valent P. Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R. PLoS One. 2014 Jan 29;9(1):e84417. doi: 10.1371/journal.pone.0084417. PMID: 24489649; PMCID: PMC3906015.

340: Valent P, Blatt K, Eisenwort G, Herrmann H, Cerny-Reiterer S, Thalhammer R, Müllauer L, Hoermann G, Sadovnik I, Schwarzinger I, Sperr WR, Mannhalter C, Horny HP. FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H. Leuk Res Rep. 2013 Nov 26;3(1):8-13. doi: 10.1016/j.lrr.2013.11.001. PMID: 24596674; PMCID: PMC3939382.

341: Jennings S, Russell N, Jennings B, Slee V, Sterling L, Castells M, Valent P, Akin C. The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions. J Allergy Clin Immunol Pract. 2014 Jan- Feb;2(1):70-6. doi: 10.1016/j.jaip.2013.09.004. Epub 2013 Dec 3. PMID: 24565772.

342: Valent P, Zuber J. BRD4: a BET(ter) target for the treatment of AML? Cell Cycle. 2014;13(5):689-90. doi: 10.4161/cc.27859. Epub 2014 Jan 21. PMID: 24526121; PMCID: PMC3979900.

343: Boehm A, Sperr WR, Kalhs P, Greinix H, Valent P, Worel N, Kainz A, Mitterbauer M, Bojic M, Rabitsch W. Long-term follow-up after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia: a single center experience. Wien Klin Wochenschr. 2014 Jan;126(1-2):23-9. doi: 10.1007/s00508-013-0449-5. Epub 2013 Nov 19. PMID: 24249320.

344: Machherndl-Spandl S, Sega W, Bösmüller H, Germing U, Gruber Ch, Nachtkamp K, Reinecke P, Sperr WR, Wimazal F, Müllauer L, Sotlar K, Horny HP, Tüchler H, Valent P, Krieger O. Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis. Ann Hematol. 2014 Jan;93(1):57-64. doi: 10.1007/s00277-013-1945-4. Epub 2013 Nov 17. PMID: 24241126.

345: Peter B, Cerny-Reiterer S, Hadzijusufovic E, Schuch K, Stefanzl G, Eisenwort G, Gleixner KV, Hoermann G, Mayerhofer M, Kundi M, Baumgartner S, Sperr WR, Pickl WF, Willmann M, Valent P. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells. J Leukoc Biol. 2014 Jan;95(1):95-104. doi: 10.1189/jlb.1112609. Epub 2013 Sep 19. PMID: 24052572.

346: Einwallner E, Jaeger E, Mitterbauer-Hohendanner G, Bilban M, Simonitsch- Klupp I, Steiner I, Pernicka E, Hoermann G, Herndlhofer S, Sillaber C, Valent P, Schwarzinger I. Endogenous erythroid colony formation in chronic myeloid leukemia: a recurrent finding associated with persistent minimal residual disease under imatinib. Stem Cells Dev. 2013 Dec 1;22(23):3043-51. doi: 10.1089/scd.2013.0096. Epub 2013 Sep 4. PMID: 23883175.

347: Sperr WR, Kundi M, Wimazal F, Nösslinger T, Schönmetzler-Makrai A, Stauder R, Krieger O, Neukirchen J, Germing U, Pfeilstöcker M, Valent P. Proposed score for survival of patients with myelodysplastic syndromes. Eur J Clin Invest. 2013 Nov;43(11):1120-8. doi: 10.1111/eci.12149. Epub 2013 Sep 18. PMID: 24102333.

348: Abramova A, Sakaguchi S, Schebesta A, Hassan H, Boucheron N, Valent P, Roers A, Ellmeier W. The transcription factor MAZR preferentially acts as a transcriptional repressor in mast cells and plays a minor role in the regulation of effector functions in response to FcεRI stimulation. PLoS One. 2013 Oct 17;8(10):e77677. doi: 10.1371/journal.pone.0077677. PMID: 24204913; PMCID: PMC3804165.

349: Rix U, Colinge J, Blatt K, Gridling M, Remsing Rix LL, Parapatics K, Cerny- Reiterer S, Burkard TR, Jäger U, Melo JV, Bennett KL, Valent P, Superti-Furga G. A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL. PLoS One. 2013 Oct 10;8(10):e77155. doi: 10.1371/journal.pone.0077155. PMID: 24130846; PMCID: PMC3795025.

350: Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, Kohlmann A, Grossmann V, Meggendorfer M, Horny HP, Valent P, Jawhar M, Teichmann M, Metzgeroth G, Erben P, Ernst T, Hochhaus A, Haferlach T, Hofmann WK, Cross NC, Reiter A. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013 Oct 3;122(14):2460-6. doi: 10.1182/blood-2013-04-496448. Epub 2013 Aug 19. PMID: 23958953.

351: Müller-Tidow C, Bug G, Lübbert M, Krämer A, Krauter J, Valent P, Nachbaur D, Berdel WE, Ottmann OG, Fritsch H, Munzert G, Garin-Chesa P, Fleischer F, Taube T, Döhner H. A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia. Br J Haematol. 2013 Oct;163(2):214-22. doi: 10.1111/bjh.12518. Epub 2013 Aug 16. PMID: 24033250.

352: Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Grau J, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. Monosomal karyotype in MDS: explaining the poor prognosis? Leukemia. 2013 Oct;27(10):1988-95. doi: 10.1038/leu.2013.187. Epub 2013 Jun 21. PMID: 23787396.

353: Garmatiuk T, Swoboda I, Twardosz-Kropfmüller A, Dall'Antonia F, Keller W, Singh MB, Bhalla PL, Okada T, Toriyama K, Weber M, Ghannadan M, Sperr WR, Blatt K, Valent P, Klein B, Niederberger V, Curin M, Balic N, Spitzauer S, Valenta R. Characterization of mutants of a highly cross-reactive calcium-binding protein from Brassica pollen for allergen-specific immunotherapy. Immunobiology. 2013 Sep;218(9):1155-1165. doi: 10.1016/j.imbio.2013.04.006. Epub 2013 Apr 24. PMID: 23790497; PMCID: PMC4573526.

354: Gleixner KV, Peter B, Blatt K, Suppan V, Reiter A, Radia D, Hadzijusufovic E, Valent P. Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. Haematologica. 2013 Sep;98(9):1450-7. doi: 10.3324/haematol.2012.079202. Epub 2013 Mar 28. PMID: 23539538; PMCID: PMC3762103.

355: Okuyama N, Sperr WR, Kadar K, Bakker S, Szombath G, Handa H, Tamura H, Kondo A, Valent P, Várkonyi J, van de Loosdrecht A, Ogata K. Prognosis of acute myeloid leukemia transformed from myelodysplastic syndromes: a multicenter retrospective study. Leuk Res. 2013 Aug;37(8):862-7. doi: 10.1016/j.leukres.2013.02.018. Epub 2013 Mar 16. PMID: 23507195.

356: Rommer A, Steinleitner K, Hackl H, Schneckenleithner C, Engelmann M, Scheideler M, Vlatkovic I, Kralovics R, Cerny-Reiterer S, Valent P, Sill H, Wieser R. Overexpression of primary microRNA 221/222 in acute myeloid leukemia. BMC Cancer. 2013 Jul 29;13:364. doi: 10.1186/1471-2407-13-364. PMID: 23895238; PMCID: PMC3733744.

357: Wicklein D, Schmidt A, Labitzky V, Ullrich S, Valent P, Schumacher U. E- and p-selectins are essential for repopulation of chronic myelogenous and chronic eosinophilic leukemias in a scid mouse xenograft model. PLoS One. 2013 Jul 26;8(7):e70139. doi: 10.1371/journal.pone.0070139. PMID: 23922938; PMCID: PMC3724803.

358: Hoermann G, Cerny-Reiterer S, Sadovnik I, Müllauer L, Bilban M, Gröger M, Horny HP, Reiter A, Schmitt-Graeff A, Mannhalter C, Valent P, Mayerhofer M. Oncostatin M is a FIP1L1/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia. Allergy. 2013 Jun;68(6):713-23. doi: 10.1111/all.12139. Epub 2013 Apr 27. PMID: 23621172.

359: Wiernik A, Sperr WR, Weisdorf D, Valent P, Ustun C. Does high-dose cytarabine cause cumulative toxicity in patients undergoing consolidation therapy for acute myeloid leukemia? Am J Hematol. 2013 Jun;88(6):533-4. doi: 10.1002/ajh.23440. Epub 2013 May 2. PMID: 23526441.

360: Valent P, Aberer E, Beham-Schmid C, Fellinger C, Fuchs W, Gleixner KV, Greul R, Hadzijusufovic E, Hoermann G, Sperr WR, Wimazal F, Wöhrl S, Zahel B, Pehamberger H. Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM). Am J Blood Res. 2013 May 5;3(2):174-80. PMID: 23675567; PMCID: PMC3649810.

361: Valent P. Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology. Am J Cancer Res. 2013 Apr 3;3(2):159-72. PMID: 23593539; PMCID: PMC3623836.

362: Weghofer M, Grote M, Resch Y, Casset A, Kneidinger M, Kopec J, Thomas WR, Fernández-Caldas E, Kabesch M, Ferrara R, Mari A, Purohit A, Pauli G, Horak F, Keller W, Valent P, Valenta R, Vrtala S. Identification of Der p 23, a peritrophin-like protein, as a new major Dermatophagoides pteronyssinus allergen associated with the peritrophic matrix of mite fecal pellets. J Immunol. 2013 Apr 1;190(7):3059-67. doi: 10.4049/jimmunol.1202288. Epub 2013 Mar 4. PMID: 23460742; PMCID: PMC4582595.

363: Marth K, Breyer I, Focke-Tejkl M, Blatt K, Shamji MH, Layhadi J, Gieras A, Swoboda I, Zafred D, Keller W, Valent P, Durham SR, Valenta R. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype. J Immunol. 2013 Apr 1;190(7):3068-78. doi: 10.4049/jimmunol.1202441. Epub 2013 Feb 25. PMID: 23440415; PMCID: PMC4148560.

364: Valent P. Mast cell activation syndromes: definition and classification. Allergy. 2013 Apr;68(4):417-24. doi: 10.1111/all.12126. Epub 2013 Feb 15. PMID: 23409940.

365: Förster A, Falcone FH, Gibbs BF, Preussner LM, Fiebig BS, Altunok H, Seeger JM, Cerny-Reiterer S, Rabenhorst A, Papenfuss K, Valent P, Kashkar H, Hartmann K. Anti-Fas/CD95 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) differentially regulate apoptosis in normal and neoplastic human basophils. Leuk Lymphoma. 2013 Apr;54(4):835-42. doi: 10.3109/10428194.2012.731600. Epub 2012 Oct 9. PMID: 22989017.

366: Gotlib J, Pardanani A, Akin C, Reiter A, George T, Hermine O, Kluin- Nelemans H, Hartmann K, Sperr WR, Brockow K, Schwartz LB, Orfao A, Deangelo DJ, Arock M, Sotlar K, Horny HP, Metcalfe DD, Escribano L, Verstovsek S, Tefferi A, Valent P. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood. 2013 Mar 28;121(13):2393-401. doi: 10.1182/blood-2012-09-458521. Epub 2013 Jan 16. PMID: 23325841; PMCID: PMC3612852.

367: Hubmann R, Hilgarth M, Schnabl S, Ponath E, Reiter M, Demirtas D, Sieghart W, Valent P, Zielinski C, Jäger U, Shehata M. Gliotoxin is a potent NOTCH2 transactivation inhibitor and efficiently induces apoptosis in chronic lymphocytic leukaemia (CLL) cells. Br J Haematol. 2013 Mar;160(5):618-29. doi: 10.1111/bjh.12183. Epub 2012 Dec 24. PMID: 23278106.

368: van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS, Bettelheim P, Bowen DT, Burbury K, Eidenschink L, Cazzola M, Chu SS, Cullen M, Cutler JA, Dräger AM, Feuillard J, Fenaux P, Font P, Germing U, Haase D, Hellström-Lindberg E, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Nikolova V, Ogata K, Oelschlaegel U, Orfao A, Ossenkoppele GJ, Porwit A, Platzbecker U, Preijers F, Psarra K, Richards SJ, Subirá D, Seymour JF, Tindell V, Vallespi T, Valent P, van der Velden VH, Wells DA, de Witte TM, Zettl F, Béné MC, Westers TM. Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leuk Lymphoma. 2013 Mar;54(3):472-5. doi: 10.3109/10428194.2012.718341. Epub 2012 Sep 14. PMID: 22916713.

369: Valent P, Bonnet D, Wöhrer S, Andreeff M, Copland M, Chomienne C, Eaves C. Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications. Cancer Res. 2013 Feb 1;73(3):1037-45. doi: 10.1158/0008-5472.CAN-12-3678. Epub 2013 Jan 23. PMID: 23345162.

370: Hebar A, Valent P, Selzer E. The impact of molecular targets in cancer drug development: major hurdles and future strategies. Expert Rev Clin Pharmacol. 2013 Jan;6(1):23-34. doi: 10.1586/ecp.12.71. PMID: 23272790.

371: Rausz E, Szilágyi A, Nedoszytko B, Lange M, Niedoszytko M, Lautner-Csorba O, Falus A, Aladzsity I, Kokai M, Valent P, Marschalko M, Hidvégi B, Szakonyi J, Csomor J, Várkonyi J. Comparative analysis of IL6 and IL6 receptor gene polymorphisms in mastocytosis. Br J Haematol. 2013 Jan;160(2):216-9. doi: 10.1111/bjh.12086. Epub 2012 Oct 18. PMID: 23078005.

372: Warsch W, Grundschober E, Berger A, Gille L, Cerny-Reiterer S, Tigan AS, Hoelbl-Kovacic A, Valent P, Moriggl R, Sexl V. STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget. 2012 Dec;3(12):1669-87. doi: 10.18632/oncotarget.806. PMID: 23458731; PMCID: PMC3681503.

373: Valent P, Klion AD, Rosenwasser LJ, Arock M, Bochner BS, Butterfield JH, Gotlib J, Haferlach T, Hellmann A, Horny HP, Leiferman KM, Metzgeroth G, Matsumoto K, Reiter A, Roufosse F, Rothenberg ME, Simon HU, Sotlar K, Vandenberghe P, Weller PF, Gleich GJ. ICON: Eosinophil Disorders. World Allergy Organ J. 2012 Dec;5(12):174-81. doi: 10.1097/WOX.0b013e31827f4192. PMID: 23282419; PMCID: PMC3651188.

374: Herrmann H, Blatt K, Shi J, Gleixner KV, Cerny-Reiterer S, Müllauer L, Vakoc CR, Sperr WR, Horny HP, Bradner JE, Zuber J, Valent P. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget. 2012 Dec;3(12):1588-99. doi: 10.18632/oncotarget.733. PMID: 23249862; PMCID: PMC3681497.

375: Valent P, Arock M, Bonadonna P, Brockow K, Broesby-Olsen S, Escribano L, Gleixner KV, Grattan C, Hadzijusufovic E, Hägglund H, Hermine O, Horny HP, Kluin-Nelemans HC, Maurer M, Niedoszytko M, Nedoszytko B, Nilsson G, Oude- Elberink HN, Orfao A, Radia D, Reiter A, Siebenhaar F, Sotlar K, Sperr WR, Triggiani M, VanDoormaal JJ, Várkonyi J, Yavuz S, Hartmann K. European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. Wien Klin Wochenschr. 2012 Dec;124(23-24):807-14. doi: 10.1007/s00508-012-0293-z. Epub 2012 Nov 20. PMID: 23179435.

376: Sotlar K, Valent P, Horny HP. Mastozytosen und myeloische Neoplasien mit Eosinophilie: Diagnostik und Klassifikation [Mastocytosis and eosinophilic leukemia: diagnostics and classification]. Pathologe. 2012 Nov;33(6):539-52. German. doi: 10.1007/s00292-012-1654-0. PMID: 23085697.

377: Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, Schiefer AI, Hassler MR, Heider S, Amenitsch L, Thallinger C, Staber PB, Simonitsch-Klupp I, Artaker M, Lagger S, Turner SD, Pileri S, Piccaluga PP, Valent P, Messana K, Landra I, Weichhart T, Knapp S, Shehata M, Todaro M, Sexl V, Höfler G, Piva R, Medico E, Ruggeri BA, Cheng M, Eferl R, Egger G, Penninger JM, Jaeger U, Moriggl R, Inghirami G, Kenner L. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med. 2012 Nov;18(11):1699-704. doi: 10.1038/nm.2966. Epub 2012 Oct 14. PMID: 23064464.

378: Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wöhrer S, Arock M, Zuber J, Cerny-Reiterer S, Johnsen HE, Andreeff M, Eaves C. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer. 2012 Nov;12(11):767-75. doi: 10.1038/nrc3368. Epub 2012 Oct 11. PMID: 23051844.

379: Winter GE, Rix U, Carlson SM, Gleixner KV, Grebien F, Gridling M, Müller AC, Breitwieser FP, Bilban M, Colinge J, Valent P, Bennett KL, White FM, Superti-Furga G. Systems-pharmacology dissection of a drug synergy in imatinib- resistant CML. Nat Chem Biol. 2012 Nov;8(11):905-912. doi: 10.1038/nchembio.1085. Epub 2012 Sep 30. PMID: 23023260; PMCID: PMC4038039.

380: Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012 Sep 20;120(12):2454-65. doi: 10.1182/blood-2012-03-420489. Epub 2012 Jun 27. PMID: 22740453; PMCID: PMC4425443.

381: Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF, Hellmann A, Metzgeroth G, Leiferman KM, Arock M, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Haferlach T, Simon HU, Reiter A, Gleich GJ. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012 Sep;130(3):607-612.e9. doi: 10.1016/j.jaci.2012.02.019. Epub 2012 Mar 28. PMID: 22460074; PMCID: PMC4091810.

382: Chen KW, Blatt K, Thomas WR, Swoboda I, Valent P, Valenta R, Vrtala S. Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy. J Allergy Clin Immunol. 2012 Aug;130(2):435-43.e4. doi: 10.1016/j.jaci.2012.05.035. Epub 2012 Jul 11. PMID: 22789398; PMCID: PMC4594766.

383: Cerny-Reiterer S, Ghanim V, Hoermann G, Aichberger KJ, Herrmann H, Muellauer L, Repa A, Sillaber C, Walls AF, Mayerhofer M, Valent P. Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression. Neoplasia. 2012 Jul;14(7):572-84. doi: 10.1593/neo.12724. PMID: 22904675; PMCID: PMC3421954.

384: Hauswirth AW, Almeida J, Nieto WG, Teodosio C, Rodriguez-Caballero A, Romero A, López A, Fernandez-Navarro P, Vega T, Perez-Andres M, Valent P, Jäger U, Orfao A; Primary Health Care Group of Salamanca for Study of MBL. Monoclonal B-cell lymphocytosis (MBL) with normal lymphocyte counts is associated with decreased numbers of normal circulating B-cell subsets. Am J Hematol. 2012 Jul;87(7):721-4. doi: 10.1002/ajh.23214. Epub 2012 Jun 8. PMID: 22685020.

385: Hadzijusufovic E, Peter B, Herrmann H, Rülicke T, Cerny-Reiterer S, Schuch K, Kenner L, Thaiwong T, Yuzbasiyan-Gurkan V, Pickl WF, Willmann M, Valent P. NI-1: a novel canine mastocytoma model for studying drug resistance and IgER- dependent mast cell activation. Allergy. 2012 Jul;67(7):858-68. doi: 10.1111/j.1398-9995.2012.02833.x. Epub 2012 May 15. Erratum in: Allergy. 2018 Nov;73(11):2264. PMID: 22583069; PMCID: PMC3401908.

386: Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, Burbury K, Cullen M, Cutler JA, Della Porta MG, Dräger AM, Feuillard J, Font P, Germing U, Haase D, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Ogata K, Orfao A, Porwit A, Psarra K, Richards SJ, Subirá D, Tindell V, Vallespi T, Valent P, van der Velden VH, de Witte TM, Wells DA, Zettl F, Béné MC, van de Loosdrecht AA. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia. 2012 Jul;26(7):1730-41. doi: 10.1038/leu.2012.30. Epub 2012 Feb 6. PMID: 22307178.

387: Twaroch TE, Focke M, Fleischmann K, Balic N, Lupinek C, Blatt K, Ferrara R, Mari A, Ebner C, Valent P, Spitzauer S, Swoboda I, Valenta R. Carrier-bound Alt a 1 peptides without allergenic activity for vaccination against Alternaria alternata allergy. Clin Exp Allergy. 2012 Jun;42(6):966-75. doi: 10.1111/j.1365-2222.2012.03996.x. PMID: 22909168; PMCID: PMC5321512.

388: Sperr WR, Valent P. Diagnosis, progression patterns and prognostication in mastocytosis. Expert Rev Hematol. 2012 Jun;5(3):261-74. doi: 10.1586/ehm.12.12. PMID: 22780207.

389: Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P, Kelaidi C, Pfeilstöcker M, Nösslinger T, Sekeres M, Maciejewski J, Haase D, Schanz J, Seymour J, Kenealy M, Weide R, Lübbert M, Platzbecker U, Valent P, Götze K, Stauder R, Blum S, Kreuzer KA, Schlenk R, Ganser A, Hofmann WK, Aul C, Krieger O, Kündgen A, Haas R, Hasford J, Giagounidis A. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia. 2012 Jun;26(6):1286-92. doi: 10.1038/leu.2011.391. Epub 2012 Jan 13. PMID: 22289990.

390: Valent P, Gastl G, Geissler K, Greil R, Hantschel O, Lang A, Linkesch W, Lion T, Petzer AL, Pittermann E, Pleyer L, Thaler J, Wolf D. Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions. Crit Rev Oncol Hematol. 2012 Jun;82(3):370-7. doi: 10.1016/j.critrevonc.2011.08.002. Epub 2011 Sep 7. PMID: 21903413.

391: Ghanim V, Herrmann H, Heller G, Peter B, Hadzijusufovic E, Blatt K, Schuch K, Cerny-Reiterer S, Mirkina I, Karlic H, Pickl WF, Zöchbauer-Müller S, Valent P. 5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS- ligand. Blood. 2012 May 3;119(18):4242-52. doi: 10.1182/blood-2011-09-382770. Epub 2012 Mar 21. PMID: 22438247.

392: Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, Cramer K, Reddy MM, Koptyra M, Penserga T, Glodkowska-Mrowka E, Bolton E, Holyoake TL, Eaves CJ, Cerny-Reiterer S, Valent P, Hochhaus A, Hughes TP, van der Kuip H, Sattler M, Wiktor-Jedrzejczak W, Richardson C, Dorrance A, Stoklosa T, Williams DA, Skorski T. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood. 2012 May 3;119(18):4253-63. doi: 10.1182/blood-2011-10-385658. Epub 2012 Mar 12. PMID: 22411871; PMCID: PMC3359741.

393: Chen KW, Focke-Tejkl M, Blatt K, Kneidinger M, Gieras A, Dall'Antonia F, Faé I, Fischer G, Keller W, Valent P, Valenta R, Vrtala S. Carrier-bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen-induced basophil activation in allergic patients. Allergy. 2012 May;67(5):609-21. doi: 10.1111/j.1398-9995.2012.02794.x. Epub 2012 Feb 17. PMID: 22339348; PMCID: PMC4594777.

394: Eckl-Dorna J, Ellinger A, Blatt K, Ghanim V, Steiner I, Pavelka M, Valent P, Valenta R, Niederberger V. Basophils are not the key antigen-presenting cells in allergic patients. Allergy. 2012 May;67(5):601-8. doi: 10.1111/j.1398-9995.2012.02792.x. Epub 2012 Feb 16. PMID: 22335568; PMCID: PMC4601523.

395: Valent P, Gleich GJ, Reiter A, Roufosse F, Weller PF, Hellmann A, Metzgeroth G, Leiferman KM, Arock M, Sotlar K, Butterfield JH, Cerny-Reiterer S, Mayerhofer M, Vandenberghe P, Haferlach T, Bochner BS, Gotlib J, Horny HP, Simon HU, Klion AD. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol. 2012 Apr;5(2):157-76. doi: 10.1586/ehm.11.81. PMID: 22475285; PMCID: PMC3625626.

396: Valent P, Horny HP, Bochner BS, Haferlach T, Reiter A. Controversies and open questions in the definitions and classification of the hypereosinophilic syndromes and eosinophilic leukemias. Semin Hematol. 2012 Apr;49(2):171-81. doi: 10.1053/j.seminhematol.2012.01.009. PMID: 22449627.

397: Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012 Mar 10;30(8):820-9. doi: 10.1200/JCO.2011.35.6394. Epub 2012 Feb 13. PMID: 22331955; PMCID: PMC4874200.

398: Hoermann G, Cerny-Reiterer S, Herrmann H, Blatt K, Bilban M, Gisslinger H, Gisslinger B, Müllauer L, Kralovics R, Mannhalter C, Valent P, Mayerhofer M. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms. FASEB J. 2012 Feb;26(2):894-906. doi: 10.1096/fj.11-193078. Epub 2011 Nov 3. PMID: 22051730.

399: Herrmann H, Cerny-Reiterer S, Gleixner KV, Blatt K, Herndlhofer S, Rabitsch W, Jäger E, Mitterbauer-Hohendanner G, Streubel B, Selzer E, Schwarzinger I, Sperr WR, Valent P. CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin. Haematologica. 2012 Feb;97(2):219-26. doi: 10.3324/haematol.2010.035006. Epub 2011 Oct 11. PMID: 21993666; PMCID: PMC3269481.

400: Valent P. Low blood counts: immune mediated, idiopathic, or myelodysplasia. Hematology Am Soc Hematol Educ Program. 2012;2012:485-91. doi: 10.1182/asheducation-2012.1.485. PMID: 23233623.

401: Herrmann H, Blatt K, Ghanim V, Kneidinger M, Marth K, Valenta R, Valent P. Glucocorticosteroids rescue basophils from dasatinib-augmented immunoglobulin E-mediated histamine release. Int Arch Allergy Immunol. 2012;159(1):15-22. doi: 10.1159/000335146. Epub 2012 Apr 27. PMID: 22555087; PMCID: PMC6624142.

402: Horny HP, Sotlar K, Valent P. Evaluation of mast cell activation syndromes: impact of pathology and immunohistology. Int Arch Allergy Immunol. 2012;159(1):1-5. doi: 10.1159/000336374. Epub 2012 Apr 27. PMID: 22555026.

403: Wicklein D, Ramos Leal N, Salamon J, Thamer M, Herrmann H, Valent P, Schumacher U, Ullrich S. Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model. PLoS One. 2012;7(2):e30567. doi: 10.1371/journal.pone.0030567. Epub 2012 Feb 14. PMID: 22348015; PMCID: PMC3279340.

404: Blatt K, Herrmann H, Mirkina I, Hadzijusufovic E, Peter B, Strommer S, Hoermann G, Mayerhofer M, Hoetzenecker K, Klepetko W, Ghanim V, Marth K, Füreder T, Wacheck V, Valenta R, Valent P. The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils. PLoS One. 2012;7(1):e29925. doi: 10.1371/journal.pone.0029925. Epub 2012 Jan 27. PMID: 22299028; PMCID: PMC3267720.

405: Herrmann H, Kneidinger M, Cerny-Reiterer S, Rülicke T, Willmann M, Gleixner KV, Blatt K, Hörmann G, Peter B, Samorapoompichit P, Pickl W, Bharate GY, Mayerhofer M, Sperr WR, Maeda H, Valent P. The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells. Curr Cancer Drug Targets. 2012 Jan;12(1):51-63. doi: 10.2174/156800912798888992. PMID: 22165967.

406: Wimazal F, Geissler P, Shnawa P, Sperr WR, Valent P. Severe life- threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience. Int Arch Allergy Immunol. 2012;157(4):399-405. doi: 10.1159/000329218. Epub 2011 Nov 25. PMID: 22123213.

407: Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, Castells M, Escribano L, Hartmann K, Lieberman P, Nedoszytko B, Orfao A, Schwartz LB, Sotlar K, Sperr WR, Triggiani M, Valenta R, Horny HP, Metcalfe DD. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215-25. doi: 10.1159/000328760. Epub 2011 Oct 27. PMID: 22041891; PMCID: PMC3224511.

408: Preuner S, Mitterbauer G, Mannhalter C, Herndlhofer S, Sperr WR, Valent P, Lion T. Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia. Eur J Cancer. 2012 Jan;48(2):233-6. doi: 10.1016/j.ejca.2011.08.015. Epub 2011 Sep 28. PMID: 21955823.

409: Valent P, Bain BJ, Bennett JM, Wimazal F, Sperr WR, Mufti G, Horny HP. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leuk Res. 2012 Jan;36(1):1-5. doi: 10.1016/j.leukres.2011.08.016. Epub 2011 Sep 13. PMID: 21920601.

410: Hudson SA, Herrmann H, Du J, Cox P, Haddad el-B, Butler B, Crocker PR, Ackerman SJ, Valent P, Bochner BS. Developmental, malignancy-related, and cross- species analysis of eosinophil, mast cell, and basophil siglec-8 expression. J Clin Immunol. 2011 Dec;31(6):1045-53. doi: 10.1007/s10875-011-9589-4. Epub 2011 Sep 22. PMID: 21938510; PMCID: PMC3329870.

411: Grebien F, Hantschel O, Wojcik J, Kaupe I, Kovacic B, Wyrzucki AM, Gish GD, Cerny-Reiterer S, Koide A, Beug H, Pawson T, Valent P, Koide S, Superti-Furga G. Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell. 2011 Oct 14;147(2):306-19. doi: 10.1016/j.cell.2011.08.046. PMID: 22000011; PMCID: PMC3202669.

412: Valent P. Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities. Haematologica. 2011 Oct;96(10):1395-7. doi: 10.3324/haematol.2011.052076. PMID: 21972208; PMCID: PMC3186297.

413: Le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndlhofer S, Dörken B, Valent P. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst. 2011 Sep 7;103(17):1347-8. doi: 10.1093/jnci/djr292. Epub 2011 Aug 2. PMID: 21813414.

414: Brünner-Kubath C, Shabbir W, Saferding V, Wagner R, Singer CF, Valent P, Berger W, Marian B, Zielinski CC, Grusch M, Grunt TW. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res Treat. 2011 Sep;129(2):387-400. doi: 10.1007/s10549-010-1232-1. Epub 2010 Nov 3. PMID: 21046231.

415: Gleixner KV, Mayerhofer M, Cerny-Reiterer S, Hörmann G, Rix U, Bennett KL, Hadzijusufovic E, Meyer RA, Pickl WF, Gotlib J, Horny HP, Reiter A, Mitterbauer- Hohendanner G, Superti-Furga G, Valent P. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood. 2011 Aug 18;118(7):1885-98. doi: 10.1182/blood-2010-06-289959. Epub 2011 Jun 16. PMID: 21680801.

416: Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, Valent P, Bradner JE, Lowe SW, Vakoc CR. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011 Aug 3;478(7370):524-8. doi: 10.1038/nature10334. PMID: 21814200; PMCID: PMC3328300.

417: Füreder W, Valent P. Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approaches. Leuk Lymphoma. 2011 Aug;52(8):1435-45. doi: 10.3109/10428194.2011.568646. Epub 2011 Jun 3. PMID: 21635205.

418: Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer- Hohendanner G, Sillaber C, Valent P. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011 Jul;86(7):533-9. doi: 10.1002/ajh.22037. Epub 2011 Apr 27. PMID: 21538470.

419: Boehm A, Rabitsch W, Locker GJ, Worel N, Robak O, Laczika KF, Staudinger T, Bojic A, Siersch V, Valent P, Sperr WR. Successful allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia during respiratory failure and invasive mechanical ventilation. Wien Klin Wochenschr. 2011 Jun;123(11-12):354-8. doi: 10.1007/s00508-011-1590-7. Epub 2011 Jun 3. PMID: 21633813.

420: Niespodziana K, Focke-Tejkl M, Linhart B, Civaj V, Blatt K, Valent P, van Hage M, Grönlund H, Valenta R. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol. 2011 Jun;127(6):1562-70.e6. doi: 10.1016/j.jaci.2011.02.004. Epub 2011 Mar 16. PMID: 21411130; PMCID: PMC6624143.

421: Schanz J, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Tuechler H, Valent P, Hildebrandt B, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Kantarjian H, Germing U, Haase D, Estey E. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol. 2011 May 20;29(15):1963-70. doi: 10.1200/JCO.2010.28.3978. Epub 2011 Apr 25. PMID: 21519021; PMCID: PMC4874202.

422: Böhm A, Herrmann H, Mitterbauer-Hohendanner G, Hauswirth AW, Rabitsch W, Mitterbauer M, Sperr WR, Kalhs P, Jäger U, Valent P. Stable non-transforming minimal residual disease in Philadelphia chromosome positive acute lymphoblastic leukemia after autologous transplantation: origin from neoplastic yet 'pre- leukemic' stem cells? Leuk Lymphoma. 2011 May;52(5):842-8. doi: 10.3109/10428194.2011.557168. Epub 2011 Apr 4. PMID: 21463112.

423: Hoermann G, Cerny-Reiterer S, Perné A, Klauser M, Hoetzenecker K, Klein K, Müllauer L, Gröger M, Nijman SM, Klepetko W, Valent P, Mayerhofer M. Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis. Am J Pathol. 2011 May;178(5):2344-56. doi: 10.1016/j.ajpath.2011.01.020. Epub 2011 Mar 31. PMID: 21457934; PMCID: PMC3081146.

424: Gieras A, Cejka P, Blatt K, Focke-Tejkl M, Linhart B, Flicker S, Stoecklinger A, Marth K, Drescher A, Thalhamer J, Valent P, Majdic O, Valenta R. Mapping of conformational IgE epitopes with peptide-specific monoclonal antibodies reveals simultaneous binding of different IgE antibodies to a surface patch on the major birch pollen allergen, Bet v 1. J Immunol. 2011 May 1;186(9):5333-44. doi: 10.4049/jimmunol.1000804. Epub 2011 Mar 30. PMID: 21451110.

425: Valent P, Sotlar K, Horny HP. Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. Leuk Lymphoma. 2011 May;52(5):740-4. doi: 10.3109/10428194.2010.550072. Epub 2011 Jan 24. PMID: 21261503.

426: Peter B, Gleixner KV, Cerny-Reiterer S, Herrmann H, Winter V, Hadzijusufovic E, Ferenc V, Schuch K, Mirkina I, Horny HP, Pickl WF, Müllauer L, Willmann M, Valent P. Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536. Haematologica. 2011 May;96(5):672-80. doi: 10.3324/haematol.2010.031328. Epub 2011 Jan 17. PMID: 21242189; PMCID: PMC3084913.

427: Loeffler-Ragg J, Germing U, Sperr WR, Herrmann H, Zwierzina H, Valent P, Ulmer H, Stauder R. Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes. Crit Rev Oncol Hematol. 2011 May;78(2):150-61. doi: 10.1016/j.critrevonc.2010.05.008. Epub 2010 Jun 26. PMID: 20580567.

428: Sotlar K, Cerny-Reiterer S, Petat-Dutter K, Hessel H, Berezowska S, Müllauer L, Valent P, Horny HP. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol. 2011 Apr;24(4):585-95. doi: 10.1038/modpathol.2010.224. Epub 2010 Dec 24. PMID: 21186345.

429: Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Hölbl A, Gleixner KV, Dworzak M, Mayerhofer M, Hoermann G, Herrmann H, Sillaber C, Egger G, Valent P, Moriggl R, Sexl V. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 2011 Mar 24;117(12):3409-20. doi: 10.1182/blood-2009-10-248211. Epub 2011 Jan 10. PMID: 21220747.

430: Vrtala S, Fohr M, Campana R, Baumgartner C, Valent P, Valenta R. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination. Vaccine. 2011 Mar 3;29(11):2140-8. doi: 10.1016/j.vaccine.2010.12.080. Epub 2011 Jan 5. PMID: 21215346; PMCID: PMC4092211.

431: Schellongowski P, Staudinger T, Kundi M, Laczika K, Locker GJ, Bojic A, Robak O, Fuhrmann V, Jäger U, Valent P, Sperr WR. Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience. Haematologica. 2011 Feb;96(2):231-7. doi: 10.3324/haematol.2010.031583. Epub 2010 Nov 11. PMID: 21071501; PMCID: PMC3031690.

432: Valent P, Jäger E, Mitterbauer-Hohendanner G, Müllauer L, Schwarzinger I, Sperr WR, Thalhammer R, Wimazal F. Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis. Am J Cancer Res. 2011;1(4):531-41. Epub 2010 Mar 16. PMID: 21984971; PMCID: PMC3186051.

433: Baranyi U, Gattringer M, Boehm A, Marth K, Focke-Tejkl M, Bohle B, Blatt K, Valent P, Valenta R, Wekerle T. Expression of a major plant allergen as membrane-anchored and secreted protein in human cells with preserved T cell and B cell epitopes. Int Arch Allergy Immunol. 2011;156(3):259-66. doi: 10.1159/000323733. Epub 2011 Jun 29. PMID: 21720171.

434: Wacheck V, Lahn M, Dickinson G, Füreder W, Meyer R, Herndlhofer S, Füreder T, Dorfner G, Pillay S, André V, Burkholder TP, Akunda JK, Flye-Blakemore L, Van Bockstaele D, Schlenk RF, Sperr WR, Valent P. Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics. Cancer Manag Res. 2011;3:157-75. doi: 10.2147/CMR.S19341. Epub 2011 May 10. PMID: 21625399; PMCID: PMC3101112.

435: Valent P, Horny HP, Triggiani M, Arock M. Clinical and laboratory parameters of mast cell activation as basis for the formulation of diagnostic criteria. Int Arch Allergy Immunol. 2011;156(2):119-27. doi: 10.1159/000323763. Epub 2011 May 16. PMID: 21576982.

436: Valent P, Horny HP. Classification and response criteria in mast cell disorders: time to revise? Int Arch Allergy Immunol. 2011;155(3):306-8. doi: 10.1159/000320381. Epub 2011 Feb 3. PMID: 21293151.

437: Campana R, Vrtala S, Maderegger B, Dall'Antonia Y, Zafred D, Blatt K, Herrmann H, Focke-Tejkl M, Swoboda I, Scheiblhofer S, Gieras A, Neubauer A, Keller W, Valent P, Thalhamer J, Spitzauer S, Valenta R. Altered IgE epitope presentation: A model for hypoallergenic activity revealed for Bet v 1 trimer. Mol Immunol. 2011 Jan;48(4):431-41. doi: 10.1016/j.molimm.2010.09.016. Epub 2010 Nov 18. PMID: 21093057; PMCID: PMC4067515.

438: Valent P. Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept. Curr Cancer Drug Targets. 2011 Jan;11(1):56-71. doi: 10.2174/156800911793743655. PMID: 21062243.

439: Krauth MT, Herndlhofer S, Schmook MT, Mitterbauer-Hohendanner G, Schlögl E, Valent P. Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily. Haematologica. 2011 Jan;96(1):163-6. doi: 10.3324/haematol.2010.030494. Epub 2010 Oct 7. PMID: 20934998; PMCID: PMC3012781.

440: Mallo M, Cervera J, Schanz J, Such E, García-Manero G, Luño E, Steidl C, Espinet B, Vallespí T, Germing U, Blum S, Ohyashiki K, Grau J, Pfeilstöcker M, Hernández JM, Noesslinger T, Giagounidis A, Aul C, Calasanz MJ, Martín ML, Valent P, Collado R, Haferlach C, Fonatsch C, Lübbert M, Stauder R, Hildebrandt B, Krieger O, Pedro C, Arenillas L, Sanz MÁ, Valencia A, Florensa L, Sanz GF, Haase D, Solé F. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia. 2011 Jan;25(1):110-20. doi: 10.1038/leu.2010.231. Epub 2010 Sep 30. PMID: 20882045.

441: Boehm A, Walcherberger B, Sperr WR, Wöhrer S, Dieckmann K, Rosenmayr A, Pernicka E, Fischer G, Worel N, Mitterbauer G, Schwarzinger I, Mitterbauer M, Haas OA, Lechner K, Hinterberger W, Valent P, Greinix HT, Rabitsch W, Kalhs P. Improved outcome in patients with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: a single-center experience. Biol Blood Marrow Transplant. 2011 Jan;17(1):133-40. doi: 10.1016/j.bbmt.2010.06.019. Epub 2010 Jul 1. PMID: 20601032.

442: Valent P, Sperr WR, Akin C. How I treat patients with advanced systemic mastocytosis. Blood. 2010 Dec 23;116(26):5812-7. doi: 10.1182/blood-2010-08-292144. Epub 2010 Sep 20. PMID: 20855864.

443: Giles FJ, Rosti G, Beris P, Clark RE, le Coutre P, Mahon FX, Steegmann JL, Valent P, Saglio G. Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. Expert Rev Hematol. 2010 Dec;3(6):665-73. doi: 10.1586/ehm.10.61. Epub 2010 Nov 9. PMID: 21091142.

444: Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol. 2010 Dec;126(6):1099-104.e4. doi: 10.1016/j.jaci.2010.08.035. Epub 2010 Oct 28. PMID: 21035176; PMCID: PMC3753019.

445: Valent P, Orazi A, Büsche G, Schmitt-Gräff A, George TI, Sotlar K, Streubel B, Beham-Schmid C, Cerny-Reiterer S, Krieger O, van de Loosdrecht A, Kern W, Ogata K, Wimazal F, Várkonyi J, Sperr WR, Werner M, Kreipe H, Horny HP. Standards and impact of hematopathology in myelodysplastic syndromes (MDS). Oncotarget. 2010 Nov;1(7):483-96. doi: 10.18632/oncotarget.101104. PMID: 21317447; PMCID: PMC3248141.

446: Valent P. Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia. Lancet Oncol. 2010 Nov;11(11):1010-1. doi: 10.1016/S1470-2045(10)70243-6. Epub 2010 Oct 19. PMID: 20965784.

447: Campana R, Vrtala S, Maderegger B, Jertschin P, Stegfellner G, Swoboda I, Focke-Tejkl M, Blatt K, Gieras A, Zafred D, Neubauer A, Valent P, Keller W, Spitzauer S, Valenta R. Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly. J Allergy Clin Immunol. 2010 Nov;126(5):1024-31, 1031.e1-8. doi: 10.1016/j.jaci.2010.05.023. Epub 2010 Jul 16. PMID: 20638112.

448: Schulenburg A, Brämswig K, Herrmann H, Karlic H, Mirkina I, Hubmann R, Laffer S, Marian B, Shehata M, Krepler C, Pehamberger H, Grunt T, Jäger U, Zielinski CC, Valent P. Neoplastic stem cells: current concepts and clinical perspectives. Crit Rev Oncol Hematol. 2010 Nov;76(2):79-98. doi: 10.1016/j.critrevonc.2010.01.001. Epub 2010 Feb 25. PMID: 20185329.

449: Schmidt S, Wolf D, Thaler J, Burgstaller S, Linkesch W, Petzer A, Fridrik M, Lang A, Agis H, Valent P, Krieger O, Walder A, Korger M, Schlögl E, Sliwa T, Wöll E, Mitterer M, Eisterer W, Pober M, Gastl G; ASHO CML registry. First annual report of the Austrian CML registry. Wien Klin Wochenschr. 2010 Oct;122(19-20):558-66. doi: 10.1007/s00508-010-1450-x. Epub 2010 Oct 11. PMID: 20936366.

450: Valent P. Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor? Eur J Clin Invest. 2010 Oct;40(10):918-31. doi: 10.1111/j.1365-2362.2010.02328.x. Epub 2010 Aug 19. PMID: 20597967.

451: Hadzijusufovic E, Peter B, Gleixner KV, Schuch K, Pickl WF, Thaiwong T, Yuzbasiyan-Gurkan V, Mirkina I, Willmann M, Valent P. H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells. Exp Hematol. 2010 Oct;38(10):896-907. doi: 10.1016/j.exphem.2010.05.008. Epub 2010 Jun 1. PMID: 20570632; PMCID: PMC4337971.

452: Friedbichler K, Kerenyi MA, Kovacic B, Li G, Hoelbl A, Yahiaoui S, Sexl V, Müllner EW, Fajmann S, Cerny-Reiterer S, Valent P, Beug H, Gouilleux F, Bunting KD, Moriggl R. Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood. 2010 Sep 2;116(9):1548-58. doi: 10.1182/blood-2009-12-258913. Epub 2010 May 27. PMID: 20508164; PMCID: PMC2938843.

453: Valent P, Cerny-Reiterer S, Herrmann H, Mirkina I, George TI, Sotlar K, Sperr WR, Horny HP. Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells. Best Pract Res Clin Haematol. 2010 Sep;23(3):369-78. doi: 10.1016/j.beha.2010.07.003. Epub 2010 Aug 12. PMID: 21112036.

454: Peter B, Hadzijusufovic E, Blatt K, Gleixner KV, Pickl WF, Thaiwong T, Yuzbasiyan-Gurkan V, Willmann M, Valent P. KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406). Exp Hematol. 2010 Sep;38(9):782-91. doi: 10.1016/j.exphem.2010.05.004. Epub 2010 May 26. PMID: 20685234.

455: Böhm A, Sonneck K, Gleixner KV, Schuch K, Pickl WF, Blatt K, Peter B, Herrmann H, Schernthaner GH, Pehamberger H, Rabitsch W, Sperr WR, Valent P. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Exp Hematol. 2010 Sep;38(9):744-55. doi: 10.1016/j.exphem.2010.05.006. Epub 2010 May 27. PMID: 20553795.

456: Valent P, Arock M, Akin C, Sperr WR, Reiter A, Sotlar K, Hartmann K, George TI, Brockow K, Kluin-Nelemans HC, Gotlib J, Metcalfe DD, Horny HP. The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD). Blood. 2010 Aug 5;116(5):850-1. doi: 10.1182/blood-2010-05-285270. PMID: 20688965; PMCID: PMC2918335.

457: Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol. 2010 Aug;3(4):497-516. doi: 10.1586/ehm.10.42. PMID: 21083038.

458: Arredondo AR, Gotlib J, Shier L, Medeiros B, Wong K, Cherry A, Corless C, Arber DA, Valent P, George TI. Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. Am J Hematol. 2010 Aug;85(8):600-6. doi: 10.1002/ajh.21713. PMID: 20658589.

459: Fritsche-Polanz R, Fritz M, Huber A, Sotlar K, Sperr WR, Mannhalter C, Födinger M, Valent P. High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V. Mol Oncol. 2010 Aug;4(4):335-46. doi: 10.1016/j.molonc.2010.04.008. Epub 2010 Apr 24. PMID: 20471335; PMCID: PMC5527910.

460: Karlic H, Herrmann H, Schulenburg A, Grunt TW, Laffer S, Mirkina I, Hubmann R, Shehata M, Marian B, Selzer E, Pfeilstöcker M, Pittermann E, Jäger U, Pehamberger H, Zielinski C, Valent P. Tumor-Stammzellforschung - Basis und Herausforderung für Diagnostik und Therapie [Tumor stem cell research - basis and challenge for diagnosis and therapy]. Wien Klin Wochenschr. 2010 Jul;122(13-14):423-36. German. doi: 10.1007/s00508-010-1408-z. Epub 2010 Jul 22. PMID: 20645015.

461: Valent P, Akin C, Sperr WR, Horny HP, Metcalfe DD. Refinements in response criteria in systemic mastocytosis: reply to a proposal. Eur J Haematol. 2010 Jul;85(1):88-9; author reply 90. doi: 10.1111/j.1600-0609.2010.01462.x. Epub 2010 Apr 26. PMID: 20456489.

462: Merz H, Kaehler C, Hoefig KP, Branke B, Uckert W, Nadrowitz R, Cerny- Reiterer S, Herrmann H, Feller AC, Valent P. Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single 'hit' and cooperate in producing a mastocytosis-like disease in mice. Oncotarget. 2010 Jun;1(2):104-19. doi: 10.18632/oncotarget.100602. PMID: 21297223; PMCID: PMC3157709.

463: Valent P. Classification and response criteria in mastocytosis: is there a need to revise? Expert Rev Hematol. 2010 Jun;3(3):247-9. doi: 10.1586/ehm.10.20. PMID: 21082975.

464: Wimazal F, Germing U, Kundi M, Noesslinger T, Blum S, Geissler P, Baumgartner C, Pfeilstoecker M, Valent P, Sperr WR. Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes. Cancer. 2010 May 15;116(10):2372-81. doi: 10.1002/cncr.25036. PMID: 20209617.

465: Sotlar K, Colak S, Bache A, Berezowska S, Krokowski M, Bültmann B, Valent P, Horny HP. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol. 2010 Apr;220(5):586-95. doi: 10.1002/path.2677. PMID: 20112369.

466: Prager GW, Lackner EM, Krauth MT, Unseld M, Poettler M, Laffer S, Cerny- Reiterer S, Lamm W, Kornek GV, Binder BR, Zielinski CC, Valent P. Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab. Mol Oncol. 2010 Apr;4(2):150-60. doi: 10.1016/j.molonc.2010.01.002. Epub 2010 Jan 7. PMID: 20106729; PMCID: PMC5527896.

467: Hubmann R, Düchler M, Schnabl S, Hilgarth M, Demirtas D, Mitteregger D, Hölbl A, Vanura K, Le T, Look T, Schwarzmeier JD, Valent P, Jäger U, Shehata M. NOTCH2 links protein kinase C delta to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cells. Br J Haematol. 2010 Mar;148(6):868-78. doi: 10.1111/j.1365-2141.2009.08024.x. Epub 2009 Dec 8. PMID: 19995395.

468: Gleixner KV, Ferenc V, Peter B, Gruze A, Meyer RA, Hadzijusufovic E, Cerny- Reiterer S, Mayerhofer M, Pickl WF, Sillaber C, Valent P. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Cancer Res. 2010 Feb 15;70(4):1513-23. doi: 10.1158/0008-5472.CAN-09-2181. Epub 2010 Feb 9. PMID: 20145140.

469: Horny HP, Sotlar K, Valent P. Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review. Pathobiology. 2010;77(4):169-80. doi: 10.1159/000305552. Epub 2010 Jul 7. PMID: 20616612.

470: Rix U, Remsing Rix LL, Terker AS, Fernbach NV, Hantschel O, Planyavsky M, Breitwieser FP, Herrmann H, Colinge J, Bennett KL, Augustin M, Till JH, Heinrich MC, Valent P, Superti-Furga G. A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells. Leukemia. 2010 Jan;24(1):44-50. doi: 10.1038/leu.2009.228. Epub 2009 Nov 5. PMID: 19890374.

471: Valent P, Dahinden CA. Role of interleukins in the regulation of basophil development and secretion. Curr Opin Hematol. 2010 Jan;17(1):60-6. doi: 10.1097/MOH.0b013e328331fae9. PMID: 19741522.

472: Nösslinger T, Tüchler H, Germing U, Sperr WR, Krieger O, Haase D, Lübbert M, Stauder R, Giagounidis A, Valent P, Pfeilstöcker M. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol. 2010 Jan;21(1):120-5. doi: 10.1093/annonc/mdp264. Epub 2009 Jul 15. PMID: 19605511.

473: Sperr WR, Wimazal F, Kundi M, Baumgartner C, Nösslinger T, Makrai A, Stauder R, Krieger O, Pfeilstöcker M, Valent P. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol. 2010 Jan;21(1):114-9. doi: 10.1093/annonc/mdp258. Epub 2009 Jul 15. PMID: 19605505.

474: Aichberger KJ, Gleixner KV, Mirkina I, Cerny-Reiterer S, Peter B, Ferenc V, Kneidinger M, Baumgartner C, Mayerhofer M, Gruze A, Pickl WF, Sillaber C, Valent P. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood. 2009 Dec 17;114(26):5342-51. doi: 10.1182/blood-2008-08-175190. Epub 2009 Oct 22. PMID: 19850739.

475: Hadzijusufovic E, Peter B, Rebuzzi L, Baumgartner C, Gleixner KV, Gruze A, Thaiwong T, Pickl WF, Yuzbasiyan-Gurkan V, Willmann M, Valent P. Growth- inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation. Vet Immunol Immunopathol. 2009 Dec 15;132(2-4):243-50. doi: 10.1016/j.vetimm.2009.05.007. Epub 2009 May 18. PMID: 19505729; PMCID: PMC6763335.

476: Baumgartner C, Cerny-Reiterer S, Sonneck K, Mayerhofer M, Gleixner KV, Fritz R, Kerenyi M, Boudot C, Gouilleux F, Kornfeld JW, Sillaber C, Moriggl R, Valent P. Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. Am J Pathol. 2009 Dec;175(6):2416-29. doi: 10.2353/ajpath.2009.080953. Epub 2009 Nov 5. PMID: 19893034; PMCID: PMC2789628.

477: Boehm A, Mayerhofer M, Herndlhofer S, Knoebl P, Sillaber C, Sperr WR, Jaeger U, Valent P. Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML. Eur J Intern Med. 2009 Dec;20(8):775-8. doi: 10.1016/j.ejim.2009.09.007. Epub 2009 Oct 7. PMID: 19892307.

478: Sillaber C, Herrmann H, Bennett K, Rix U, Baumgartner C, Böhm A, Herndlhofer S, Tschachler E, Superti-Furga G, Jäger U, Valent P. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest. 2009 Dec;39(12):1098-109. doi: 10.1111/j.1365-2362.2009.02206.x. Epub 2009 Sep 9. PMID: 19744184.

479: Valent P, Sperr WR, Födinger M, Kundi M. Comorbidity, iron overload and HFE variants: a new prognostic complex in MDS? Eur J Clin Invest. 2009 Dec;39(12):1112-3. doi: 10.1111/j.1365-2362.2009.02196.x. Epub 2009 Jul 10. PMID: 19614957.

480: Willmann M, Müllauer L, Schwendenwein I, Wolfesberger B, Kleiter M, Pagitz M, Hadzijusufovic E, Shibly S, Reifinger M, Thalhammer JG, Valent P. Chemotherapy in canine acute megakaryoblastic leukemia: a case report and review of the literature. In Vivo. 2009 Nov-Dec;23(6):911-8. PMID: 20023232.

481: Krauth MT, Mirkina I, Herrmann H, Baumgartner C, Kneidinger M, Valent P. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells. Clin Exp Allergy. 2009 Nov;39(11):1711-20. doi: 10.1111/j.1365-2222.2009.03353.x. PMID: 19860818.

482: Schmidt U, Abramova A, Boucheron N, Eckelhart E, Schebesta A, Bilic I, Kneidinger M, Unger B, Hammer M, Sibilia M, Valent P, Ellmeier W. The protein tyrosine kinase Tec regulates mast cell function. Eur J Immunol. 2009 Nov;39(11):3228-38. doi: 10.1002/eji.200838839. PMID: 19688741.

483: Sperr WR, El-Samahi A, Kundi M, Girschikofsky M, Winkler S, Lutz D, Endler G, Rumpold H, Agis H, Sillaber C, Jäger U, Valent P. Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. Eur J Clin Invest. 2009 Oct;39(10):914-23. doi: 10.1111/j.1365-2362.2009.02184.x. Epub 2009 Jun 12. PMID: 19522836.

484: van de Loosdrecht AA, Alhan C, Béné MC, Della Porta MG, Dräger AM, Feuillard J, Font P, Germing U, Haase D, Homburg CH, Ireland R, Jansen JH, Kern W, Malcovati L, Te Marvelde JG, Mufti GJ, Ogata K, Orfao A, Ossenkoppele GJ, Porwit A, Preijers FW, Richards SJ, Schuurhuis GJ, Subirá D, Valent P, van der Velden VH, Vyas P, Westra AH, de Witte TM, Wells DA, Loken MR, Westers TM. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica. 2009 Aug;94(8):1124-34. doi: 10.3324/haematol.2009.005801. Epub 2009 Jun 22. PMID: 19546437; PMCID: PMC2719035.

485: Gleixner KV, Mayerhofer M, Vales A, Gruze A, Hörmann G, Cerny-Reiterer S, Lackner E, Hadzijusufovic E, Herrmann H, Iyer AK, Krauth MT, Pickl WF, Marian B, Panzer-Grümayer R, Sillaber C, Maeda H, Zielinski C, Valent P. Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy. Curr Cancer Drug Targets. 2009 Aug;9(5):675-89. doi: 10.2174/156800909789057024. Epub 2009 Aug 1. PMID: 19508170.

486: Valent P, Horny HP. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Invest. 2009 Jul;39(7):548-53. doi: 10.1111/j.1365-2362.2009.02151.x. Epub 2009 May 6. PMID: 19453651.

487: Valent P. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. Blood Rev. 2009 Jul;23(4):157-65. doi: 10.1016/j.blre.2009.01.001. Epub 2009 Feb 25. PMID: 19246139.

488: Valent P, Hofmann WK, Büsche G, Sotlar K, Horny HP, Haase D, Haferlach T, Kern W, Bettelheim P, Baumgartner C, Sperr WR, Nösslinger T, Wimazal F, Giagounidis AA, Lübbert M, Krieger O, Kolb HJ, Stauder R, Pfeilstöcker M, Gattermann N, Fonatsch C, Aul C, Germing U. Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes. Ann Hematol. 2009 Jul;88(7):607-11. doi: 10.1007/s00277-008-0673-7. Epub 2009 Jan 16. PMID: 19148644.

489: Edlmayr J, Niespodziana K, Linhart B, Focke-Tejkl M, Westritschnig K, Scheiblhofer S, Stoecklinger A, Kneidinger M, Valent P, Campana R, Thalhamer J, Popow-Kraupp T, Valenta R. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J Immunol. 2009 May 15;182(10):6298-306. doi: 10.4049/jimmunol.0713622. PMID: 19414783.

490: Böhm A, Aichberger KJ, Mayerhofer M, Herrmann H, Florian S, Krauth MT, Derdak S, Samorapoompichit P, Sonneck K, Vales A, Gleixner KV, Pickl WF, Sperr WR, Valent P. Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells. Eur J Clin Invest. 2009 May;39(5):395-405. doi: 10.1111/j.1365-2362.2009.02101.x. PMID: 19320940.

491: Wimazal F, Nösslinger T, Baumgartner C, Sperr WR, Pfeilstöcker M, Valent P. Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes. Eur J Clin Invest. 2009 May;39(5):406-11. doi: 10.1111/j.1365-2362.2009.02108.x. PMID: 19320908.

492: Lupinek C, Roux KH, Laffer S, Rauter I, Reginald K, Kneidinger M, Blatt K, Ball T, Pree I, Jahn-Schmid B, Allam JP, Novak N, Drescher A, Kricek F, Valent P, Englund H, Valenta R. Trimolecular complex formation of IgE, Fc epsilon RI, and a recombinant nonanaphylactic single-chain antibody fragment with high affinity for IgE. J Immunol. 2009 Apr 15;182(8):4817-29. doi: 10.4049/jimmunol.0800726. PMID: 19342660.

493: Ball T, Linhart B, Sonneck K, Blatt K, Herrmann H, Valent P, Stoecklinger A, Lupinek C, Thalhamer J, Fedorov AA, Almo SC, Valenta R. Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination. Allergy. 2009 Apr;64(4):569-80. doi: 10.1111/j.1398-9995.2008.01910.x. Epub 2009 Feb 19. PMID: 19243361.

494: Valent P, Wieser R. Update on genetic and molecular markers associated with myelodysplastic syndromes. Leuk Lymphoma. 2009 Mar;50(3):341-8. doi: 10.1080/10428190902756107. PMID: 19263296.

495: Gangl K, Reininger R, Bernhard D, Campana R, Pree I, Reisinger J, Kneidinger M, Kundi M, Dolznig H, Thurnher D, Valent P, Chen KW, Vrtala S, Spitzauer S, Valenta R, Niederberger V. Cigarette smoke facilitates allergen penetration across respiratory epithelium. Allergy. 2009 Mar;64(3):398-405. doi: 10.1111/j.1398-9995.2008.01861.x. Epub 2008 Dec 16. PMID: 19120070.

496: Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Müller A, Baumgartner C, Valent P, Augustin M, Till JH, Superti-Furga G. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2009 Mar;23(3):477-85. doi: 10.1038/leu.2008.334. Epub 2008 Nov 27. PMID: 19039322.

497: Kluin-Nelemans HC, Ferenc V, van Doormaal JJ, van Iperen C, Peters WG, Akin C, Valent P. Lenalidomide therapy in systemic mastocytosis. Leuk Res. 2009 Mar;33(3):e19-22. doi: 10.1016/j.leukres.2008.06.013. Epub 2008 Jul 21. PMID: 18644623.

498: Valent P. Interleukin-33: a regulator of basophils. Blood. 2009 Feb 12;113(7):1396-7. doi: 10.1182/blood-2008-11-189811. PMID: 19221042.

499: Nedoszytko B, Niedoszytko M, Lange M, van Doormaal J, Gleń J, Zabłotna M, Renke J, Vales A, Buljubasic F, Jassem E, Roszkiewicz J, Valent P. Interleukin-13 promoter gene polymorphism -1112C/T is associated with the systemic form of mastocytosis. Allergy. 2009 Feb;64(2):287-94. doi: 10.1111/j.1398-9995.2008.01827.x. PMID: 19178408.

500: Boehm A, Sperr WR, Leitner G, Worel N, Oehler L, Jaeger E, Mitterbauer M, Haas OA, Valent P, Kalhs P, Rabitsch W. Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation. Eur J Clin Invest. 2008 Dec;38(12):945-52. doi: 10.1111/j.1365-2362.2008.02041.x. PMID: 19021720.

501: Zebedin E, Simma O, Schuster C, Putz EM, Fajmann S, Warsch W, Eckelhart E, Stoiber D, Weisz E, Schmid JA, Pickl WF, Baumgartner C, Valent P, Piekorz RP, Freissmuth M, Sexl V. Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. Blood. 2008 Dec 1;112(12):4655-64. doi: 10.1182/blood-2008-02-139105. Epub 2008 Aug 6. PMID: 18684865.

502: Aichberger KJ, Sperr WR, Gleixner KV, Kretschmer A, Valent P. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest. 2008 Nov;38(11):869-73. doi: 10.1111/j.1365-2362.2008.02036.x. PMID: 19021706.

503: Platzbecker U, Bornhäuser M, Germing U, Stumpf J, Scott BL, Kröger N, Schwerdtfeger R, Böhm A, Kobbe G, Theuser C, Rabitsch W, Valent P, Sorror ML, Ehninger G, Deeg HJ. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant. 2008 Nov;14(11):1217-25. doi: 10.1016/j.bbmt.2008.08.006. PMID: 18940675; PMCID: PMC2759308.

504: Hadzijusufovic E, Rebuzzi L, Gleixner KV, Ferenc V, Peter B, Kondo R, Gruze A, Kneidinger M, Krauth MT, Mayerhofer M, Samorapoompichit P, Greish K, Iyer AK, Pickl WF, Maeda H, Willmann M, Valent P. Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis. Exp Hematol. 2008 Nov;36(11):1461-70. doi: 10.1016/j.exphem.2008.06.002. Epub 2008 Aug 23. PMID: 18723263.

505: Krauth MT, Binder T, Ohler L, Jäger U, Valent P. Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapy. Leuk Res. 2008 Nov;32(11):1779-83. doi: 10.1016/j.leukres.2008.02.023. Epub 2008 Apr 15. PMID: 18417214.

506: Horny HP, Sotlar K, Valent P, Hartmann K. Mastocytosis: a disease of the hematopoietic stem cell. Dtsch Arztebl Int. 2008 Oct;105(40):686-92. doi: 10.3238/arztebl.2008.0686. Epub 2008 Oct 3. PMID: 19623287; PMCID: PMC2696962.

507: Hantschel O, Gstoettenbauer A, Colinge J, Kaupe I, Bilban M, Burkard TR, Valent P, Superti-Furga G. The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia. Mol Oncol. 2008 Oct;2(3):272-81. doi: 10.1016/j.molonc.2008.07.003. Epub 2008 Jul 23. PMID: 19383348; PMCID: PMC5527809.

508: Hauswirth AW, Escribano L, Prados A, Nuñez R, Mirkina I, Kneidinger M, Florian S, Sonneck K, Vales A, Schernthaner GH, Sanchez-Muñoz L, Sperr WR, Bühring HJ, Orfao A, Valent P. CD203c is overexpressed on neoplastic mast cells in systemic mastocytosis and is upregulated upon IgE receptor cross-linking. Int J Immunopathol Pharmacol. 2008 Oct-Dec;21(4):797-806. doi: 10.1177/039463200802100404. PMID: 19144265.

509: Stauder R, Nösslinger T, Pfeilstöcker M, Sperr WR, Wimazal F, Krieger O, Valent P. Impact of age and comorbidity in myelodysplastic syndromes. J Natl Compr Canc Netw. 2008 Oct;6(9):927-34. doi: 10.6004/jnccn.2008.0070. PMID: 18926101.

510: Valent P. Anaemia of the elderly (AOE): does it exist and does it matter in clinical practice? Eur J Clin Invest. 2008 Oct;38(10):782-3. doi: 10.1111/j.1365-2362.2008.02013.x. PMID: 18837804.

511: Mothes-Luksch N, Stumvoll S, Linhart B, Focke M, Krauth MT, Hauswirth A, Valent P, Verdino P, Pavkov T, Keller W, Grote M, Valenta R. Disruption of allergenic activity of the major grass pollen allergen Phl p 2 by reassembly as a mosaic protein. J Immunol. 2008 Oct 1;181(7):4864-73. doi: 10.4049/jimmunol.181.7.4864. PMID: 18802090.

512: Baumgartner C, Gleixner KV, Peter B, Ferenc V, Gruze A, Remsing Rix LL, Bennett KL, Samorapoompichit P, Lee FY, Pickl WF, Esterbauer H, Sillaber C, Superti-Furga G, Valent P. Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. Exp Hematol. 2008 Oct;36(10):1244-53. doi: 10.1016/j.exphem.2008.04.017. Epub 2008 Jul 10. PMID: 18619723.

513: Harir N, Boudot C, Friedbichler K, Sonneck K, Kondo R, Martin-Lannerée S, Kenner L, Kerenyi M, Yahiaoui S, Gouilleux-Gruart V, Gondry J, Bénit L, Dusanter-Fourt I, Lassoued K, Valent P, Moriggl R, Gouilleux F. Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood. 2008 Sep 15;112(6):2463-73. doi: 10.1182/blood-2007-09-115477. Epub 2008 Jun 25. Erratum in: Blood. 2009 Aug 20;114(8):1720. PMID: 18579792; PMCID: PMC2532813.

514: Valent P. Low erythropoietin production as non-oncogenic co-factor contributing to disease-manifestation in low-risk MDS: a hypothesis supported by unique case reports. Leuk Res. 2008 Sep;32(9):1333-7. doi: 10.1016/j.leukres.2008.02.022. Epub 2008 Apr 15. PMID: 18417212.

515: Wappl M, Jaeger E, Streubel B, Gisslinger H, Schwarzinger I, Valent P, Oehler L. Dasatinib inhibits progenitor cell proliferation from polycythaemia vera. Eur J Clin Invest. 2008 Aug;38(8):578-84. doi: 10.1111/j.1365-2362.2008.01982.x. PMID: 18717827.

516: Valent P. Revealing the pathogenesis of the 5q- syndrome. Eur J Clin Invest. 2008 Aug;38(8):539-40. doi: 10.1111/j.1365-2362.2008.01981.x. PMID: 18717823.

517: Linhart B, Mothes-Luksch N, Vrtala S, Kneidinger M, Valent P, Valenta R. A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6. Biol Chem. 2008 Jul;389(7):925-33. doi: 10.1515/BC.2008.105. PMID: 18627317.

518: Valent P. Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. Br J Haematol. 2008 Jul;142(3):361-78. doi: 10.1111/j.1365-2141.2008.07197.x. Epub 2008 Jun 5. PMID: 18540942.

519: Hauswirth AW, Födinger M, Fritz M, Müllauer L, Simonitsch-Klupp I, Streubel B, Chott A, Sperr WR, Jäger U, Valent P. Indolent systemic mastocytosis associated with atypical small lymphocytic lymphoma: a rare form of concomitant lymphoproliferative disease. Hum Pathol. 2008 Jun;39(6):917-24. doi: 10.1016/j.humpath.2007.10.022. Epub 2008 May 2. PMID: 18448146.

520: Weghofer M, Dall'Antonia Y, Grote M, Stöcklinger A, Kneidinger M, Balic N, Krauth MT, Fernández-Caldas E, Thomas WR, van Hage M, Vieths S, Spitzauer S, Horak F, Svergun DI, Konarev PV, Valent P, Thalhamer J, Keller W, Valenta R, Vrtala S. Characterization of Der p 21, a new important allergen derived from the gut of house dust mites. Allergy. 2008 Jun;63(6):758-67. doi: 10.1111/j.1398-9995.2008.01647.x. PMID: 18445190.

521: Wimazal F, Baumgartner C, Sonneck K, Zauner C, Geissler P, Schur S, Samorapoompichit P, Müllauer L, Födinger M, Agis H, Sperr WR, Valent P. Mixed- lineage eosinophil/basophil crisis in MDS: a rare form of progression. Eur J Clin Invest. 2008 Jun;38(6):447-55. doi: 10.1111/j.1365-2362.2008.01950.x. Epub 2008 Apr 24. PMID: 18445043.

522: Laffer S, Lupinek C, Rauter I, Kneidinger M, Drescher A, Jordan JH, Krauth MT, Valent P, Kricek F, Spitzauer S, Englund H, Valenta R. A high-affinity monoclonal anti-IgE antibody for depletion of IgE and IgE-bearing cells. Allergy. 2008 Jun;63(6):695-702. doi: 10.1111/j.1398-9995.2008.01664.x. Epub 2008 Mar 5. PMID: 18325077.

523: Mittermann I, Reininger R, Zimmermann M, Gangl K, Reisinger J, Aichberger KJ, Greisenegger EK, Niederberger V, Seipelt J, Bohle B, Kopp T, Akdis CA, Spitzauer S, Valent P, Valenta R. The IgE-reactive autoantigen Hom s 2 induces damage of respiratory epithelial cells and keratinocytes via induction of IFN- gamma. J Invest Dermatol. 2008 Jun;128(6):1451-9. doi: 10.1038/sj.jid.5701195. Epub 2007 Dec 13. PMID: 18079747.

524: Baumgartner C, Sonneck K, Krauth MT, Kneidinger M, Födinger M, Hauswirth AW, Müllauer L, Valent P. Immunohistochemical assessment of CD25 is equally sensitive and diagnostic in mastocytosis compared to flow cytometry. Eur J Clin Invest. 2008 May;38(5):326-35. doi: 10.1111/j.1365-2362.2008.01942.x. Epub 2008 Mar 20. PMID: 18363719.

525: Chen KW, Fuchs G, Sonneck K, Gieras A, Swoboda I, Douladiris N, Linhart B, Jankovic M, Pavkov T, Keller W, Papadopoulos NG, Valent P, Valenta R, Vrtala S. Reduction of the in vivo allergenicity of Der p 2, the major house-dust mite allergen, by genetic engineering. Mol Immunol. 2008 May;45(9):2486-98. doi: 10.1016/j.molimm.2008.01.006. Epub 2008 Mar 4. PMID: 18295887.

526: Wimazal F, Sperr WR, Kundi M, Vales A, Fonatsch C, Thalhammer-Scherrer R, Schwarzinger I, Valent P. Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes. Ann Oncol. 2008 May;19(5):970-6. doi: 10.1093/annonc/mdm595. Epub 2008 Feb 13. PMID: 18272915.

527: Mayerhofer M, Gleixner KV, Hoelbl A, Florian S, Hoermann G, Aichberger KJ, Bilban M, Esterbauer H, Krauth MT, Sperr WR, Longley JB, Kralovics R, Moriggl R, Zappulla J, Liblau RS, Schwarzinger I, Sexl V, Sillaber C, Valent P. Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol. 2008 Apr 15;180(8):5466-76. doi: 10.4049/jimmunol.180.8.5466. PMID: 18390729; PMCID: PMC2976849.

528: Valent P, Agis H, Sperr W, Sillaber C, Horny HP. Diagnostic and prognostic value of new biochemical and immunohistochemical parameters in chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):635-8. doi: 10.1080/10428190701858849. PMID: 18398724.

529: Valent P, Deininger M. Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):604-9. doi: 10.1080/10428190801923212. PMID: 18398718.

530: Haas K, Kundi M, Sperr WR, Esterbauer H, Ludwig WD, Ratei R, Koller E, Gruener H, Sauerland C, Fonatsch C, Valent P, Wieser R. Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration. Genes Chromosomes Cancer. 2008 Apr;47(4):288-98. doi: 10.1002/gcc.20532. PMID: 18181178.

531: Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. PMID: 18180381.

532: Hauswirth AW, Skrabs C, Schützinger C, Raderer M, Chott A, Valent P, Lechner K, Jäger U. Autoimmune thrombocytopenia in non-Hodgkin's lymphomas. Haematologica. 2008 Mar;93(3):447-50. doi: 10.3324/haematol.11934. Epub 2008 Feb 20. PMID: 18287133.

533: Valent P, Krieger O, Stauder R, Wimazal F, Nösslinger T, Sperr WR, Sill H, Bettelheim P, Pfeilstöcker M. Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. Eur J Clin Invest. 2008 Mar;38(3):143-9. doi: 10.1111/j.1365-2362.2007.01915.x. Epub 2008 Jan 24. PMID: 18218040; PMCID: PMC2438601.

534: Kastl SP, Speidl WS, Kaun C, Katsaros KM, Rega G, Afonyushkin T, Bochkov VN, Valent P, Assadian A, Hagmueller GW, Hoeth M, de Martin R, Ma Y, Maurer G, Huber K, Wojta J. In human macrophages the complement component C5a induces the expression of oncostatin M via AP-1 activation. Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):498-503. doi: 10.1161/ATVBAHA.107.160580. Epub 2008 Jan 10. PMID: 18187666.

535: Mayerhofer M, Gleixner KV, Mayerhofer J, Hoermann G, Jaeger E, Aichberger KJ, Ott RG, Greish K, Nakamura H, Derdak S, Samorapoompichit P, Pickl WF, Sexl V, Esterbauer H, Schwarzinger I, Sillaber C, Maeda H, Valent P. Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood. 2008 Feb 15;111(4):2200-10. doi: 10.1182/blood-2006-11-055723. Epub 2007 Nov 16. PMID: 18024796.

536: Valent P, Lion T, Wolf D, Sillaber C, Agis H, Petzer A, Lang A, Kalhs P, Geissler D, Greil R, Linkesch W, Burgstaller S, Thaler J, Gastl G. Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform. Wien Klin Wochenschr. 2008;120(21-22):697-709. doi: 10.1007/s00508-008-1100-8. PMID: 19116712.

537: Stauder R, Wimazal F, Nösslinger T, Krieger O, Sperr WR, Sill H, Pfeilstöcker M, Valent P. Die individualisierte Riskoeinschätzung und Therapieplanung bei myelodysplastischen Syndromen [Individualized management and therapy of myelodysplastic syndromes]. Wien Klin Wochenschr. 2008;120(17-18):523-37. German. doi: 10.1007/s00508-008-1058-6. PMID: 18988005.

538: Weghofer M, Grote M, Dall'Antonia Y, Fernández-Caldas E, Krauth MT, van Hage M, Horak F, Thomas WR, Valent P, Keller W, Valenta R, Vrtala S. Characterization of folded recombinant Der p 5, a potential diagnostic marker allergen for house dust mite allergy. Int Arch Allergy Immunol. 2008;147(2):101-9. doi: 10.1159/000135696. Epub 2008 Jun 3. PMID: 18520154.

539: Valent P, Lechner K. Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review. Wien Klin Wochenschr. 2008;120(5-6):136-51. doi: 10.1007/s00508-008-0945-1. PMID: 18365153.

540: Sonneck K, Baumgartner C, Rebuzzi L, Marth K, Chen KW, Hauswirth AW, Florian S, Vrtala S, Bühring HJ, Valenta R, Valent P. Recombinant allergens promote expression of aminopeptidase-n (CD13) on basophils in allergic patients. Int J Immunopathol Pharmacol. 2008 Jan-Mar;21(1):11-21. doi: 10.1177/039463200802100103. PMID: 18336727.

541: Valent P. Systemic mastocytosis. Cancer Treat Res. 2008;142:399-419. doi: 10.1007/978-0-387-73744-7_18. PMID: 18283797.

542: Sillaber C, Mayerhofer M, Böhm A, Vales A, Gruze A, Aichberger KJ, Esterbauer H, Pfeilstöcker M, Sperr WR, Pickl WF, Haas OA, Valent P. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest. 2008 Jan;38(1):43-52. doi: 10.1111/j.1365-2362.2007.01892.x. PMID: 18173550.

543: Sotlar K, Bache A, Stellmacher F, Bültmann B, Valent P, Horny HP. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F. J Mol Diagn. 2008 Jan;10(1):58-66. doi: 10.2353/jmoldx.2008.070061. Epub 2007 Dec 28. Erratum in: J Mol Diagn. 2009 May;10(3):276. PMID: 18165278; PMCID: PMC2175544.

544: Rauter I, Krauth MT, Westritschnig K, Horak F, Flicker S, Gieras A, Repa A, Balic N, Spitzauer S, Huss-Marp J, Brockow K, Darsow U, Behrendt H, Ring J, Kricek F, Valent P, Valenta R. Mast cell-derived proteases control allergic inflammation through cleavage of IgE. J Allergy Clin Immunol. 2008 Jan;121(1):197-202. doi: 10.1016/j.jaci.2007.08.015. Epub 2007 Sep 29. PMID: 17904627.

545: Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Kundgen A, Lübbert M, Kunzmann R, Giagounidis AA, Aul C, Trümper L, Krieger O, Stauder R, Müller TH, Wimazal F, Valent P, Fonatsch C, Steidl C. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007 Dec 15;110(13):4385-95. doi: 10.1182/blood-2007-03-082404. Epub 2007 Aug 28. PMID: 17726160.

546: Valent P. Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches. Biologics. 2007 Dec;1(4):433-48. PMID: 19707313; PMCID: PMC2721289.

547: Krauth MT, Födinger M, Rebuzzi L, Greul R, Chott A, Valent P. Aggressive systemic mastocytosis with sarcoma-like growth in the skeleton, leukemic progression, and partial loss of mast cell differentiation antigens. Haematologica. 2007 Dec;92(12):e126-9. doi: 10.3324/haematol.11996. PMID: 18055976.

548: Westritschnig K, Linhart B, Focke-Tejkl M, Pavkov T, Keller W, Ball T, Mari A, Hartl A, Stöcklinger A, Scheiblhofer S, Thalhamer J, Ferreira F, Vieths S, Vogel L, Böhm A, Valent P, Valenta R. A hypoallergenic vaccine obtained by tail- to-head restructuring of timothy grass pollen profilin, Phl p 12, for the treatment of cross-sensitization to profilin. J Immunol. 2007 Dec 1;179(11):7624-34. doi: 10.4049/jimmunol.179.11.7624. PMID: 18025208.

549: Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, Köcher T, Superti-Furga G. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007 Dec 1;110(12):4055-63. doi: 10.1182/blood-2007-07-102061. Epub 2007 Aug 24. PMID: 17720881.

550: Horny HP, Sotlar K, Valent P. Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes. Leuk Res. 2007 Dec;31(12):1609-16. doi: 10.1016/j.leukres.2007.05.010. Epub 2007 Jul 2. PMID: 17604834.

551: Wöhrer S, Rabitsch W, Shehata M, Kondo R, Esterbauer H, Streubel B, Sillaber C, Raderer M, Jaeger U, Zielinski C, Valent P. Mesenchymal stem cells in patients with chronic myelogenous leukaemia or bi-phenotypic Ph+ acute leukaemia are not related to the leukaemic clone. Anticancer Res. 2007 Nov- Dec;27(6B):3837-41. PMID: 18225540.

552: Gleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C, Lee FY, Aichberger KJ, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica. 2007 Nov;92(11):1451-9. doi: 10.3324/haematol.11339. PMID: 18024392.

553: Sperr W, Valent P. Biology and clinical features of myeloid neoplasms with inv(3)(q21q26) or t(3;3)(q21q26). Leuk Lymphoma. 2007 Nov;48(11):2096-7. doi: 10.1080/10428190701713671. PMID: 17990175.

554: Agis H, Sperr WR, Herndlhofer S, Semper H, Pirc-Danoewinata H, Haas OA, Mannhalter C, Esterbauer H, Geissler K, Sillaber C, Jäger U, Valent P. Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571). Ann Oncol. 2007 Nov;18(11):1834-41. doi: 10.1093/annonc/mdm343. Epub 2007 Sep 5. PMID: 17804468.

555: Wimazal F, Fonatsch C, Thalhammer R, Schwarzinger I, Müllauer L, Sperr WR, Bennett JM, Valent P. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res. 2007 Nov;31(11):1461-8. doi: 10.1016/j.leukres.2007.03.015. Epub 2007 May 16. PMID: 17507091.

556: Vales A, Kondo R, Aichberger KJ, Mayerhofer M, Kainz B, Sperr WR, Sillaber C, Jäger U, Valent P. Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2. Leuk Lymphoma. 2007 Oct;48(10):1997-2007. doi: 10.1080/10428190701534424. PMID: 17917967.

557: Pfeilstöcker M, Karlic H, Nösslinger T, Sperr W, Stauder R, Krieger O, Valent P. Myelodysplastic syndromes, aging, and age: correlations, common mechanisms, and clinical implications. Leuk Lymphoma. 2007 Oct;48(10):1900-9. doi: 10.1080/10428190701534382. PMID: 17917959.

558: Noack F, Balleisen L, Valent P, Horny HP. Angiosarcoma of bone marrow with unusual expression of chymase: diagnosis in a trephine biopsy specimen. J Clin Pathol. 2007 Oct;60(10):1183. doi: 10.1136/jcp.2006.045427. PMID: 17906075; PMCID: PMC2014849.

559: Aichberger KJ, Herndlhofer S, Agis H, Sperr WR, Esterbauer H, Rabitsch W, Knöbl P, Haas OA, Thalhammer R, Schwarzinger I, Sillaber C, Jäger U, Valent P. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. Eur J Clin Invest. 2007 Oct;37(10):808-13. doi: 10.1111/j.1365-2362.2007.01859.x. Epub 2007 Aug 28. PMID: 17727673.

560: Schulenburg A, Cech P, Herbacek I, Marian B, Wrba F, Valent P, Ulrich-Pur H. CD44-positive colorectal adenoma cells express the potential stem cell markers musashi antigen (msi1) and ephrin B2 receptor (EphB2). J Pathol. 2007 Oct;213(2):152-60. doi: 10.1002/path.2220. PMID: 17708598.

561: Gleixner KV, Rebuzzi L, Mayerhofer M, Gruze A, Hadzijusufovic E, Sonneck K, Vales A, Kneidinger M, Samorapoompichit P, Thaiwong T, Pickl WF, Yuzbasiyan- Gurkan V, Sillaber C, Willmann M, Valent P. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Exp Hematol. 2007 Oct;35(10):1510-21. doi: 10.1016/j.exphem.2007.06.005. Epub 2007 Aug 2. PMID: 17681669.

562: Thallinger C, Werzowa J, Poeppl W, Kovar FM, Pratscher B, Valent P, Quehenberger P, Joukhadar C. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice. J Invest Dermatol. 2007 Oct;127(10):2411-7. doi: 10.1038/sj.jid.5700872. Epub 2007 May 17. PMID: 17508024.

563: Zatkova A, Fonatsch C, Sperr WR, Valent P. A patient with de novo AML M1 and t(16;21) with karyotype evolution. Leuk Res. 2007 Sep;31(9):1319-21. doi: 10.1016/j.leukres.2006.10.010. Epub 2006 Nov 28. PMID: 17126398.

564: Hantschel O, Rix U, Schmidt U, Bürckstümmer T, Kneidinger M, Schütze G, Colinge J, Bennett KL, Ellmeier W, Valent P, Superti-Furga G. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13283-8. doi: 10.1073/pnas.0702654104. Epub 2007 Aug 7. PMID: 17684099; PMCID: PMC1940229.

565: Vrtala S, Focke M, Kopec J, Verdino P, Hartl A, Sperr WR, Fedorov AA, Ball T, Almo S, Valent P, Thalhamer J, Keller W, Valenta R. Genetic engineering of the major timothy grass pollen allergen, Phl p 6, to reduce allergenic activity and preserve immunogenicity. J Immunol. 2007 Aug 1;179(3):1730-9. doi: 10.4049/jimmunol.179.3.1730. PMID: 17641039.

566: Kondo R, Gleixner KV, Mayerhofer M, Vales A, Gruze A, Samorapoompichit P, Greish K, Krauth MT, Aichberger KJ, Pickl WF, Esterbauer H, Sillaber C, Maeda H, Valent P. Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells. Blood. 2007 Jul 15;110(2):661-9. doi: 10.1182/blood-2006-10-054411. Epub 2007 Apr 9. PMID: 17420286.

567: Mayerhofer M, Aichberger KJ, Florian S, Valent P. Recognition sites for microbes and components of the immune system on human mast cells: relationship to CD antigens and implications for host defense. Int J Immunopathol Pharmacol. 2007 Jul-Sep;20(3):421-34. doi: 10.1177/039463200702000301. PMID: 17880756.

568: Böhm A, Födinger M, Wimazal F, Haas OA, Mayerhofer M, Sperr WR, Esterbauer H, Valent P. Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance. J Allergy Clin Immunol. 2007 Jul;120(1):192-9. doi: 10.1016/j.jaci.2007.03.015. Epub 2007 Apr 23. PMID: 17451799.

569: Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K, Castells M, Sperr WR, Kluin-Nelemans HC, Hamdy NA, Lortholary O, Robyn J, van Doormaal J, Sotlar K, Hauswirth AW, Arock M, Hermine O, Hellmann A, Triggiani M, Niedoszytko M, Schwartz LB, Orfao A, Horny HP, Metcalfe DD. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007 Jun;37(6):435-53. doi: 10.1111/j.1365-2362.2007.01807.x. PMID: 17537151.

570: Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, Haferlach T, Haase D, Kolb HJ, Krieger O, Loken M, van de Loosdrecht A, Ogata K, Orfao A, Pfeilstöcker M, Rüter B, Sperr WR, Stauder R, Wells DA. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res. 2007 Jun;31(6):727-36. doi: 10.1016/j.leukres.2006.11.009. Epub 2007 Jan 25. PMID: 17257673.

571: Swoboda I, Bugajska-Schretter A, Linhart B, Verdino P, Keller W, Schulmeister U, Sperr WR, Valent P, Peltre G, Quirce S, Douladiris N, Papadopoulos NG, Valenta R, Spitzauer S. A recombinant hypoallergenic parvalbumin mutant for immunotherapy of IgE-mediated fish allergy. J Immunol. 2007 May 15;178(10):6290-6. doi: 10.4049/jimmunol.178.10.6290. PMID: 17475857.

572: Hauswirth AW, Sonneck K, Florian S, Krauth MT, Bohm A, Sperr WR, Valenta R, Schernthaner GH, Printz D, Fritsch G, Buhring HJ, Valent P. Interleukin-3 promotes the expression of E-NPP3/CD203C on human blood basophils in healthy subjects and in patients with birch pollen allergy. Int J Immunopathol Pharmacol. 2007 Apr-Jun;20(2):267-78. doi: 10.1177/039463200702000207. PMID: 17624239.

573: Niederberger V, Reisinger J, Valent P, Krauth MT, Pauli G, van Hage M, Cromwell O, Horak F, Valenta R. Vaccination with genetically modified birch pollen allergens: immune and clinical effects on oral allergy syndrome. J Allergy Clin Immunol. 2007 Apr;119(4):1013-6. doi: 10.1016/j.jaci.2006.12.661. Epub 2007 Feb 9. PMID: 17292956.

574: Aichberger KJ, Mayerhofer M, Gleixner KV, Krauth MT, Gruze A, Pickl WF, Wacheck V, Selzer E, Müllauer L, Agis H, Sillaber C, Valent P. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood. 2007 Apr 1;109(7):3031-41. doi: 10.1182/blood-2006-07-032714. PMID: 17110460.

575: Rebuzzi L, Willmann M, Sonneck K, Gleixner KV, Florian S, Kondo R, Mayerhofer M, Vales A, Gruze A, Pickl WF, Thalhammer JG, Valent P. Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Vet Immunol Immunopathol. 2007 Feb 15;115(3-4):320-33. doi: 10.1016/j.vetimm.2006.11.009. Epub 2006 Nov 17. PMID: 17196258.

576: Harir N, Pecquet C, Kerenyi M, Sonneck K, Kovacic B, Nyga R, Brevet M, Dhennin I, Gouilleux-Gruart V, Beug H, Valent P, Lassoued K, Moriggl R, Gouilleux F. Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood. 2007 Feb 15;109(4):1678-86. doi: 10.1182/blood-2006-01-029918. Epub 2006 Oct 12. PMID: 17038539.

577: Valent P, Akin C, Metcalfe DD. FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis. Eur J Clin Invest. 2007 Feb;37(2):153-4. doi: 10.1111/j.1365-2362.2007.01757.x. PMID: 17217382.

578: Horny HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology. 2007;74(2):121-32. doi: 10.1159/000101711. PMID: 17587883.

579: Thallinger C, Poeppl W, Pratscher B, Mayerhofer M, Valent P, Tappeiner G, Joukhadar C. CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model. Pharmacology. 2007;79(4):207-13. doi: 10.1159/000101008. Epub 2007 Mar 22. PMID: 17377418.

580: Krauth MT, Böhm A, Agis H, Sonneck K, Samorapoompichit P, Florian S, Sotlar K, Valent P. Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils. Exp Hematol. 2007 Jan;35(1):108-16. doi: 10.1016/j.exphem.2006.09.008. PMID: 17198879.

581: Hauswirth AW, Florian S, Printz D, Sotlar K, Krauth MT, Fritsch G, Schernthaner GH, Wacheck V, Selzer E, Sperr WR, Valent P. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. Eur J Clin Invest. 2007 Jan;37(1):73-82. doi: 10.1111/j.1365-2362.2007.01746.x. PMID: 17181570.

582: Sonneck K, Florian S, Müllauer L, Wimazal F, Födinger M, Sperr WR, Valent P. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: Monoclonal mast cell activation syndrome. Int Arch Allergy Immunol. 2007;142(2):158-64. doi: 10.1159/000096442. Epub 2006 Oct 20. PMID: 17057414.

583: Niederberger V, Ring J, Rakoski J, Jager S, Spitzauer S, Valent P, Horak F, Kundi M, Valenta R. Antigens drive memory IgE responses in human allergy via the nasal mucosa. Int Arch Allergy Immunol. 2007;142(2):133-44. doi: 10.1159/000096439. Epub 2006 Oct 19. PMID: 17057411.

584: Schulenburg A, Ulrich-Pur H, Thurnher D, Erovic B, Florian S, Sperr WR, Kalhs P, Marian B, Wrba F, Zielinski CC, Valent P. Neoplastic stem cells: a novel therapeutic target in clinical oncology. Cancer. 2006 Nov 15;107(10):2512-20. doi: 10.1002/cncr.22277. PMID: 17039500.

585: Aichberger KJ, Mayerhofer M, Vales A, Krauth MT, Gleixner KV, Bilban M, Esterbauer H, Sonneck K, Florian S, Derdak S, Pickl WF, Agis H, Falus A, Sillaber C, Valent P. The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells. Blood. 2006 Nov 15;108(10):3538-47. doi: 10.1182/blood-2005-12-028456. Epub 2006 Jul 18. PMID: 16849647.

586: Valent P. Use of interleukin-11 to stimulate platelet production in myelodysplastic syndromes. Leuk Lymphoma. 2006 Oct;47(10):1999-2001. doi: 10.1080/10428190600727970. PMID: 17071464.

587: Eiwegger T, Rigby N, Mondoulet L, Bernard H, Krauth MT, Boehm A, Dehlink E, Valent P, Wal JM, Mills EN, Szépfalusi Z. Gastro-duodenal digestion products of the major peanut allergen Ara h 1 retain an allergenic potential. Clin Exp Allergy. 2006 Oct;36(10):1281-8. doi: 10.1111/j.1365-2222.2006.02565.x. PMID: 17014437.

588: Florian S, Sonneck K, Czerny M, Hennersdorf F, Hauswirth AW, Bühring HJ, Valent P. Detection of novel leukocyte differentiation antigens on basophils and mast cells by HLDA8 antibodies. Allergy. 2006 Sep;61(9):1054-62. doi: 10.1111/j.1398-9995.2006.01171.x. PMID: 16918507.

589: Florian S, Esterbauer H, Binder T, Müllauer L, Haas OA, Sperr WR, Sillaber C, Valent P. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. Leuk Res. 2006 Sep;30(9):1201-5. doi: 10.1016/j.leukres.2005.11.014. Epub 2006 Jan 6. PMID: 16406018.

590: Valent P. Diagnostic evaluation and classification of mastocytosis. Immunol Allergy Clin North Am. 2006 Aug;26(3):515-34. doi: 10.1016/j.iac.2006.05.002. PMID: 16931291.

591: Kastl SP, Speidl WS, Kaun C, Rega G, Assadian A, Weiss TW, Valent P, Hagmueller GW, Maurer G, Huber K, Wojta J. The complement component C5a induces the expression of plasminogen activator inhibitor-1 in human macrophages via NF- kappaB activation. J Thromb Haemost. 2006 Aug;4(8):1790-7. doi: 10.1111/j.1538-7836.2006.02046.x. PMID: 16879222.

592: Sotlar K, Saeger W, Stellmacher F, Stahmer J, Jäckle S, Valent P, Horny HP. "Occult" mastocytosis with activating c-kit point mutation evolving into systemic mastocytosis associated with plasma cell myeloma and secondary amyloidosis. J Clin Pathol. 2006 Aug;59(8):875-8. doi: 10.1136/jcp.2005.028837. PMID: 16873565; PMCID: PMC1860446.

593: Akin C, Valent P, Escribano L. Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment. Curr Allergy Asthma Rep. 2006 Jul;6(4):282-8. doi: 10.1007/s11882-006-0061-0. PMID: 16822380.

594: Flicker S, Steinberger P, Ball T, Krauth MT, Verdino P, Valent P, Almo S, Valenta R. Spatial clustering of the IgE epitopes on the major timothy grass pollen allergen Phl p 1: importance for allergenic activity. J Allergy Clin Immunol. 2006 Jun;117(6):1336-43. doi: 10.1016/j.jaci.2006.02.012. Epub 2006 Apr 27. PMID: 16750995.

595: Agis H, Jaeger E, Doninger B, Sillaber C, Marosi C, Drach J, Schwarzinger I, Valent P, Oehler L. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells. Eur J Clin Invest. 2006 Jun;36(6):402-8. doi: 10.1111/j.1365-2362.2006.01645.x. PMID: 16684124.

596: Sonneck K, Florian S, Böhm A, Krauth MT, Kondo R, Hauswirth AW, Gleixner KV, Aichberger KJ, Derdak S, Pickl WF, Sperr WR, Schwartz LB, Valent P. Evaluation of biologic activity of tryptase secreted from blast cells in acute myeloid leukemia. Leuk Lymphoma. 2006 May;47(5):897-906. doi: 10.1080/10428190500513652. PMID: 16753876.

597: Rauter I, Krauth MT, Flicker S, Gieras A, Westritschnig K, Vrtala S, Balic N, Spitzauer S, Huss-Marp J, Brockow K, Darsow U, Ring J, Behrendt H, Semper H, Valent P, Valenta R. Allergen cleavage by effector cell-derived proteases regulates allergic inflammation. FASEB J. 2006 May;20(7):967-9. doi: 10.1096/fj.05-3999fje. Epub 2006 Apr 3. PMID: 16585063.

598: Krauth MT, Agis H, Aichberger KJ, Simonitsch-Klupp I, Müllauer L, Mayerhofer M, Böhm A, Horny HP, Valent P. Immunohistochemical detection of histidine decarboxylase in neoplastic mast cells in patients with systemic mastocytosis. Hum Pathol. 2006 Apr;37(4):439-47. doi: 10.1016/j.humpath.2005.11.015. Epub 2006 Feb 7. PMID: 16564918.

599: Agis H, Krauth MT, Mosberger I, Müllauer L, Simonitsch-Klupp I, Schwartz LB, Printz D, Böhm A, Fritsch G, Horny HP, Valent P. Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7. J Clin Pathol. 2006 Apr;59(4):396-402. doi: 10.1136/jcp.2005.029215. Epub 2006 Feb 3. PMID: 16461568; PMCID: PMC1860377.

600: Horny HP, Sotlar K, Stellmacher F, Krokowski M, Agis H, Schwartz LB, Valent P. The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers. J Clin Pathol. 2006 Mar;59(3):298-302. doi: 10.1136/jcp.2005.028738. PMID: 16505282; PMCID: PMC1860329.

601: Horny HP, Sotlar K, Stellmacher F, Valent P, Grabbe J. An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL). J Clin Pathol. 2006 Mar;59(3):264-8. doi: 10.1136/jcp.2005.026989. PMID: 16505276; PMCID: PMC1860346.

602: Krauth MT, Majlesi Y, Sonneck K, Samorapoompichit P, Ghannadan M, Hauswirth AW, Baghestanian M, Schernthaner GH, Worda C, Müller MR, Sperr WR, Valent P. Effects of various statins on cytokine-dependent growth and IgE-dependent release of histamine in human mast cells. Allergy. 2006 Mar;61(3):281-8. doi: 10.1111/j.1398-9995.2006.00997.x. PMID: 16436135.

603: Wimazal F, Krauth MT, Vales A, Böhm A, Agis H, Sonneck K, Aichberger KJ, Mayerhofer M, Simonitsch-Klupp I, Müllauer L, Sperr WR, Valent P. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category. Leuk Lymphoma. 2006 Mar;47(3):451-60. doi: 10.1080/10428190500353083. PMID: 16396768.

604: Samorapoompichit P, Schernthaner GH, Worda C, Wimazal F, Krauth MT, Sperr WR, Valent P. Evaluation of neoplastic human mast cells by tryptase- immunoelectron microscopy. Histopathology. 2006 Feb;48(3):247-57. doi: 10.1111/j.1365-2559.2005.02314.x. PMID: 16430471.

605: Krauth MT, Florian S, Böhm A, Sonneck K, Agis H, Samorapoompichit P, Hauswirth AW, Sperr WR, Valent P. Immunological characterization and antibacterial function of persisting granulocytes in leukemic patients receiving pulse cytosine arabinoside-consolidation chemotherapy on days 1, 3, and 5. J Immunol. 2006 Feb 1;176(3):1759-68. doi: 10.4049/jimmunol.176.3.1759. PMID: 16424206.

606: Agis H, Krauth MT, Böhm A, Mosberger I, Müllauer L, Simonitsch-Klupp I, Walls AF, Horny HP, Valent P. Identification of basogranulin (BB1) as a novel immunohistochemical marker of basophils in normal bone marrow and patients with myeloproliferative disorders. Am J Clin Pathol. 2006 Feb;125(2):273-81. doi: 10.1309/M9FQ-MQGF-6616-7N2X. PMID: 16393678.

607: Florian S, Sonneck K, Hauswirth AW, Krauth MT, Schernthaner GH, Sperr WR, Valent P. Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies. Leuk Lymphoma. 2006 Feb;47(2):207-22. doi: 10.1080/10428190500272507. PMID: 16321850.

608: Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Böhm A, Gruze A, Samorapoompichit P, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood. 2006 Jan 15;107(2):752-9. doi: 10.1182/blood-2005-07-3022. Epub 2005 Sep 27. PMID: 16189265.

609: Pardanani A, Akin C, Valent P. Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol. 2006;19(3):595-615. doi: 10.1016/j.beha.2005.07.010. PMID: 16781490.

610: Füreder W, Krauth MT, Sperr WR, Sonneck K, Simonitsch-Klupp I, Müllauer L, Willmann M, Horny HP, Valent P. Evaluation of angiogenesis and vascular endothelial growth factor expression in the bone marrow of patients with aplastic anemia. Am J Pathol. 2006 Jan;168(1):123-30. doi: 10.2353/ajpath.2006.050034. PMID: 16400015; PMCID: PMC1592664.

611: Hauswirth AW, Florian S, Schernthaner GH, Krauth MT, Sonneck K, Sperr WR, Valent P. Expression of cell surface antigens on mast cells: mast cell phenotyping. Methods Mol Biol. 2006;315:77-90. doi: 10.1385/1-59259-967-2:077. PMID: 16110150.

612: Germing U, Hildebrandt B, Pfeilstöcker M, Nösslinger T, Valent P, Fonatsch C, Lübbert M, Haase D, Steidl C, Krieger O, Stauder R, Giagounidis AA, Strupp C, Kündgen A, Mueller T, Haas R, Gattermann N, Aul C. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia. 2005 Dec;19(12):2223-31. doi: 10.1038/sj.leu.2403963. PMID: 16193087.

613: Krauth MT, Bankier A, Valent P, Kalhs P, Drach J. Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib. Leuk Res. 2005 Dec;29(12):1473-7. doi: 10.1016/j.leukres.2005.05.003. Epub 2005 Jun 16. PMID: 15964068.

614: Sillaber C, Valent P. New insights into the pathogenesis of the hyperimmunoglobulinaemia E syndrome. Eur J Clin Invest. 2005 Nov;35(11):667-8. doi: 10.1111/j.1365-2362.2005.01563.x. PMID: 16269015.

615: Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S, Pickl WF, Selzer E, Deininger M, Druker BJ, Sillaber C, Esterbauer H, Valent P. Low- level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res. 2005 Oct 15;65(20):9436-44. doi: 10.1158/0008-5472.CAN-05-0972. PMID: 16230407.

616: Sperr WR, Drach J, Hauswirth AW, Ackermann J, Mitterbauer M, Mitterbauer G, Foedinger M, Fonatsch C, Simonitsch-Klupp I, Kalhs P, Valent P. Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6787-92. doi: 10.1158/1078-0432.CCR-05-1064. PMID: 16203765.

617: Krauth MT, Majlesi Y, Florian S, Bohm A, Hauswirth AW, Ghannadan M, Wimazal F, Raderer M, Wrba F, Valent P. Cell surface membrane antigen phenotype of human gastrointestinal mast cells. Int Arch Allergy Immunol. 2005 Oct;138(2):111-20. doi: 10.1159/000088432. Epub 2005 Sep 20. PMID: 16179791.

618: Krokowski M, Sotlar K, Krauth MT, Födinger M, Valent P, Horny HP. Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia. Am J Clin Pathol. 2005 Oct;124(4):560-8. doi: 10.1309/CX45R79PCU9HCV6V. PMID: 16146815.

619: Schernthaner GH, Hauswirth AW, Baghestanian M, Agis H, Ghannadan M, Worda C, Krauth MT, Printz D, Fritsch G, Sperr WR, Valent P. Detection of differentiation- and activation-linked cell surface antigens on cultured mast cell progenitors. Allergy. 2005 Oct;60(10):1248-55. doi: 10.1111/j.1398-9995.2005.00865.x. PMID: 16134990.

620: Agis H, Sotlar K, Valent P, Horny HP. Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis. Leuk Res. 2005 Oct;29(10):1227-32. doi: 10.1016/j.leukres.2005.04.004. PMID: 16111540.

621: Sperr WR, Mitterbauer M, Mitterbauer G, Kundi M, Jäger U, Lechner K, Valent P. Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse. Clin Cancer Res. 2005 Sep 15;11(18):6536-43. doi: 10.1158/1078-0432.CCR-05-0732. PMID: 16166430.

622: Sperr WR, Florian S, Hauswirth AW, Valent P. CD 33 as a target of therapy in acute myeloid leukemia: current status and future perspectives. Leuk Lymphoma. 2005 Aug;46(8):1115-20. doi: 10.1080/10428190500126075. PMID: 16085551.

623: Aichberger KJ, Mittermann I, Reininger R, Seiberler S, Swoboda I, Spitzauer S, Kopp T, Stingl G, Sperr WR, Valent P, Repa A, Bohle B, Kraft D, Valenta R. Hom s 4, an IgE-reactive autoantigen belonging to a new subfamily of calcium- binding proteins, can induce Th cell type 1-mediated autoreactivity. J Immunol. 2005 Jul 15;175(2):1286-94. doi: 10.4049/jimmunol.175.2.1286. PMID: 16002733.

624: Sonneck K, Mannhalter C, Krauth MT, Sperr WR, Schwarzinger I, Fonatsch C, Haas O, Geissler K, Valent P. An unusual case of myelodysplastic syndrome with prolonged clonal stability, indolent clinical course over a decade, and spontaneous regression of AML in the terminal phase. Eur J Haematol. 2005 Jul;75(1):73-7. doi: 10.1111/j.1600-0609.2005.00423.x. PMID: 15946315.

625: Böhm A, Piribauer M, Wimazal F, Geissler K, Gisslinger H, Knöbl P, Jäger U, Fonatsch C, Kyrle PA, Valent P, Lechner K, Sperr WR. High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. Leuk Res. 2005 Jun;29(6):609-15. doi: 10.1016/j.leukres.2004.10.009. Epub 2005 Jan 25. PMID: 15863199.

626: Mayerhofer M, Aichberger KJ, Florian S, Krauth MT, Hauswirth AW, Derdak S, Sperr WR, Esterbauer H, Wagner O, Marosi C, Pickl WF, Deininger M, Weisberg E, Druker BJ, Griffin JD, Sillaber C, Valent P. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB J. 2005 Jun;19(8):960-2. doi: 10.1096/fj.04-1973fje. Epub 2005 Mar 22. PMID: 15784722.

627: Florian S, Ghannadan M, Mayerhofer M, Aichberger KJ, Hauswirth AW, Schernthaner GH, Printz D, Fritsch G, Böhm A, Sonneck K, Krauth MT, Müller MR, Sillaber C, Sperr WR, Bühring HJ, Valent P. Evaluation of normal and neoplastic human mast cells for expression of CD172a (SIRPalpha), CD47, and SHP-1. J Leukoc Biol. 2005 Jun;77(6):984-92. doi: 10.1189/jlb.0604349. Epub 2005 Mar 22. PMID: 15784688.

628: Hennersdorf F, Florian S, Jakob A, Baumgärtner K, Sonneck K, Nordheim A, Biedermann T, Valent P, Bühring HJ. Identification of CD13, CD107a, and CD164 as novel basophil-activation markers and dissection of two response patterns in time kinetics of IgE-dependent upregulation. Cell Res. 2005 May;15(5):325-35. doi: 10.1038/sj.cr.7290301. PMID: 15916720.

629: Linhart B, Hartl A, Jahn-Schmid B, Verdino P, Keller W, Krauth MT, Valent P, Horak F, Wiedermann U, Thalhamer J, Ebner C, Kraft D, Valenta R. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J Allergy Clin Immunol. 2005 May;115(5):1010-6. doi: 10.1016/j.jaci.2004.12.1142. PMID: 15867859.

630: Reisinger J, Triendl A, Küchler E, Bohle B, Krauth MT, Rauter I, Valent P, Koenig F, Valenta R, Niederberger V. IFN-gamma-enhanced allergen penetration across respiratory epithelium augments allergic inflammation. J Allergy Clin Immunol. 2005 May;115(5):973-81. doi: 10.1016/j.jaci.2005.01.021. PMID: 15867854.

631: Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood. 2005 Apr 15;105(8):3303-11. doi: 10.1182/blood-2004-02-0749. Epub 2004 Dec 30. PMID: 15626746.

632: Florian S, Krauth MT, Simonitsch-Klupp I, Sperr WR, Fritsche-Polanz R, Sonneck K, Födinger M, Agis H, Böhm A, Wimazal F, Horny HP, Valent P. Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. Int Arch Allergy Immunol. 2005 Mar;136(3):273-80. doi: 10.1159/000083954. Epub 2005 Feb 17. PMID: 15722637.

633: Batard T, Didierlaurent A, Chabre H, Mothes N, Bussières L, Bohle B, Couret MN, Ball T, Lemoine P, Focks Tejkl M, Chenal A, Clément G, Dupont F, Valent P, Krauth MT, André C, Valenta R, Moingeon P. Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy. Int Arch Allergy Immunol. 2005 Mar;136(3):239-49. doi: 10.1159/000083950. Epub 2005 Feb 16. PMID: 15722633.

634: Moriggl R, Sexl V, Kenner L, Duntsch C, Stangl K, Gingras S, Hoffmeyer A, Bauer A, Piekorz R, Wang D, Bunting KD, Wagner EF, Sonneck K, Valent P, Ihle JN, Beug H. Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell. 2005 Jan;7(1):87-99. doi: 10.1016/j.ccr.2004.12.010. PMID: 15652752.

635: Ball T, Edstrom W, Mauch L, Schmitt J, Leistler B, Fiebig H, Sperr WR, Hauswirth AW, Valent P, Kraft D, Almo SC, Valenta R. Gain of structure and IgE epitopes by eukaryotic expression of the major Timothy grass pollen allergen, Phl p 1. FEBS J. 2005 Jan;272(1):217-27. doi: 10.1111/j.1432-1033.2004.04403.x. PMID: 15634345.

636: Valent P, Akin C, Sperr WR, Mayerhofer M, Födinger M, Fritsche-Polanz R, Sotlar K, Escribano L, Arock M, Horny HP, Metcalfe DD. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma. 2005 Jan;46(1):35-48. doi: 10.1080/10428190400010775. PMID: 15621779.

637: Ziegler S, Sperr WR, Knöbl P, Lehr S, Weltermann A, Jäger U, Valent P, Lechner K. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. Thromb Res. 2005;115(1-2):59-64. doi: 10.1016/j.thromres.2004.07.016. PMID: 15567454.

638: Noack F, Sotlar K, Notter M, Thiel E, Valent P, Horny HP. Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V. Leuk Lymphoma. 2004 Nov;45(11):2295-302. doi: 10.1080/10428190412331272695. PMID: 15512820.

639: Valent P, Arock M, Bischoff SC, Bühring HJ, Brockow K, Escribano L, Födinger M, Grabbe J, Hartmann K, Henz BM, Horny HP, Kluin-Nelemans HC, Lima M, Marone G, Orfao A, Parwaresch RM, Sillaber C, Sotlar K, Sperr WR, Triggiani M, Van Doormaal JJ, Wolff K, Zuberbier T. The European Competence Network on Mastocytosis (ECNM). Wien Klin Wochenschr. 2004 Oct 30;116(19-20):647-51. doi: 10.1007/s00508-004-0253-3. PMID: 15941072.

640: Valent P. Mast cells, masters, and mastocytosis: development of research since the times of Paul Ehrlich. Wien Klin Wochenschr. 2004 Oct 30;116(19-20):645-6. doi: 10.1007/s00508-004-0254-2. PMID: 15941071.

641: Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P, Reisinger J, Pelzmann M, Hayek B, Kronqvist M, Gafvelin G, Grönlund H, Purohit A, Suck R, Fiebig H, Cromwell O, Pauli G, van Hage-Hamsten M, Valenta R. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2(Suppl 2):14677-82. doi: 10.1073/pnas.0404735101. Epub 2004 Aug 13. PMID: 15310844; PMCID: PMC521981.

642: Focke M, Linhart B, Hartl A, Wiedermann U, Sperr WR, Valent P, Thalhamer J, Kraft D, Valenta R. Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin Exp Allergy. 2004 Oct;34(10):1525-33. doi: 10.1111/j.1365-2222.2004.02081.x. PMID: 15479266.

643: Sotlar K, Horny HP, Simonitsch I, Krokowski M, Aichberger KJ, Mayerhofer M, Printz D, Fritsch G, Valent P. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol. 2004 Oct;28(10):1319-25. doi: 10.1097/01.pas.0000138181.89743.7b. PMID: 15371947.

644: Valent P, Ghannadan M, Akin C, Krauth MT, Selzer E, Mayerhofer M, Sperr WR, Arock M, Samorapoompichit P, Horny HP, Metcalfe DD. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. Eur J Clin Invest. 2004 Aug;34 Suppl 2:41-52. doi: 10.1111/j.0960-135X.2004.01369.x. PMID: 15291805.

645: Sperr WR, Hauswirth AW, Florian S, Ohler L, Geissler K, Valent P. Human leukaemic stem cells: a novel target of therapy. Eur J Clin Invest. 2004 Aug;34 Suppl 2:31-40. doi: 10.1111/j.0960-135X.2004.01368.x. PMID: 15291804.

646: Sillaber C, Mayerhofer M, Aichberger KJ, Krauth MT, Valent P. Expression of angiogenic factors in chronic myeloid leukaemia: role of the bcr/abl oncogene, biochemical mechanisms, and potential clinical implications. Eur J Clin Invest. 2004 Aug;34 Suppl 2:2-11. doi: 10.1111/j.0960-135X.2004.01365.x. PMID: 15291801.

647: Agis H, Mannhalter C, Sperr WR, Keil F, Kalhs P, Pirc-Danoewinata H, Krauth MT, Haas OA, Geissler K, Lechner K, Valent P. Detection of trisomy 8 in donor- derived Ph- cells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantation. Leuk Lymphoma. 2004 Jul;45(7):1453-8. doi: 10.1080/10428190410001670637. PMID: 15359647.

648: Rabitsch W, Sperr WR, Lechner K, Chott A, Prinz E, Valent P, Kalhs P. Bone marrow microvessel density and its prognostic significance in AML. Leuk Lymphoma. 2004 Jul;45(7):1369-73. doi: 10.1080/10428190410001663707. PMID: 15359635.

649: Valent P, Sperr WR, Schwartz LB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol. 2004 Jul;114(1):3-11; quiz 12. doi: 10.1016/j.jaci.2004.02.045. PMID: 15241337.

650: Sperr WR, Piribauer M, Wimazal F, Fonatsch C, Thalhammer-Scherrer R, Schwarzinger I, Geissler K, Knöbl P, Jäger U, Lechner K, Valent P. A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5). Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3965-71. doi: 10.1158/1078-0432.CCR-04-0185. PMID: 15217926.

651: Horny HP, Sotlar K, Sperr WR, Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol. 2004 Jun;57(6):604-8. doi: 10.1136/jcp.2003.014860. PMID: 15166264; PMCID: PMC1770310.

652: Valent P, Fonatsch C, Stindl R, Schwarzinger I, Haas OA, Sperr WR, Geissler K, Lechner K. Normal bone marrow function over 6 years in a patient with dysplastic hematopoiesis and a complex karyotype. Leuk Res. 2004 Jun;28(6):651-5. doi: 10.1016/j.leukres.2003.10.023. PMID: 15120944.

653: Swoboda I, Grote M, Verdino P, Keller W, Singh MB, De Weerd N, Sperr WR, Valent P, Balic N, Reichelt R, Suck R, Fiebig H, Valenta R, Spitzauer S. Molecular characterization of polygalacturonases as grass pollen-specific marker allergens: expulsion from pollen via submicronic respirable particles. J Immunol. 2004 May 15;172(10):6490-500. doi: 10.4049/jimmunol.172.10.6490. PMID: 15128842.

654: Mayerhofer M, Florian S, Krauth MT, Aichberger KJ, Bilban M, Marculescu R, Printz D, Fritsch G, Wagner O, Selzer E, Sperr WR, Valent P, Sillaber C. Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. Cancer Res. 2004 May 1;64(9):3148-54. doi: 10.1158/0008-5472.can-03-1200. PMID: 15126353.

655: Westritschnig K, Focke M, Verdino P, Goessler W, Keller W, Twardosz A, Mari A, Horak F, Wiedermann U, Hartl A, Thalhamer J, Sperr WR, Valent P, Valenta R. Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, Phl p 7. J Immunol. 2004 May 1;172(9):5684-92. doi: 10.4049/jimmunol.172.9.5684. PMID: 15100313.

656: Stellmacher F, Sotlar K, Balleisen L, Valent P, Horny HP. Bone marrow mastocytosis associated with IgM kappa plasma cell myeloma. Leuk Lymphoma. 2004 Apr;45(4):801-5. doi: 10.1080/10428190310001615693. PMID: 15160959.

657: Wimazal F, Schwarzmeier J, Sotlar K, Simonitsch I, Sperr WR, Fritsche- Polanz R, Födinger M, Schubert J, Horny HP, Valent P. Splenic mastocytosis: report of two cases and detection of the transforming somatic C-KIT mutation D816V. Leuk Lymphoma. 2004 Apr;45(4):723-9. doi: 10.1080/1042819032000140979. PMID: 15160946.

658: Krauth MT, Simonitsch I, Aichberger KJ, Mayerhofer M, Sperr WR, Sillaber C, Schneeweiss B, Mann G, Gadner H, Valent P. Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease. Am J Clin Pathol. 2004 Apr;121(4):473-81. doi: 10.1309/3JLT-FNNE-DQHB-4A0P. PMID: 15080298.

659: Bühring HJ, Streble A, Valent P. The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosis. Int Arch Allergy Immunol. 2004 Apr;133(4):317-29. doi: 10.1159/000077351. Epub 2004 Mar 17. PMID: 15031605.

660: Bernd HW, Sotlar K, Lorenzen J, Osieka R, Fabry U, Valent P, Horny HP. Acute myeloid leukaemia with t(8;21) associated with "occult" mastocytosis. Report of an unusual case and review of the literature. J Clin Pathol. 2004 Mar;57(3):324-8. doi: 10.1136/jcp.2003.012864. PMID: 14990611; PMCID: PMC1770248.

661: Valent P, Hauswirth AW, Natter S, Sperr WR, Bühring HJ, Valenta R. Assays for measuring in vitro basophil activation induced by recombinant allergens. Methods. 2004 Mar;32(3):265-70. doi: 10.1016/j.ymeth.2003.08.006. PMID: 14962761.

662: Hauswirth AW, Simonitsch-Klupp I, Uffmann M, Koller E, Sperr WR, Lechner K, Valent P. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res. 2004 Mar;28(3):249-57. doi: 10.1016/s0145-2126(03)00259-5. PMID: 14687620.

663: Weltermann A, Fonatsch C, Haas OA, Greinix HT, Kahls P, Mitterbauer G, Jäger U, Kainz B, Geissler K, Valent P, Sperr WR, Knöbl P, Schwarzinger I, Gleiss A, Lechner K. Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse. Leukemia. 2004 Feb;18(2):293-302. doi: 10.1038/sj.leu.2403243. PMID: 14671635.

664: O'Brien S, Tefferi A, Valent P. Chronic myelogenous leukemia and myeloproliferative disease. Hematology Am Soc Hematol Educ Program. 2004:146-62. doi: 10.1182/asheducation-2004.1.146. PMID: 15561681.

665: Wieser R, Lechner K, Valent P, Fonatsch C. Deletion of sequences telomeric of the EVI1 gene in 3q26 associated with a novel pericentric inv(3)(p25q26) in a patient with acute myelogenous leukemia. Haematologica. 2003 Dec;88(12):1427-9. PMID: 14688000.

666: Reininger R, Swoboda I, Bohle B, Hauswirth AW, Valent P, Rumpold H, Valenta R, Spitzauer S. Characterization of recombinant cat albumin. Clin Exp Allergy. 2003 Dec;33(12):1695-702. doi: 10.1111/j.1365-2222.2003.01817.x. PMID: 14656357.

667: Grönlund H, Bergman T, Sandström K, Alvelius G, Reininger R, Verdino P, Hauswirth A, Liderot K, Valent P, Spitzauer S, Keller W, Valenta R, van Hage- Hamsten M. Formation of disulfide bonds and homodimers of the major cat allergen Fel d 1 equivalent to the natural allergen by expression in Escherichia coli. J Biol Chem. 2003 Oct 10;278(41):40144-51. doi: 10.1074/jbc.M301416200. Epub 2003 May 5. PMID: 12732623.

668: Valent P, Akin C, Sperr WR, Horny HP, Metcalfe DD. Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. Hematol Oncol Clin North Am. 2003 Oct;17(5):1227-41. doi: 10.1016/s0889-8588(03)00089-3. PMID: 14560784.

669: Li S, Dudczak R, Koller E, Baghestanian M, Ghannadan M, Minar E, Pirich C, Angelberger P, Virgolini I, Li M, Valent P. Effect of statins on lipoprotein receptor expression in cell lines from human mast cells and basophils. Eur J Clin Pharmacol. 2003 Oct;59(7):507-16. doi: 10.1007/s00228-003-0668-1. Epub 2003 Sep 10. PMID: 13680038.

670: Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y, Semper H, Valent P, Niederberger V, Kraft D, Valenta R. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy. 2003 Sep;33(9):1198-208. doi: 10.1046/j.1365-2222.2003.01699.x. PMID: 12956739.

671: Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K, Bennett JM, Metcalfe DD. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol. 2003 Sep;122(5):695-717. doi: 10.1046/j.1365-2141.2003.04575.x. PMID: 12930381.

672: Valent P, Wimazal F, Schwarzinger I, Sperr WR, Geissler K. Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS). Wien Klin Wochenschr. 2003 Aug 14;115(13-14):515-36. doi: 10.1007/BF03041035. PMID: 13677270.

673: Sperr WR, Hauswirth AW, Wimazal F, Knöbl P, Geissler K, Valent P. Treatment concepts for elderly patients with acute myeloid leukemia. Wien Klin Wochenschr. 2003 Aug 14;115(13-14):505-14. doi: 10.1007/BF03041034. PMID: 13677269.

674: Sillaber C, Mayerhofer M, Agis H, Sagaster V, Mannhalter C, Sperr WR, Geissler K, Valent P. Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts. Wien Klin Wochenschr. 2003 Aug 14;115(13-14):485-504. doi: 10.1007/BF03041033. PMID: 13677268.

675: Horny HP, Lange K, Sotlar K, Valent P. Increase of bone marrow lymphocytes in systemic mastocytosis: reactive lymphocytosis or malignant lymphoma? Immunohistochemical and molecular findings on routinely processed bone marrow biopsy specimens. J Clin Pathol. 2003 Aug;56(8):575-8. doi: 10.1136/jcp.56.8.575. PMID: 12890804; PMCID: PMC1770043.

676: Chott A, Guenther P, Huebner A, Selzer E, Parwaresch RM, Horny HP, Valent P. Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma. Am J Surg Pathol. 2003 Jul;27(7):1013-9. doi: 10.1097/00000478-200307000-00019. PMID: 12826896.

677: Jordan JH, Jäger E, Sperr WR, Schwarzinger I, Födinger M, Fritsche-Polanz R, Ohler L, Geissler K, Valent P. Numbers of colony-forming progenitors in patients with systemic mastocytosis: potential diagnostic implications and comparison with myeloproliferative disorders. Eur J Clin Invest. 2003 Jul;33(7):611-8. doi: 10.1046/j.1365-2362.2003.01172.x. PMID: 12814399.

678: Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny HP, Bennett JM, Metcalfe DD. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res. 2003 Jul;27(7):635-41. doi: 10.1016/s0145-2126(02)00168-6. PMID: 12681363.

679: Laffer S, Hamdi S, Lupinek C, Sperr WR, Valent P, Verdino P, Keller W, Grote M, Hoffmann-Sommergruber K, Scheiner O, Kraft D, Rideau M, Valenta R. Molecular characterization of recombinant T1, a non-allergenic periwinkle (Catharanthus roseus) protein, with sequence similarity to the Bet v 1 plant allergen family. Biochem J. 2003 Jul 1;373(Pt 1):261-9. doi: 10.1042/BJ20030331. PMID: 12656672; PMCID: PMC1223461.

680: Ghannadan M, Wimazal F, Simonitsch I, Sperr WR, Mayerhofer M, Sillaber C, Hauswirth AW, Gadner H, Chott A, Horny HP, Lechner K, Valent P. Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correlation between VEGF expression and the FAB category. Am J Clin Pathol. 2003 May;119(5):663-71. doi: 10.1309/331Q-X7AX-KWFJ-FKXM. PMID: 12760284.

681: Berer A, Jäger E, Sagaster V, Streubel B, Wimazal F, Sperr WR, Welterman A, Schwarzinger I, Frommlet F, Haas OA, Valent P, Lechner K, Geissler K, Ohler L. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes. Ann Hematol. 2003 May;82(5):271-7. doi: 10.1007/s00277-003-0619-z. Epub 2003 Mar 22. PMID: 12739063.

682: Samorapoompichit P, Steiner M, Lucas T, Wachtler F, Schedled A, Sperr WR, Valent P. Induction of apoptosis in the human mast cell leukemia cell line HMC-1 by various antineoplastic drugs. Leuk Lymphoma. 2003 Mar;44(3):509-15. doi: 10.1080/1042819021000046976. PMID: 12688323.

683: Rezaie-Majd A, Prager GW, Bucek RA, Schernthaner GH, Maca T, Kress HG, Valent P, Binder BR, Minar E, Baghestanian M. Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2003 Mar 1;23(3):397-403. doi: 10.1161/01.ATV.0000059384.34874.F0. Epub 2003 Jan 30. PMID: 12615677.

684: Noack F, Escribano L, Sotlar K, Nunez R, Schuetze K, Valent P, Horny HP. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL. Leuk Lymphoma. 2003 Feb;44(2):313-9. doi: 10.1080/1042819021000037967. PMID: 12688351.

685: Horny HP, Greschniok A, Jordan JH, Menke DM, Valent P. Chymase expressing bone marrow mast cells in mastocytosis and myelodysplastic syndromes: an immunohistochemical and morphometric study. J Clin Pathol. 2003 Feb;56(2):103-6. doi: 10.1136/jcp.56.2.103. PMID: 12560387; PMCID: PMC1769884.

686: Wojta J, Huber K, Valent P. New aspects in thrombotic research: complement induced switch in mast cells from a profibrinolytic to a prothrombotic phenotype. Pathophysiol Haemost Thromb. 2003 Sep-2004 Dec;33(5-6):438-41. doi: 10.1159/000083842. PMID: 15692257.

687: Núñez-López R, Escribano L, Schernthaner GH, Prados A, Rodríguez-González R, Díaz-Agustín B, López A, Hauswirth A, Valent P, Almeida J, Bravo P, Orfao A. Overexpression of complement receptors and related antigens on the surface of bone marrow mast cells in patients with systemic mastocytosis. Br J Haematol. 2003 Jan;120(2):257-65. doi: 10.1046/j.1365-2141.2003.04055.x. PMID: 12542483.

688: Majlesi Y, Samorapoompichit P, Hauswirth AW, Schernthaner GH, Ghannadan M, Baghestanian M, Rezaie-Majd A, Valenta R, Sperr WR, Bühring HJ, Valent P. Cerivastatin and atorvastatin inhibit IL-3-dependent differentiation and IgE- mediated histamine release in human basophils and downmodulate expression of the basophil-activation antigen CD203c/E-NPP3. J Leukoc Biol. 2003 Jan;73(1):107-17. doi: 10.1189/jlb.0202075. PMID: 12525568.

689: Sperr WR, Hauswirth AW, Valent P. Tryptase a novel biochemical marker of acute myeloid leukemia. Leuk Lymphoma. 2002 Dec;43(12):2257-61. doi: 10.1080/1042819021000039965. PMID: 12613510.

690: Mayerhofer M, Valent P, Sperr WR, Griffin JD, Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood. 2002 Nov 15;100(10):3767-75. doi: 10.1182/blood-2002-01-0109. Epub 2002 Jul 18. PMID: 12393646.

691: Baghestanian M, Jordan JH, Kiener HP, Bevec D, Agis H, Fritsch G, Müller MR, Bankl HC, Schernthaner GH, Lechner K, Valent P. Activation of human mast cells through stem cell factor receptor (KIT) is associated with expression of bcl-2. Int Arch Allergy Immunol. 2002 Nov;129(3):228-36. doi: 10.1159/000066773. PMID: 12444320.

692: Zettinig G, Becherer A, Szabo M, Uffmann M, Dudczak R, Valent P, Kletter K. FDG positron emission tomography in patients with systemic mastocytosis. AJR Am J Roentgenol. 2002 Nov;179(5):1235-7. doi: 10.2214/ajr.179.5.1791235. PMID: 12388504.

693: Sotlar K, Fridrich C, Mall A, Jaussi R, Bültmann B, Valent P, Horny HP. Detection of c-kit point mutation Asp-816 --> Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. Leuk Res. 2002 Nov;26(11):979-84. doi: 10.1016/s0145-2126(02)00041-3. PMID: 12363464.

694: Binder M, Fierlbeck G, King Ti, Valent P, Bühring HJ. Individual hymenoptera venom compounds induce upregulation of the basophil activation marker ectonucleotide pyrophosphatase/phosphodiesterase 3 (CD203c) in sensitized patients. Int Arch Allergy Immunol. 2002 Oct;129(2):160-8. doi: 10.1159/000065875. PMID: 12403934.

695: Stumvoll S, Lidholm J, Thunberg R, DeWitt AM, Eibensteiner P, Swoboda I, Bugajska-Schretter A, Spitzauer S, Vangelista L, Kazemi-Shirazi L, Sperr WR, Valent P, Kraft D, Valenta R. Purification, structural and immunological characterization of a timothy grass (Phleum pratense) pollen allergen, Phl p 4, with cross-reactive potential. Biol Chem. 2002 Sep;383(9):1383-96. doi: 10.1515/BC.2002.157. PMID: 12437131.

696: Marknell DeWitt A, Niederberger V, Lehtonen P, Spitzauer S, Sperr WR, Valent P, Valenta R, Lidholm J. Molecular and immunological characterization of a novel timothy grass (Phleum pratense) pollen allergen, Phl p 11. Clin Exp Allergy. 2002 Sep;32(9):1329-40. doi: 10.1046/j.1365-2222.2002.01467.x. PMID: 12220472.

697: Flicker S, Steinberger P, Norderhaug L, Sperr WR, Majlesi Y, Valent P, Kraft D, Valenta R. Conversion of grass pollen allergen-specific human IgE into a protective IgG(1) antibody. Eur J Immunol. 2002 Aug;32(8):2156-62. doi: 10.1002/1521-4141(200208)32:8<2156::AID-IMMU2156>3.0.CO;2-A. PMID: 12209627.

698: Wojta J, Kaun C, Zorn G, Ghannadan M, Hauswirth AW, Sperr WR, Fritsch G, Printz D, Binder BR, Schatzl G, Zwirner J, Maurer G, Huber K, Valent P. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood. 2002 Jul 15;100(2):517-23. doi: 10.1182/blood.v100.2.517. PMID: 12091343.

699: Rezaie-Majd A, Maca T, Bucek RA, Valent P, Müller MR, Husslein P, Kashanipour A, Minar E, Baghestanian M. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1194-9. doi: 10.1161/01.atv.0000022694.16328.cc. PMID: 12117737.

700: Hauswirth AW, Natter S, Ghannadan M, Majlesi Y, Schernthaner GH, Sperr WR, Bühring HJ, Valenta R, Valent P. Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J Allergy Clin Immunol. 2002 Jul;110(1):102-9. doi: 10.1067/mai.2002.125257. PMID: 12110828.

701: Sperr WR, Jordan JH, Fiegl M, Escribano L, Bellas C, Dirnhofer S, Semper H, Simonitsch-Klupp I, Horny HP, Valent P. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol. 2002 Jun;128(2):136-41. doi: 10.1159/000059404. PMID: 12065914.

702: Angermayr B, Cejna M, Schoder M, Wrba F, Valent P, Gangl A, Peck- Radosavljevic M. Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary hematopoiesis in idiopathic myelofibrosis. Blood. 2002 Jun 1;99(11):4246-7. doi: 10.1182/blood-2002-01-0282. PMID: 12043694.

703: Hauswirth AW, Sperr WR, Ghannadan M, Schernthaner GH, Jordan JH, Fritsche- Polanz R, Simonitsch-Klupp I, Födinger M, Lechner K, Valent P. A case of smouldering mastocytosis with peripheral blood eosinophilia and lymphadenopathy. Leuk Res. 2002 Jun;26(6):601-6. doi: 10.1016/s0145-2126(01)00172-2. PMID: 12007509.

704: Sperr WR, Stehberger B, Wimazal F, Baghestanian M, Schwartz LB, Kundi M, Semper H, Jordan JH, Chott A, Drach J, Jäger U, Geissler K, Greschniok A, Horny HP, Lechner K, Valent P. Serum tryptase measurements in patients with myelodysplastic syndromes. Leuk Lymphoma. 2002 May;43(5):1097-105. doi: 10.1080/10428190290021470. PMID: 12148892.

705: Valent P, Ghannadan M, Hauswirth AW, Schernthaner GH, Sperr WR, Arock M. Signal transduction-associated and cell activation-linked antigens expressed in human mast cells. Int J Hematol. 2002 May;75(4):357-62. doi: 10.1007/BF02982124. PMID: 12041664.

706: Valent P, Baghestanian M, Bankl HC, Sillaber C, Sperr WR, Wojta J, Binder BR, Lechner K. New aspects in thrombosis research: possible role of mast cells as profibrinolytic and antithrombotic cells. Thromb Haemost. 2002 May;87(5):786-90. PMID: 12038777.

707: Wimazal F, Jordan JH, Sperr WR, Chott A, Dabbass S, Lechner K, Horny HP, Valent P. Increased angiogenesis in the bone marrow of patients with systemic mastocytosis. Am J Pathol. 2002 May;160(5):1639-45. doi: 10.1016/S0002-9440(10)61111-X. PMID: 12000716; PMCID: PMC1850883.

708: Swoboda I, Bugajska-Schretter A, Verdino P, Keller W, Sperr WR, Valent P, Valenta R, Spitzauer S. Recombinant carp parvalbumin, the major cross-reactive fish allergen: a tool for diagnosis and therapy of fish allergy. J Immunol. 2002 May 1;168(9):4576-84. doi: 10.4049/jimmunol.168.9.4576. PMID: 11971005.

709: Ghannadan M, Hauswirth AW, Schernthaner GH, Müller MR, Klepetko W, Schatzl G, Sperr WR, Bühring HJ, Valent P. Detection of novel CD antigens on the surface of human mast cells and basophils. Int Arch Allergy Immunol. 2002 Apr;127(4):299-307. doi: 10.1159/000057747. PMID: 12021549.

710: Kazemi-Shirazi L, Gasche CH, Natter S, Gangl A, Smolen J, Spitzauer S, Valent P, Kraft D, Valenta R. IgA autoreactivity: a feature common to inflammatory bowel and connective tissue diseases. Clin Exp Immunol. 2002 Apr;128(1):102-9. doi: 10.1046/j.1365-2249.2002.01804.x. PMID: 11982597; PMCID: PMC1906379.

711: Selzer E, Wacheck V, Lucas T, Heere-Ress E, Wu M, Weilbaecher KN, Schlegel W, Valent P, Wrba F, Pehamberger H, Fisher D, Jansen B. The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma. Cancer Res. 2002 Apr 1;62(7):2098-103. PMID: 11929831.

712: Horny HP, Krokowski M, Feller AC, Hintze G, Sotlar K, Valent P. Aleukämische Mastzellenleukämie (vormals: "maligne Mastozytose"): Eine extrem seltene Leukämieform. Ein Fallbericht und gleichzeitig ein Beitrag zu einer revidierten Klassifikation der Mastozytosen [Aleukemic mast cell leukemia (formerly: "malignant mastocytosis"): an extremely rare form of leukemia. A case report and simultaneously a contribution to revised classification of mastocytosis]. Wien Klin Wochenschr. 2002 Mar 28;114(5-6):222-8. German. PMID: 12238313.

713: Valent P. Mast cell leukemia--a rare form of myeloid leukemia. Wien Klin Wochenschr. 2002 Mar 28;114(5-6):173-4. PMID: 12238304.

714: Jordan JH, Schernthaner GH, Fritsche-Polanz R, Sperr WR, Födinger M, Chott A, Geissler K, Lechner K, Horny HP, Valent P. Stem cell factor-induced bone marrow mast cell hyperplasia mimicking systemic mastocytosis (SM): histopathologic and morphologic evaluation with special reference to recently established SM-criteria. Leuk Lymphoma. 2002 Mar;43(3):575-82. doi: 10.1080/10428190290012065. PMID: 12002761.

715: Bankl HC, Valent P. Mast cells, thrombosis, and fibrinolysis: the emerging concept. Thromb Res. 2002 Feb 15;105(4):359-65. doi: 10.1016/s0049-3848(02)00016-6. PMID: 12031832.

716: Sperr WR, Horny HP, Valent P. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int Arch Allergy Immunol. 2002 Feb;127(2):140-2. doi: 10.1159/000048186. PMID: 11919425.

717: Valent P, Akin C, Sperr WR, Horny HP, Metcalfe DD. Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression. Int Arch Allergy Immunol. 2002 Feb;127(2):137-9. doi: 10.1159/000048185. PMID: 11919424.

718: Horny HP, Valent P. Histopathological and immunohistochemical aspects of mastocytosis. Int Arch Allergy Immunol. 2002 Feb;127(2):115-7. doi: 10.1159/000048180. PMID: 11919419.

719: Féger F, Ribadeau Dumas A, Leriche L, Valent P, Arock M. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol. 2002 Feb;127(2):110-4. doi: 10.1159/000048179. PMID: 11919418.

720: Agis H, Weltermann A, Fonatsch C, Haas O, Mitterbauer G, Müllauer L, Schreiber S, Schwarzinger I, Juretzka W, Valent P, Jäger U, Lechner K, Geissler K. A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis. Ann Hematol. 2002 Feb;81(2):90-5. doi: 10.1007/s00277-001-0412-9. Epub 2002 Jan 23. PMID: 11907789.

721: Valent P, Samorapoompichit P, Sperr WR, Horny HP, Lechner K. Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells. Hematol J. 2002;3(2):90-4. doi: 10.1038/sj.thj.6200164. PMID: 12032870.

722: Swoboda I, De Weerd N, Bhalla PL, Niederberger V, Sperr WR, Valent P, Kahlert H, Fiebig H, Verdino P, Keller W, Ebner C, Spitzauer S, Valenta R, Singh MB. Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE- binding capacity: candidates for grass pollen-specific immunotherapy. Eur J Immunol. 2002 Jan;32(1):270-80. doi: 10.1002/1521-4141(200201)32:1<270::AID- IMMU270>3.0.CO;2-X. PMID: 11782018.

723: Schernthaner GH, Jordan JH, Ghannadan M, Agis H, Bevec D, Nuñez R, Escribano L, Majdic O, Willheim M, Worda C, Printz D, Fritsch G, Lechner K, Valent P. Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood. 2001 Dec 15;98(13):3784-92. doi: 10.1182/blood.v98.13.3784. PMID: 11739187.

724: Platz IJ, Binder M, Marxer A, Lischka G, Valent P, Bühring HJ. Hymenoptera- venom-induced upregulation of the basophil activation marker ecto-nucleotide pyrophosphatase/phosphodiesterase 3 in sensitized individuals. Int Arch Allergy Immunol. 2001 Dec;126(4):335-42. doi: 10.1159/000049531. Erratum in: Int Arch Allergy Immunol 2002 Apr;127(4):293. PMID: 11815741.

725: Binder M, Mahler V, Hayek B, Sperr WR, Schöller M, Prozell S, Wiedermann G, Valent P, Valenta R, Duchêne M. Molecular and immunological characterization of arginine kinase from the Indianmeal moth, Plodia interpunctella, a novel cross- reactive invertebrate pan-allergen. J Immunol. 2001 Nov 1;167(9):5470-7. doi: 10.4049/jimmunol.167.9.5470. PMID: 11673567.

726: Samorapoompichit P, Kiener HP, Schernthaner GH, Jordan JH, Agis H, Wimazal F, Baghestanian M, Rezaie-Majd A, Sperr WR, Lechner K, Valent P. Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. Blood. 2001 Oct 15;98(8):2580-3. doi: 10.1182/blood.v98.8.2580. PMID: 11588060.

727: Füreder W, Schernthaner GH, Ghannadan M, Hauswirth A, Sperr WR, Semper H, Majlesi Y, Zwirner J, Götze O, Bühring HJ, Lechner K, Valent P. Quantitative, phenotypic, and functional evaluation of basophils in myelodysplastic syndromes. Eur J Clin Invest. 2001 Oct;31(10):894-901. doi: 10.1046/j.1365-2362.2001.00887.x. PMID: 11737228.

728: Sperr WR, Jordan JH, Baghestanian M, Kiener HP, Samorapoompichit P, Semper H, Hauswirth A, Schernthaner GH, Chott A, Natter S, Kraft D, Valenta R, Schwartz LB, Geissler K, Lechner K, Valent P. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood. 2001 Oct 1;98(7):2200-9. doi: 10.1182/blood.v98.7.2200. PMID: 11568008.

729: Laffer S, Hogbom E, Roux KH, Sperr WR, Valent P, Bankl HC, Vangelista L, Kricek F, Kraft D, Grönlund H, Valenta R. A molecular model of type I allergy: identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcepsilonRI interaction and reacts with receptor- bound IgE. J Allergy Clin Immunol. 2001 Sep;108(3):409-16. doi: 10.1067/mai.2001.117593. PMID: 11544461.

730: Focke M, Mahler V, Ball T, Sperr WR, Majlesi Y, Valent P, Kraft D, Valenta R. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J. 2001 Sep;15(11):2042-4. doi: 10.1096/fj.01-0016fje. Epub 2001 Jul 24. PMID: 11511525.

731: Vrtala S, Hirtenlehner K, Susani M, Akdis M, Kussebi F, Akdis CA, Blaser K, Hufnagl P, Binder BR, Politou A, Pastore A, Vangelista L, Sperr WR, Semper H, Valent P, Ebner C, Kraft D, Valenta R. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J. 2001 Sep;15(11):2045-7. doi: 10.1096/fj.00-0767fje. Epub 2001 Jul 24. PMID: 11511511.

732: Fonatsch C, Nowotny H, Pittermann-Höcker E, Streubel B, Jäger U, Valent P, Büchner T, Lechner K. Amplification of ribosomal RNA genes in acute myeloid leukemia. Genes Chromosomes Cancer. 2001 Sep;32(1):11-7. doi: 10.1002/gcc.1161. PMID: 11477656.

733: Dziegielewska KM, Horny HP, Valent P, Habgood MD, Schumacher U. Fetuin in human bone marrow: detection in foetal tissue and patients with mastocytosis. Histochem J. 2001 Aug;33(8):443-51. doi: 10.1023/a:1014412013445. PMID: 11931384.

734: Bankl HC, Samorapoompichit P, Pikula B, Latinovic L, Bankl H, Lechner K, Valent P. Characterization of human prostate mast cells and their increase in periprostatic vein thrombosis. Am J Clin Pathol. 2001 Jul;116(1):97-106. doi: 10.1309/C0TP-MA3M-K5FX-3Q2F. PMID: 11447759.

735: Jordan JH, Fritsche-Polanz R, Sperr WR, Mitterbauer G, Födinger M, Schernthaner GH, Christian Bankl H, Gebhart W, Chott A, Lechner K, Valent P. A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val. Leuk Res. 2001 Jul;25(7):627-34. doi: 10.1016/s0145-2126(01)00019-4. PMID: 11377687.

736: Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, Marone G, Nuñez R, Akin C, Sotlar K, Sperr WR, Wolff K, Brunning RD, Parwaresch RM, Austen KF, Lennert K, Metcalfe DD, Vardiman JW, Bennett JM. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001 Jul;25(7):603-25. doi: 10.1016/s0145-2126(01)00038-8. PMID: 11377686.

737: Valent P, Sperr WR, Samorapoompichit P, Geissler K, Lechner K, Horny HP, Bennett JM. Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis. Leuk Res. 2001 Jul;25(7):595-602. doi: 10.1016/s0145-2126(01)00040-6. PMID: 11377685.

738: Escribano L, Díaz-Agustín B, Bellas C, Navalón R, Nuñez R, Sperr WR, Schernthaner GH, Valent P, Orfao A. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res. 2001 Jul;25(7):563-70. doi: 10.1016/s0145-2126(01)00050-9. PMID: 11377681.

739: Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res. 2001 Jul;25(7):543-51. doi: 10.1016/s0145-2126(01)00021-2. PMID: 11377679.

740: Sperr WR, Escribano L, Jordan JH, Schernthaner GH, Kundi M, Horny HP, Valent P. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res. 2001 Jul;25(7):529-36. doi: 10.1016/s0145-2126(01)00041-8. PMID: 11377677.

741: Bühring HJ, Seiffert M, Giesert C, Marxer A, Kanz L, Valent P, Sano K. The basophil activation marker defined by antibody 97A6 is identical to the ectonucleotide pyrophosphatase/phosphodiesterase 3. Blood. 2001 May 15;97(10):3303-5. doi: 10.1182/blood.v97.10.3303. PMID: 11342463.

742: Sperr WR, Wimazal F, Kundi M, Fonatsch C, Thalhammer-Scherrer R, Schernthaner GH, Schwarzinger I, Haas OA, Geissler K, Lechner K, Valent P. Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems. Ann Hematol. 2001 May;80(5):272-7. doi: 10.1007/s002770000280. PMID: 11446729.

743: Jordan JH, Walchshofer S, Jurecka W, Mosberger I, Sperr WR, Wolff K, Chott A, Bühring HJ, Lechner K, Horny HP, Valent P. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum Pathol. 2001 May;32(5):545-52. doi: 10.1053/hupa.2001.24319. PMID: 11381374.

744: Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P, Födinger M. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol. 2001 May;113(2):357-64. doi: 10.1046/j.1365-2141.2001.02783.x. PMID: 11380399.

745: Wimazal F, Sperr WR, Kundi M, Meidlinger P, Fonatsch C, Jordan JH, Thalhammer-Scherrer R, Schwarzinger I, Geissler K, Lechner K, Valent P. Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. Leuk Res. 2001 Apr;25(4):287-94. doi: 10.1016/s0145-2126(00)00140-5. PMID: 11248325.

746: Li S, Peck-Radosavljevic M, Koller E, Koller F, Kaserer K, Kreil A, Kapiotis S, Hamwi A, Weich HA, Valent P, Angelberger P, Dudczak R, Virgolini I. Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy. Int J Cancer. 2001 Mar 15;91(6):789-96. doi: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1126>3.0.co;2-k. PMID: 11275981.

747: Natter S, Granditsch G, Reichel GL, Baghestanian M, Valent P, Elfman L, Grönlund H, Kraft D, Valenta R. IgA cross-reactivity between a nuclear autoantigen and wheat proteins suggests molecular mimicry as a possible pathomechanism in celiac disease. Eur J Immunol. 2001 Mar;31(3):918-28. doi: 10.1002/1521-4141(200103)31:3&#60;918::aid-immu918&#62;3.0.co;2-u. PMID: 11241297.

748: Li SR, Koller E, Valent P, Gludovacz D, Yang Q, Patri P, Angelberger P, Dudczak R, Virgolini I. Effects of vasoactive intestinal peptide (VIP) and somatostatin (SST) on lipoprotein receptor expression by A431 tumor cells. Life Sci. 2001 Feb 2;68(11):1243-57. doi: 10.1016/s0024-3205(00)01023-7. PMID: 11233992.

749: Valent P, Schernthaner GH, Sperr WR, Fritsch G, Agis H, Willheim M, Bühring HJ, Orfao A, Escribano L. Variable expression of activation-linked surface antigens on human mast cells in health and disease. Immunol Rev. 2001 Feb;179:74-81. doi: 10.1034/j.1600-065x.2001.790108.x. PMID: 11292030.

750: Streubel B, Valent P, Lechner K, Fonatsch C. Amplification of the AML1(CBFA2) gene on ring chromosomes in a patient with acute myeloid leukemia and a constitutional ring chromosome 21. Cancer Genet Cytogenet. 2001 Jan 1;124(1):42-6. doi: 10.1016/s0165-4608(00)00318-6. PMID: 11165321.

751: Schernthaner GH, Spanblöchl E, Sperr WR, Sillaber C, Semper H, Jurecka W, Hagen W, Wolff K, Chott A, Lechner K, Valent P. Effects of interferon-alpha2b treatment on ex vivo differentiation of mast cells from circulating progenitor cells in a patient with systemic mastocytosis. Ann Hematol. 2000 Dec;79(12):660-6. doi: 10.1007/s002770000206. PMID: 11195002.

752: Stoiser B, Knöbl P, Fonatsch C, Haas OA, Mitterbauer G, Weltermann A, Geissler K, Valent P, Sperr W, Pabinger I, Lechner K, Jaeger U. Prognosis of patients with a second relapse of acute myeloid leukemia. Leukemia. 2000 Dec;14(12):2059-63. doi: 10.1038/sj.leu.2401968. PMID: 11187893.

753: Flicker S, Vrtala S, Steinberger P, Vangelista L, Bufe A, Petersen A, Ghannadan M, Sperr WR, Valent P, Norderhaug L, Bohle B, Stockinger H, Suphioglu C, Ong EK, Kraft D, Valenta R. A human monoclonal IgE antibody defines a highly allergenic fragment of the major timothy grass pollen allergen, Phl p 5: molecular, immunological, and structural characterization of the epitope- containing domain. J Immunol. 2000 Oct 1;165(7):3849-59. doi: 10.4049/jimmunol.165.7.3849. PMID: 11034391.

754: Füreder W, Streubel B, Jordan JH, Walchshofer S, Wimazal F, Jäger U, Geissler K, Schwartz LB, Chott A, Lechner K, Valent P, Fonatsch C. Reciprocal translocation (3;5)(q26;q22) and possible BCHE gene involvement in an unusual myelogenous disorder with both myeloproliferative and dysplastic features. Cancer Genet Cytogenet. 2000 Sep;121(2):133-8. doi: 10.1016/s0165-4608(00)00245-4. PMID: 11063796.

755: Sotlar K, Marafioti T, Griesser H, Theil J, Aepinus C, Jaussi R, Stein H, Valent P, Horny HP. Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol Pathol. 2000 Aug;53(4):188-93. doi: 10.1136/mp.53.4.188. PMID: 11040941; PMCID: PMC1186968.

756: Sperr WR, Natter S, Baghestanian M, Smolen J, Wolff K, Binder BR, Müller MR, Lechner K, Valenta R, Valent P. Autoantibody reactivity in a case of Schnitzler's syndrome: evidence for a Th1-like response and detection of IgG2 anti-FcepsilonRIalpha antibodies. Int Arch Allergy Immunol. 2000 Aug;122(4):279-86. doi: 10.1159/000024410. PMID: 10971119.

757: Geissler K, Gisslinger H, Knöbl P, Sperr W, Valent P, Dieckmann K, Chott A, Pötter R, Lechner K, Jäger U. Efficacy of standard treatment in patients with Hodgkin's disease--a single center experience. Wien Klin Wochenschr. 2000 Jul 28;112(14):624-8. PMID: 11008324.

758: Sperr WR, Horny HP, Lechner K, Valent P. Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk Lymphoma. 2000 May;37(5-6):473-86. doi: 10.3109/10428190009058500. PMID: 11042508.

759: Bugajska-Schretter A, Grote M, Vangelista L, Valent P, Sperr WR, Rumpold H, Pastore A, Reichelt R, Valenta R, Spitzauer S. Purification, biochemical, and immunological characterisation of a major food allergen: different immunoglobulin E recognition of the apo- and calcium-bound forms of carp parvalbumin. Gut. 2000 May;46(5):661-9. doi: 10.1136/gut.46.5.661. PMID: 10764710; PMCID: PMC1727915.

760: Streubel B, Valent P, Jäger U, Edelhäuser M, Wandt H, Wagner T, Büchner T, Lechner K, Fonatsch C. Amplification of the MLL gene on double minutes, a homogeneously staining region, and ring chromosomes in five patients with acute myeloid leukemia or myelodysplastic syndrome. Genes Chromosomes Cancer. 2000 Apr;27(4):380-6. PMID: 10719368.

761: Mahler V, Fischer S, Fuchs T, Ghannadan M, Valent P, Fartasch M, Kraft D, Schuler G, Valenta R. Prevention of latex allergy by selection of low-allergen gloves. Clin Exp Allergy. 2000 Apr;30(4):509-20. doi: 10.1046/j.1365-2222.2000.00721.x. PMID: 10718848.

762: Kiener HP, Hofbauer R, Tohidast-Akrad M, Walchshofer S, Redlich K, Bitzan P, Kapiotis S, Steiner G, Smolen JS, Valent P. Tumor necrosis factor alpha promotes the expression of stem cell factor in synovial fibroblasts and their capacity to induce mast cell chemotaxis. Arthritis Rheum. 2000 Jan;43(1):164-74. doi: 10.1002/1529-0131(200001)43:1<164::AID-ANR21>3.0.CO;2-Z. PMID: 10643713.

763: Füreder W, Weltermann A, Chott A, Gisslinger H, Valent P, Jäger U, Geissler K, Lechner K. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine). Wien Klin Wochenschr. 1999 Dec 23;111(24):1027-30. PMID: 10677889.

764: Vrtala S, Fischer S, Grote M, Vangelista L, Pastore A, Sperr WR, Valent P, Reichelt R, Kraft D, Valenta R. Molecular, immunological, and structural characterization of Phl p 6, a major allergen and P-particle-associated protein from Timothy grass (Phleum pratense) pollen. J Immunol. 1999 Nov 15;163(10):5489-96. PMID: 10553075.

765: Wimazal F, Ghannadan M, Müller MR, End A, Willheim M, Meidlinger P, Schernthaner GH, Jordan JH, Hagen W, Agis H, Sperr WR, Czerwenka K, Lechner K, Valent P. Expression of homing receptors and related molecules on human mast cells and basophils: a comparative analysis using multi-color flow cytometry and toluidine blue/immunofluorescence staining techniques. Tissue Antigens. 1999 Nov;54(5):499-507. doi: 10.1034/j.1399-0039.1999.540507.x. PMID: 10599889.

766: Seiberler S, Bugajska-Schretter A, Hufnagl P, Binder BR, Stöckl J, Spitzauer S, Valent P, Valenta R. Characterization of IgE-reactive autoantigens in atopic dermatitis. 1. Subcellular distribution and tissue-specific expression. Int Arch Allergy Immunol. 1999 Oct;120(2):108-16. doi: 10.1159/000024228. PMID: 10545764.

767: Bühring HJ, Simmons PJ, Pudney M, Müller R, Jarrossay D, van Agthoven A, Willheim M, Brugger W, Valent P, Kanz L. The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors. Blood. 1999 Oct 1;94(7):2343-56. PMID: 10498606.

768: Valent P, Escribano L, Parwaresch RM, Schemmel V, Schwartz LB, Sotlar K, Sperr WR, Horny HP. Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998. Int Arch Allergy Immunol. 1999 Sep;120(1):1-7. doi: 10.1159/000024214. PMID: 10529583.

769: Streicher J, Valent P, Schmidt H, Sengölge G, Wagner O, Strobl W, Hörl WH, Derfler K. Up-regulation of LDL-receptor expression by LDL-immunoapheresis in patients with familial hypercholesterolemia. J Investig Med. 1999 Sep;47(8):378-87. PMID: 10510590.

770: Ball T, Fuchs T, Sperr WR, Valent P, Vangelista L, Kraft D, Valenta R. B cell epitopes of the major timothy grass pollen allergen, phl p 1, revealed by gene fragmentation as candidates for immunotherapy. FASEB J. 1999 Aug;13(11):1277-90. doi: 10.1096/fasebj.13.11.1277. PMID: 10428753.

771: Agis H, Weltermann A, Mitterbauer G, Thalhammer R, Edelhäuser M, Seewann HL, Valent P, Lechner K, Fonatsch C, Geissler K. Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia. Ann Hematol. 1999 Jul;78(7):329-32. doi: 10.1007/s002770050523. PMID: 10466445.

772: Sillaber C, Walchshofer S, Mosberger I, Gaiger A, Simonitsch I, Chott A, Lechner K, Valent P. Immunophenotypic characterization of human bone marrow endosteal cells. Tissue Antigens. 1999 Jun;53(6):559-68. doi: 10.1034/j.1399-0039.1999.530606.x. PMID: 10395106.

773: Ball T, Sperr WR, Valent P, Lidholm J, Spitzauer S, Ebner C, Kraft D, Valenta R. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol. 1999 Jun;29(6):2026-36. doi: 10.1002/(SICI)1521-4141(199906)29:06<2026::AID- IMMU2026>3.0.CO;2-2. PMID: 10382766.

774: Vangelista L, Laffer S, Turek R, Grönlund H, Sperr WR, Valent P, Pastore A, Valenta R. The immunoglobulin-like modules Cepsilon3 and alpha2 are the minimal units necessary for human IgE-FcepsilonRI interaction. J Clin Invest. 1999 Jun;103(11):1571-8. doi: 10.1172/JCI6551. PMID: 10359566; PMCID: PMC408375.

775: Wimazal F, Sperr WR, Horny HP, Carroll V, Binder BR, Fonatsch C, Walchshofer S, Födinger M, Schwarzinger I, Samorapoompichit P, Chott A, Dvorak AM, Lechner K, Valent P. Hyperfibrinolysis in a case of myelodysplastic syndrome with leukemic spread of mast cells. Am J Hematol. 1999 May;61(1):66-77. doi: 10.1002/(sici)1096-8652(199905)61:1<66::aid-ajh12>3.0.co;2-3. PMID: 10331514.

776: Niederberger V, Hayek B, Vrtala S, Laffer S, Twardosz A, Vangelista L, Sperr WR, Valent P, Rumpold H, Kraft D, Ehrenberger K, Valenta R, Spitzauer S. Calcium-dependent immunoglobulin E recognition of the apo- and calcium-bound form of a cross-reactive two EF-hand timothy grass pollen allergen, Phl p 7. FASEB J. 1999 May;13(8):843-56. doi: 10.1096/fasebj.13.8.843. PMID: 10224228.

777: Vrtala S, Hirtenlehner K, Susani M, Hufnagl P, Binder BR, Vangelista L, Pastore A, Sperr WR, Valent P, Ebner C, Kraft D, Valenta R. Genetic engineering of recombinant hypoallergenic oligomers of the major birch pollen allergen, Bet v 1: candidates for specific immunotherapy. Int Arch Allergy Immunol. 1999 Feb- Apr;118(2-4):218-9. doi: 10.1159/000024075. PMID: 10224386.

778: Laffer S, Hogbom E, Adrianson J, Grönlund H, Sillaber C, Valent P, Vangelista L, Kricek F, Kraft D, Valenta R. An in vitro model for the allergen- IgE-FcARI interaction. Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):116-8. doi: 10.1159/000024044. PMID: 10224355.

779: Bankl HC, Grossschmidt K, Pikula B, Bankl H, Lechner K, Valent P. Mast cells are augmented in deep vein thrombosis and express a profibrinolytic phenotype. Hum Pathol. 1999 Feb;30(2):188-94. doi: 10.1016/s0046-8177(99)90274-5. PMID: 10029447.

780: Skyllouriotis P, Skyllouriotis-Lazarou M, Natter S, Steiner R, Spitzauer S, Kapiotis S, Valent P, Hirschl AM, Guber SE, Laufer G, Wollenek G, Wolner E, Wimmer M, Valenta R. IgG subclass reactivity to human cardiac myosin in cardiomyopathy patients is indicative of a Th1-like autoimmune disease. Clin Exp Immunol. 1999 Feb;115(2):236-47. doi: 10.1046/j.1365-2249.1999.00807.x. PMID: 9933448; PMCID: PMC1905170.

781: Sillaber C, Baghestanian M, Bevec D, Willheim M, Agis H, Kapiotis S, Füreder W, Bankl HC, Kiener HP, Speiser W, Binder BR, Lechner K, Valent P. The mast cell as site of tissue-type plasminogen activator expression and fibrinolysis. J Immunol. 1999 Jan 15;162(2):1032-41. PMID: 9916730.

782: Hayek B, Vangelista L, Pastore A, Sperr WR, Valent P, Vrtala S, Niederberger V, Twardosz A, Kraft D, Valenta R. Molecular and immunologic characterization of a highly cross-reactive two EF-hand calcium-binding alder pollen allergen, Aln g 4: structural basis for calcium-modulated IgE recognition. J Immunol. 1998 Dec 15;161(12):7031-9. PMID: 9862740.

783: Ceponis A, Konttinen YT, Takagi M, Xu JW, Sorsa T, Matucci-Cerinic M, Santavirta S, Bankl HC, Valent P. Expression of stem cell factor (SCF) and SCF receptor (c-kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation. J Rheumatol. 1998 Dec;25(12):2304-14. PMID: 9858422.

784: Sperr WR, Walchshofer S, Horny HP, Födinger M, Simonitsch I, Fritsche- Polanz R, Schwarzinger I, Tschachler E, Sillaber C, Hagen W, Geissler K, Chott A, Lechner K, Valent P. Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val. Br J Haematol. 1998 Dec;103(3):740-9. doi: 10.1046/j.1365-2141.1998.01072.x. PMID: 9858225.

785: Valenta R, Natter S, Seiberler S, Wichlas S, Maurer D, Hess M, Pavelka M, Grote M, Ferreira F, Szepfalusi Z, Valent P, Stingl G. Molecular characterization of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients. J Invest Dermatol. 1998 Dec;111(6):1178-83. doi: 10.1046/j.1523-1747.1998.00413.x. PMID: 9856836.

786: Natter S, Seiberler S, Hufnagl P, Binder BR, Hirschl AM, Ring J, Abeck D, Schmidt T, Valent P, Valenta R. Isolation of cDNA clones coding for IgE autoantigens with serum IgE from atopic dermatitis patients. FASEB J. 1998 Nov;12(14):1559-69. doi: 10.1096/fasebj.12.14.1559. PMID: 9806765.

787: Ghannadan M, Baghestanian M, Wimazal F, Eisenmenger M, Latal D, Kargül G, Walchshofer S, Sillaber C, Lechner K, Valent P. Phenotypic characterization of human skin mast cells by combined staining with toluidine blue and CD antibodies. J Invest Dermatol. 1998 Oct;111(4):689-95. doi: 10.1046/j.1523-1747.1998.00359.x. PMID: 9764855.

788: Schedle A, Rausch-Fan XH, Samorapoompichit P, Franz A, Leutmezer F, Spittler A, Baghestanian M, Lucas T, Valent P, Slavicek R, Boltz-Nitulescu G. Effects of dental amalgam and heavy metal cations on cytokine production by peripheral blood mononuclear cells in vitro. J Biomed Mater Res. 1998 Oct;42(1):76-84. doi: 10.1002/(sici)1097-4636(199810)42:1<76::aid- jbm10>3.0.co;2-m. PMID: 9740009.

789: Virgolini I, Kurtaran A, Leimer M, Kaserer K, Peck-Radosavljevic M, Angelberger P, Hübsch P, Dvorak M, Valent P, Niederle B. Location of a VIPoma by iodine-123-vasoactive intestinal peptide scintigraphy. J Nucl Med. 1998 Sep;39(9):1575-9. PMID: 9744346.

790: Horny HP, Sillaber C, Menke D, Kaiserling E, Wehrmann M, Stehberger B, Chott A, Lechner K, Lennert K, Valent P. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol. 1998 Sep;22(9):1132-40. doi: 10.1097/00000478-199809000-00013. PMID: 9737247.

791: Weltermann A, Pabinger I, Geissler K, Jäger U, Gisslinger H, Knöbl P, Eichinger S, Kyrle PA, Valent P, Speiser W, Schwarzinger I, Mannhalter C, Lechner K. Hypofibrinogenemia in non-M3 acute myeloid leukemia. Incidence, clinical and laboratory characteristics and prognosis. Leukemia. 1998 Aug;12(8):1182-6. doi: 10.1038/sj.leu.2401101. PMID: 9697871.

792: Schedle A, Samorapoompichit P, Ghannadan M, Franz A, Sperr WR, Sperr W, Valent P. Effects of dental amalgam and its components of histamine release from human basophils and tissue mast cells. Wien Klin Wochenschr. 1998 Jul 31;110(13-14):467-72. Erratum in: Wien Klin Wochenschr 1998 Sep 4;110(16):585. PMID: 9746959.

793: Geissler K, Kabrna E, Stengg S, Schwarzinger I, Knöbl P, Valent P, Eichinger S, Barge A, Lechner K. Recombinant human megakaryocyte growth and development factor increases levels of circulating haemopoietic progenitor cells post chemotherapy in patients with acute myeloid leukaemia. Br J Haematol. 1998 Jul;102(2):535-43. doi: 10.1046/j.1365-2141.1998.00789.x. PMID: 9695971.

794: Valenta R, Almo S, Ball T, Dolecek C, Steinberger P, Laffer S, Eibensteiner P, Flicker S, Vrtala S, Spitzauer S, Valent P, Denepoux S, Kraft D, Banchereau J, Lebecque S. The immunoglobulin E-allergen interaction: a target for therapy of type I allergic diseases. Int Arch Allergy Immunol. 1998 Jul;116(3):167-76. doi: 10.1159/000023942. PMID: 9693264.

795: Vrtala S, Ball T, Spitzauer S, Pandjaitan B, Suphioglu C, Knox B, Sperr WR, Valent P, Kraft D, Valenta R. Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation. J Immunol. 1998 Jun 15;160(12):6137-44. PMID: 9637531.

796: Virgolini I, Leimer M, Handmaker H, Lastoria S, Bischof C, Muto P, Pangerl T, Gludovacz D, Peck-Radosavljevic M, Lister-James J, Hamilton G, Kaserer K, Valent P, Dean R. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829. Cancer Res. 1998 May 1;58(9):1850-9. PMID: 9581824.

797: Schedle A, Samorapoompichit P, Füreder W, Rausch-Fan XH, Franz A, Sperr WR, Sperr W, Slavicek R, Simak S, Klepetko W, Ellinger A, Ghannadan M, Baghestanian M, Valent P. Metal ion-induced toxic histamine release from human basophils and mast cells. J Biomed Mater Res. 1998 Mar 15;39(4):560-7. doi: 10.1002/(sici)1097-4636(19980315)39:4<560::aid-jbm9>3.0.co;2-h. PMID: 9492216.

798: Hagen W, Schwarzmeier J, Walchshofer S, Zojer N, Chott A, Sillaber C, Ackermann J, Simonitsch I, Bühring HJ, Drach J, Lechner K, Horny HP, Valent P. A case of bone marrow mastocytosis associated with multiple myeloma. Ann Hematol. 1998 Mar-Apr;76(3-4):167-74. doi: 10.1007/s002770050382. PMID: 9619735.

799: Wimazal F, Walchshofer S, Baghestanian M, Chott A, Sperr WR, Kopp C, Sillaber C, Semper H, Horny HP, Tröndle U, Födinger M, Schwarzinger I, Lechner K, Valent P. Detection of mi transcription factor (MITF) mRNA in a case of myelodysplastic syndrome and bone marrow mastocytosis. Wien Klin Wochenschr. 1998 Feb 13;110(3):79-88. Erratum in: Wien Klin Wochenschr 1998 Mar 27;110(6):238. PMID: 9553202.

800: Hirschwehr R, Heppner C, Spitzauer S, Sperr WR, Valent P, Berger U, Horak F, Jäger S, Kraft D, Valenta R. Identification of common allergenic structures in mugwort and ragweed pollen. J Allergy Clin Immunol. 1998 Feb;101(2 Pt 1):196-206. doi: 10.1016/s0091-6749(98)70384-7. PMID: 9500752.

801: Kiener HP, Baghestanian M, Dominkus M, Walchshofer S, Ghannadan M, Willheim M, Sillaber C, Graninger WB, Smolen JS, Valent P. Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. Arthritis Rheum. 1998 Feb;41(2):233-45. doi: 10.1002/1529-0131(199802)41:2<233::AID- ART7>3.0.CO;2-V. PMID: 9485081.

802: Beil WJ, Füreder W, Wiener H, Grossschmidt K, Maier U, Schedle A, Bankl HC, Lechner K, Valent P. Phenotypic and functional characterization of mast cells derived from renal tumor tissues. Exp Hematol. 1998 Feb;26(2):158-69. PMID: 9472805.

803: Valent P, Sillaber C, Baghestanian M, Bankl HC, Kiener HP, Lechner K, Binder BR. What have mast cells to do with edema formation, the consecutive repair and fibrinolysis? Int Arch Allergy Immunol. 1998 Jan;115(1):2-8. doi: 10.1159/000023823. PMID: 9430489.

804: Baghestanian M, Hofbauer R, Kiener HP, Bankl HC, Wimazal F, Willheim M, Scheiner O, Füreder W, Müller MR, Bevec D, Lechner K, Valent P. The c-kit ligand stem cell factor and anti-IgE promote expression of monocyte chemoattractant protein-1 in human lung mast cells. Blood. 1997 Dec 1;90(11):4438-49. PMID: 9373254.

805: Bankl HC, Radaszkiewicz T, Pikula B, Baghestanian M, Mehrabi MR, Bankl H, Lechner K, Valent P. Expression of fibrinolytic antigens in redistributed cardiac mast cells in auricular thrombosis. Hum Pathol. 1997 Nov;28(11):1283-90. doi: 10.1016/s0046-8177(97)90202-1. PMID: 9385934.

806: Sperr WR, Agis H, Semper H, Valenta R, Susani M, Sperr M, Willheim M, Scheiner O, Liehl E, Lechner K, Valent P. Inhibition of allergen-induced histamine release from human basophils by cyclosporine A and FK-506. Int Arch Allergy Immunol. 1997 Sep;114(1):68-73. doi: 10.1159/000237645. PMID: 9303333.

807: Virgolini I, Kurtaran A, Leimer M, Smith-Jones P, Agis H, Angelberger P, Kletter K, Valent P, Linkesch W, Eichler HG. Inhalation scintigraphy with iodine-123-labeled interferon gamma-1b: pulmonary deposition and dose escalation study in healthy volunteers. J Nucl Med. 1997 Sep;38(9):1475-81. PMID: 9293812.

808: Vrtala S, Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, Sperr WR, Valent P, Ebner C, Kraft D, Valenta R. Division of the major birch pollen allergen, Bet v 1, into two non-anaphylactic fragments. Int Arch Allergy Immunol. 1997 May-Jul;113(1-3):246-8. doi: 10.1159/000237560. PMID: 9130536.

809: Füreder W, Bankl HC, Toth J, Walchshofer S, Sperr W, Agis H, Semper H, Sillaber C, Lechner K, Valent P. Immunophenotypic and functional characterization of human tonsillar mast cells. J Leukoc Biol. 1997 May;61(5):592-9. doi: 10.1002/jlb.61.5.592. PMID: 9129208.

810: Horny HP, Kaiserling E, Sillaber C, Walchshofer S, Valent P. Bone marrow mastocytosis associated with an undifferentiated extramedullary tumor of hemopoietic origin. Arch Pathol Lab Med. 1997 Apr;121(4):423-6. PMID: 9140315.

811: Vrtala S, Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, Sperr WR, Valent P, Ebner C, Kraft D, Valenta R. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest. 1997 Apr 1;99(7):1673-81. doi: 10.1172/JCI119330. PMID: 9120011; PMCID: PMC507987.

812: Sillaber C, Baghestanian M, Hofbauer R, Virgolini I, Bankl HC, Füreder W, Agis H, Willheim M, Leimer M, Scheiner O, Binder BR, Kiener HP, Bevec D, Fritsch G, Majdic O, Kress HG, Gadner H, Lechner K, Valent P. Molecular and functional characterization of the urokinase receptor on human mast cells. J Biol Chem. 1997 Mar 21;272(12):7824-32. doi: 10.1074/jbc.272.12.7824. PMID: 9065447.

813: Baghestanian M, Hofbauer R, Kress HG, Wojta J, Fabry A, Binder BR, Kaun C, Müller MR, Mehrabi MR, Kapiotis S, Sengoelge G, Ghannadan M, Lechner K, Valent P. Thrombin augments vascular cell-dependent migration of human mast cells: role of MGF. Thromb Haemost. 1997 Mar;77(3):577-84. PMID: 9066013.

814: Baghestanian M, Agis H, Bevec D, Bankl HC, Hofbauer R, Kress HG, Butterfield JH, Müller MR, Ashman LK, Füreder W, Willheim M, Lechner K, Valent P. Stem cell factor-induced downregulation of c-kit in human lung mast cells and HMC-1 mast cells. Exp Hematol. 1996 Oct;24(12):1377-86. PMID: 8913283.

815: Virgolini I, Angelberger P, Li S, Yang Q, Kurtaran A, Raderer M, Neuhold N, Kaserer K, Leimer M, Peck-Radosavljevic M, Scheithauer W, Niederle B, Eichler HG, Valent P. In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT. Eur J Nucl Med. 1996 Oct;23(10):1388-99. doi: 10.1007/BF01367597. PMID: 8781146.

816: Vrtala S, Wiedemann P, Mittermann I, Eichler HG, Sperr WR, Valent P, Kraft D, Valenta R. High-level expression in Escherichia coli and purification of recombinant plant profilins: comparison of IgE-binding capacity and allergenic activity. Biochem Biophys Res Commun. 1996 Sep 4;226(1):42-50. doi: 10.1006/bbrc.1996.1309. PMID: 8806590.

817: Virgolini I, Raderer M, Kurtaran A, Angelberger P, Yang Q, Radosavljevic M, Leimer M, Kaserer K, Li SR, Kornek G, Hübsch P, Niederle B, Pidlich J, Scheithauer W, Valent P. 123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Nucl Med Biol. 1996 Aug;23(6):685-92. doi: 10.1016/0969-8051(96)00066-2. PMID: 8940711.

818: Valenta R, Maurer D, Steiner R, Seiberler S, Sperr WR, Valent P, Spitzauer S, Kapiotis S, Smolen J, Stingl G. Immunoglobulin E response to human proteins in atopic patients. J Invest Dermatol. 1996 Aug;107(2):203-8. doi: 10.1111/1523-1747.ep12329617. PMID: 8757763.

819: Sperr WR, Agis H, Czerwenka K, Virgolini I, Bankl HC, Müller MR, Zsebo K, Lechner K, Valent P. Effects of cyclosporin A and FK-506 on stem cell factor- induced histamine secretion and growth of human mast cells. J Allergy Clin Immunol. 1996 Aug;98(2):389-99. doi: 10.1016/s0091-6749(96)70163-x. PMID: 8757216.

820: Agis H, Beil WJ, Bankl HC, Füreder W, Sperr WR, Ghannadan M, Baghestanian M, Sillaber C, Bettelheim P, Lechner K, Valent P. Mast cell-lineage versus basophil lineage involvement in myeloproliferative and myelodysplastic syndromes: diagnostic role of cell-immunophenotyping. Leuk Lymphoma. 1996 Jul;22(3-4):187-204. doi: 10.3109/10428199609051750. PMID: 8819068.

821: Wong DA, Valent P, Bettelheim P, Switzer J, Denburg JA. Immunophenotypic analysis of HL-60 cells during basophilic differentiation. Int Arch Allergy Immunol. 1996 Jul;110(3):252-60. doi: 10.1159/000237295. PMID: 8688672.

822: Agis H, Füreder W, Bankl HC, Kundi M, Sperr WR, Willheim M, Boltz-Nitulescu G, Butterfield JH, Kishi K, Lechner K, Valent P. Comparative immunophenotypic analysis of human mast cells, blood basophils and monocytes. Immunology. 1996 Apr;87(4):535-43. doi: 10.1046/j.1365-2567.1996.493578.x. PMID: 8675206; PMCID: PMC1384130.

823: Vrtala S, Susani M, Sperr WR, Valent P, Laffer S, Dolecek C, Kraft D, Valenta R. Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p2, Phl p 5). J Allergy Clin Immunol. 1996 Mar;97(3):781-7. doi: 10.1016/s0091-6749(96)80156-4. PMID: 8613635.

824: Valenta R, Laffer S, Vrtala S, Grönlund H, Elfman L, Sperr WR, Valent P, Ferreira F, Mayer P, Liehl E, Heiss S, Steiner R, Eichler HG, Susani M, Kraft D. Recombinant allergens. Steps on the way to diagnosis and therapy of type I allergy. Adv Exp Med Biol. 1996;409:185-96. PMID: 9095240.

825: Valent P. Biology, classification and treatment of human mastocytosis. Wien Klin Wochenschr. 1996;108(13):385-97. PMID: 8766423.

826: Kapiotis S, Sengoelge G, Sperr WR, Baghestanian M, Quehenberger P, Bevec D, Li SR, Menzel EJ, Mühl A, Zapolska D, Virgolini I, Valent P, Speiser W. Ibuprofen inhibits pyrogen-dependent expression of VCAM-1 and ICAM-1 on human endothelial cells. Life Sci. 1996;58(23):2167-81. doi: 10.1016/0024-3205(96)00210-x. PMID: 8649201.

827: Ferreira FD, Mayer P, Sperr WR, Valent P, Seiberler S, Ebner C, Liehl E, Scheiner O, Kraft D, Valenta R. Induction of IgE antibodies with predefined specificity in rhesus monkeys with recombinant birch pollen allergens, Bet v 1 and Bet v 2. J Allergy Clin Immunol. 1996 Jan;97(1 Pt 1):95-103. doi: 10.1016/s0091-6749(96)70287-7. PMID: 8568143.

828: Baghestanian M, Bankl Hc, Sillaber C, Beil WJ, Radaszkiewicz T, Füreder W, Preiser J, Vesely M, Schernthaner G, Lechner K, Valent P. A case of malignant mastocytosis with circulating mast cell precursors: biologic and phenotypic characterization of the malignant clone. Leukemia. 1996 Jan;10(1):159-66. PMID: 8558922.

829: Susani M, Jertschin P, Dolecek C, Sperr WR, Valent P, Ebner C, Kraft D, Valenta R, Scheiner O. High level expression of birch pollen profilin (Bet v 2) in Escherichia coli: purification and characterization of the recombinant allergen. Biochem Biophys Res Commun. 1995 Oct 4;215(1):250-63. doi: 10.1006/bbrc.1995.2460. PMID: 7575599.

830: Valent P. 1995 Mack-Forster Award Lecture. Review. Mast cell differentiation antigens: expression in normal and malignant cells and use for diagnostic purposes. Eur J Clin Invest. 1995 Oct;25(10):715-20. doi: 10.1111/j.1365-2362.1995.tb01948.x. PMID: 8557056.

831: Virgolini I, Kurtaran A, Raderer M, Leimer M, Angelberger P, Havlik E, Li S, Scheithauer W, Niederle B, Valent P, et al. Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med. 1995 Oct;36(10):1732-9. PMID: 7562036.

832: Füreder W, Agis H, Willheim M, Bankl HC, Maier U, Kishi K, Müller MR, Czerwenka K, Radaszkiewicz T, Butterfield JH, Klappacher GW, Sperr WR, Oppermann M, Lechner K, Valent P. Differential expression of complement receptors on human basophils and mast cells. Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cells. J Immunol. 1995 Sep 15;155(6):3152-60. PMID: 7673728.

833: Valent P. Cytokines involved in growth and differentiation of human basophils and mast cells. Exp Dermatol. 1995 Aug;4(4 Pt 2):255-9. doi: 10.1111/j.1600-0625.1995.tb00254.x. PMID: 8528598.

834: Schedle A, Samorapoompichit P, Rausch-Fan XH, Franz A, Füreder W, Sperr WR, Sperr W, Ellinger A, Slavicek R, Boltz-Nitulescu G, Valent P. Response of L-929 fibroblasts, human gingival fibroblasts, and human tissue mast cells to various metal cations. J Dent Res. 1995 Aug;74(8):1513-20. doi: 10.1177/00220345950740081301. PMID: 7560408.

835: Willheim M, Agis H, Sperr WR, Köller M, Bankl HC, Kiener H, Fritsch G, Füreder W, Spittler A, Graninger W, Scheiner O, Gadner H, Lechner K, Boltz- Nitulescu G, Valent P. Purification of human basophils and mast cells by multistep separation technique and mAb to CDw17 and CD117/c-kit. J Immunol Methods. 1995 May 11;182(1):115-29. doi: 10.1016/0022-1759(95)00034-8. PMID: 7539467.

836: Füreder W, Agis H, Semper H, Keil F, Maier U, Müller MR, Czerwenka K, Höfler H, Lechner K, Valent P. Differential response of human basophils and mast cells to recombinant chemokines. Ann Hematol. 1995 May;70(5):251-8. doi: 10.1007/BF01784044. PMID: 7541256.

837: Bankl HC, Radaszkiewicz T, Klappacher GW, Glogar D, Sperr WR, Grossschmidt K, Bankl H, Lechner K, Valent P. Increase and redistribution of cardiac mast cells in auricular thrombosis. Possible role of kit ligand. Circulation. 1995 Jan 15;91(2):275-83. doi: 10.1161/01.cir.91.2.275. PMID: 7528649.

838: Valent P. Immunophenotypic characterization of human basophils and mast cells. Chem Immunol. 1995;61:34-48. PMID: 7662145.

839: Virgolini I, Li SR, Yang Q, Koller E, Sperr WR, Leimer M, Angelberger P, Nimpf J, Schneider W, Valent P. Characterization of LDL and VLDL binding sites on human basophils and mast cells. Arterioscler Thromb Vasc Biol. 1995 Jan;15(1):17-26. doi: 10.1161/01.atv.15.1.17. PMID: 7538422.

840: Valent P, Spanblöchl E, Bankl HC, Sperr WR, Marosi C, Pirc-Danoewinata H, Virgolini I, Eichler HG, Agis H, Sillaber C, et al. Kit ligand/mast cell growth factor-independent differentiation of mast cells in myelodysplasia and chronic myeloid leukemic blast crisis. Blood. 1994 Dec 15;84(12):4322-32. PMID: 7527672.

841: Valent P. The phenotype of human eosinophils, basophils, and mast cells. J Allergy Clin Immunol. 1994 Dec;94(6 Pt 2):1177-83. doi: 10.1016/0091-6749(94)90329-8. PMID: 7798557.

842: Füreder W, Agis H, Sperr WR, Lechner K, Valent P. The surface membrane antigen phenotype of human blood basophils. Allergy. 1994 Dec;49(10):861-5. doi: 10.1111/j.1398-9995.1994.tb00788.x. PMID: 7709996.

843: Sperr WR, Bankl HC, Mundigler G, Klappacher G, Grossschmidt K, Agis H, Simon P, Laufer P, Imhof M, Radaszkiewicz T, Glogar D, Lechner K, Valent P. The human cardiac mast cell: localization, isolation, phenotype, and functional characterization. Blood. 1994 Dec 1;84(11):3876-84. PMID: 7524750.

844: Ball T, Vrtala S, Sperr WR, Valent P, Susani M, Kraft D, Valenta R. Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction. J Biol Chem. 1994 Nov 11;269(45):28323-8. PMID: 7525573.

845: Bevec D, Klier H, Holter W, Tschachler E, Valent P, Lottspeich F, Baumruker T, Hauber J. Induced gene expression of the hypusine-containing protein eukaryotic initiation factor 5A in activated human T lymphocytes. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10829-33. doi: 10.1073/pnas.91.23.10829. PMID: 7971969; PMCID: PMC45119.

846: Födinger M, Fritsch G, Winkler K, Emminger W, Mitterbauer G, Gadner H, Valent P, Mannhalter C. Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. Blood. 1994 Nov 1;84(9):2954-9. PMID: 7949167.

847: Sillaber C, Sperr WR, Agis H, Spanblöchl E, Lechner K, Valent P. Inhibition of stem cell factor dependent formation of human mast cells by interleukin-3 and interleukin-4. Int Arch Allergy Immunol. 1994 Nov;105(3):264-8. doi: 10.1159/000236767. PMID: 7522690.

848: Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, Li S, Banyai M, Pidlich J, Niederle B, Scheithauer W, Valent P. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med. 1994 Oct 27;331(17):1116-21. doi: 10.1056/NEJM199410273311703. PMID: 7935635.

849: Valent P. The riddle of the mast cell: kit(CD117)-ligand as the missing link? Immunol Today. 1994 Mar;15(3):111-4. doi: 10.1016/0167-5699(94)90153-8. PMID: 7513517.

850: Spitzauer S, Schweiger C, Sperr WR, Pandjaitan B, Valent P, Mühl S, Ebner C, Scheiner O, Kraft D, Rumpold H, et al. Molecular characterization of dog albumin as a cross-reactive allergen. J Allergy Clin Immunol. 1994 Mar;93(3):614-27. doi: 10.1016/s0091-6749(94)70073-7. PMID: 7512102.

851: Virgolini I, Yang Q, Li S, Angelberger P, Neuhold N, Niederle B, Scheithauer W, Valent P. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res. 1994 Feb 1;54(3):690-700. PMID: 7905785.

852: Fritsch G, Stimpfl M, Buchinger P, Printz D, Sliutz G, Wagner T, Agis H, Valent P, Gadner H. Does cord blood contain enough progenitor cells for transplantation? J Hematother. 1994 Winter;3(4):291-8. doi: 10.1089/scd.1.1994.3.291. PMID: 7735824.

853: Vrtala S, Sperr WR, Reimitzer I, van Ree R, Laffer S, Müller WD, Valent P, Lechner K, Rumpold H, Kraft D, et al. cDNA cloning of a major allergen from timothy grass (Phleum pratense) pollen; characterization of the recombinant Phl pV allergen. J Immunol. 1993 Nov 1;151(9):4773-81. PMID: 7691956.

854: Agis H, Willheim M, Sperr WR, Wilfing A, Krömer E, Kabrna E, Spanblöchl E, Strobl H, Geissler K, Spittler A, Boltz-Nitulescu G, Majdic O, Lechner K, Valent P. Monocytes do not make mast cells when cultured in the presence of SCF. Characterization of the circulating mast cell progenitor as a c-kit+, CD34+, Ly-, CD14-, CD17-, colony-forming cell. J Immunol. 1993 Oct 15;151(8):4221-7. PMID: 7691941.

855: Ferreira FD, Hoffmann-Sommergruber K, Breiteneder H, Pettenburger K, Ebner C, Sommergruber W, Steiner R, Bohle B, Sperr WR, Valent P, et al. Purification and characterization of recombinant Bet v I, the major birch pollen allergen. Immunological equivalence to natural Bet v I. J Biol Chem. 1993 Sep 15;268(26):19574-80. PMID: 8366100.

856: Asano Y, Brach MA, Ahlers A, de Vos S, Butterfield JH, Ashman LK, Valent P, Gruss HJ, Herrmann F. Phorbol ester 12-O-tetradecanoylphorbol-13-acetate down- regulates expression of the c-kit proto-oncogene product. J Immunol. 1993 Sep 1;151(5):2345-54. PMID: 7689605.

857: Sillaber C, Bevec D, Butterfield JH, Heppner C, Valenta R, Scheiner O, Kraft D, Lechner K, Bettelheim P, Valent P. Tumor necrosis factor alpha and interleukin-1 beta mRNA expression in HMC-1 cells: differential regulation of gene product expression by recombinant interleukin-4. Exp Hematol. 1993 Aug;21(9):1271-5. PMID: 8330651.

858: Valent P, Sillaber C, Geissler K, Andreeff M, Tafuri A, Vieder L, Schulz G, Lechner K, Bettelheim P. Combination treatment of acute myeloblastic leukemia with rhGM-CSF and standard induction chemotherapy. Cancer Invest. 1993;11(2):229-34. doi: 10.3109/07357909309024844. PMID: 8462024.

859: Sperr WR, Czerwenka K, Mundigler G, Müller MR, Semper H, Klappacher G, Glogar HD, Lechner K, Valent P. Specific activation of human mast cells by the ligand for c-kit: comparison between lung, uterus and heart mast cells. Int Arch Allergy Immunol. 1993;102(2):170-5. doi: 10.1159/000236568. PMID: 7691300.

860: Valenta R, Sperr WR, Ferreira F, Valent P, Sillaber C, Tejkl M, Duchêne M, Ebner C, Lechner K, Kraft D, et al. Induction of specific histamine release from basophils with purified natural and recombinant birch pollen allergens. J Allergy Clin Immunol. 1993 Jan;91(1 Pt 1):88-97. doi: 10.1016/0091-6749(93)90300-5. PMID: 7678614.

861: Valenta R, Steinberger P, Vrtala S, Grote M, Laffer S, Sperr WR, Valent P, Kraft D, Scheiner O. Neue Konzepte zur Therapie von Typ I allergischen Erkrankungen [New concepts in therapy of type I allergic diseases]. Wien Klin Wochenschr. 1993;105(23):682-6. German. PMID: 7508663.

862: Sperr WR, Agis H, Valenta R, Bankl HC, Sillaber C, Scheiner O, Kraft D, Lechner K, Valent P. Die Effektorzellen der Allergie: Biologische Grundlagen und neue pharmakologische Konzepte [Effector cells in allergy: biological principles and new pharmacologic concepts]. Wien Klin Wochenschr. 1993;105(23):677-81. German. PMID: 7508662.

863: Hirschwehr R, Valenta R, Ebner C, Ferreira F, Sperr WR, Valent P, Rohac M, Rumpold H, Scheiner O, Kraft D. Identification of common allergenic structures in hazel pollen and hazelnuts: a possible explanation for sensitivity to hazelnuts in patients allergic to tree pollen. J Allergy Clin Immunol. 1992 Dec;90(6 Pt 1):927-36. doi: 10.1016/0091-6749(92)90465-e. PMID: 1281178.

864: Valent P, Spanblöchl E, Sperr WR, Sillaber C, Zsebo KM, Agis H, Strobl H, Geissler K, Bettelheim P, Lechner K. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood. 1992 Nov 1;80(9):2237-45. PMID: 1384799.

865: Sillaber C, Geissler K, Scherrer R, Kaltenbrunner R, Bettelheim P, Lechner K, Valent P. Type beta transforming growth factors promote interleukin-3 (IL-3)-dependent differentiation of human basophils but inhibit IL-3-dependent differentiation of human eosinophils. Blood. 1992 Aug 1;80(3):634-41. PMID: 1379084.

866: Sperr WR, Agis H, Czerwenka K, Klepetko W, Kubista E, Boltz-Nitulescu G, Lechner K, Valent P. Differential expression of cell surface integrins on human mast cells and human basophils. Ann Hematol. 1992 Jul;65(1):10-6. doi: 10.1007/BF01715119. PMID: 1643154.

867: Virgolini I, Li S, Sillaber C, Majdic O, Sinzinger H, Lechner K, Bettelheim P, Valent P. Characterization of prostaglandin (PG)-binding sites expressed on human basophils. Evidence for a prostaglandin E1, I2, and a D2 receptor. J Biol Chem. 1992 Jun 25;267(18):12700-8. PMID: 1377673.

868: Valent P, Sillaber KC, Scherrer R, Geissler K, Kier P, Kalhs P, Kundi M, Papoian R, Bettelheim P, Hinterberger W, et al. Detection of circulating endogenous interleukin-3 in extensive chronic graft-versus-host disease. Bone Marrow Transplant. 1992 May;9(5):331-6. PMID: 1617317.

869: Geissler K, Valent P, Bettelheim P, Sillaber C, Wagner B, Kyrle P, Hinterberger W, Lechner K, Liehl E, Mayer P. In vivo synergism of recombinant human interleukin-3 and recombinant human interleukin-6 on thrombopoiesis in primates. Blood. 1992 Mar 1;79(5):1155-60. PMID: 1536942.

870: Valenta R, Duchene M, Ebner C, Valent P, Sillaber C, Deviller P, Ferreira F, Tejkl M, Edelmann H, Kraft D, et al. Profilins constitute a novel family of functional plant pan-allergens. J Exp Med. 1992 Feb 1;175(2):377-85. doi: 10.1084/jem.175.2.377. PMID: 1370681; PMCID: PMC2119109.

871: Valenta R, Duchêne M, Vrtala S, Valent P, Sillaber C, Ferreira F, Tejkl M, Hirschwehr R, Ebner C, Kraft D, Scheiner O. Profilin, a Novel Plant Pan- Allergen. Int Arch Allergy Immunol. 1992;99(2-4):271-273. doi: 10.1159/000236263. Epub 2009 Sep 2. PMID: 34167231.

872: Valent P, Bettelheim P. Cell surface structures on human basophils and mast cells: biochemical and functional characterization. Adv Immunol. 1992;52:333-423. doi: 10.1016/s0065-2776(08)60879-2. PMID: 1332448.

873: Valent P, Sillaber C, Geissler K, Andreeff M, Tafuri A, Vieder L, Schulz G, Lechner K, Bettelheim P. Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: effect of granulocyte macrophage-colony- stimulating factor on white blood cell counts. Med Pediatr Oncol Suppl. 1992;2:18-22. doi: 10.1002/mpo.2950200705. PMID: 1306881.

874: Sillaber C, Strobl H, Bevec D, Ashman LK, Butterfield JH, Lechner K, Maurer D, Bettelheim P, Valent P. IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells. J Immunol. 1991 Dec 15;147(12):4224-8. PMID: 1721642.

875: Valenta R, Duchêne M, Pettenburger K, Sillaber C, Valent P, Bettelheim P, Breitenbach M, Rumpold H, Kraft D, Scheiner O. Identification of profilin as a novel pollen allergen; IgE autoreactivity in sensitized individuals. Science. 1991 Aug 2;253(5019):557-60. doi: 10.1126/science.1857985. PMID: 1857985.

876: Mayer P, Geissler K, Valent P, Ceska M, Bettelheim P, Liehl E. Recombinant human interleukin 6 is a potent inducer of the acute phase response and elevates the blood platelets in nonhuman primates. Exp Hematol. 1991 Aug;19(7):688-96. PMID: 1909969.

877: Kapiotis S, Besemer J, Bevec D, Valent P, Bettelheim P, Lechner K, Speiser W. Interleukin-4 counteracts pyrogen-induced downregulation of thrombomodulin in cultured human vascular endothelial cells. Blood. 1991 Jul 15;78(2):410-5. PMID: 1648981.

878: Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L, et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst. 1991 May 15;83(10):708-12. doi: 10.1093/jnci/83.10.708. PMID: 2023272.

879: Valent P, Bevec D, Maurer D, Besemer J, Di Padova F, Butterfield JH, Speiser W, Majdic O, Lechner K, Bettelheim P. Interleukin 4 promotes expression of mast cell ICAM-1 antigen. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3339-42. doi: 10.1073/pnas.88.8.3339. PMID: 1673030; PMCID: PMC51442.

880: Volc-Platzer B, Valent P, Radaszkiewicz T, Mayer P, Bettelheim P, Wolff K. Recombinant human interleukin 3 induces proliferation of inflammatory cells and keratinocytes in vivo. Lab Invest. 1991 Apr;64(4):557-66. PMID: 1850054.

881: Bettelheim P, Valent P, Andreeff M, Tafuri A, Haimi J, Gorischek C, Muhm M, Sillaber C, Haas O, Vieder L, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood. 1991 Feb 15;77(4):700-11. PMID: 1993213.

882: Valent P, Sillaber C, Bettelheim P. The growth and differentiation of mast cells. Prog Growth Factor Res. 1991;3(1):27-41. doi: 10.1016/0955-2235(91)90011-r. PMID: 1777598.

883: Fischer GF, Faé I, Valent P, Pickl WF. Der Einsatz hochpolymorpher Systeme der DNA zum Nachweis des gemischten Chimärismus nach Knochenmarkstransplantation [The use of highly polymorphic DNA systems in the demonstration of mixed chimerism following bone marrow transplantation]. Wien Klin Wochenschr. 1991;103(5):152-4. German. PMID: 1674392.

884: Valent P, Geissler K, Sillaber C, Lechner K, Bettelheim P. Why clinicians should be interested in interleukin-3. Blut. 1990 Dec;61(6):338-45. doi: 10.1007/BF01738546. PMID: 2291980.

885: Valent P, Besemer J, Sillaber C, Butterfield JH, Eher R, Majdic O, Kishi K, Klepetko W, Eckersberger F, Lechner K, et al. Failure to detect IL-3-binding sites on human mast cells. J Immunol. 1990 Nov 15;145(10):3432-7. PMID: 2230127.

886: Valent P, Besemer J, Kishi K, Di Padova F, Geissler K, Lechner K, Bettelheim P. Human basophils express interleukin-4 receptors. Blood. 1990 Nov 1;76(9):1734-8. PMID: 1699621.

887: Valent P, Besemer J, Kishi K, Kaltenbrunner R, Kuhn B, Maurer D, Lechner K, Bettelheim P. IL-3 promotes basophilic differentiation of KU812 cells through high affinity binding sites. J Immunol. 1990 Sep 15;145(6):1885-9. PMID: 2144011.

888: Bettelheim P, Muhm M, Valent P, Geissler K, Andreeff M, Haimi J, Sillaber C, Hinterberger W, Vieder L, Schulz G, et al. GM-CSF in combination with cytotoxic chemotherapy in AML patients. Bone Marrow Transplant. 1990 Jul;6 Suppl 1:127-30. PMID: 2202464.

889: Geissler K, Valent P, Mayer P, Liehl E, Hinterberger W, Lechner K, Bettelheim P. Recombinant human interleukin-3 expands the pool of circulating hematopoietic progenitor cells in primates--synergism with recombinant human granulocyte/macrophage colony-stimulating factor. Blood. 1990 Jun 15;75(12):2305-10. PMID: 2190639.

890: Stockinger H, Valent P, Majdic O, Bettelheim P, Knapp W. Human blood basophils synthesize interleukin-2 binding sites. Blood. 1990 May 1;75(9):1820-6. PMID: 1691935.

891: Schwarzinger I, Valent P, Köller U, Marosi C, Schneider B, Haas O, Knapp W, Lechner K, Bettelheim P. Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. J Clin Oncol. 1990 Mar;8(3):423-30. doi: 10.1200/JCO.1990.8.3.423. PMID: 2307987.

892: Valent P, Bettelheim P. The human basophil. Crit Rev Oncol Hematol. 1990;10(4):327-52. doi: 10.1016/1040-8428(90)90009-h. PMID: 2278641.

893: Valent P, Majdic O, Maurer D, Bodger M, Muhm M, Bettelheim P. Further characterization of surface membrane structures expressed on human basophils and mast cells. Int Arch Allergy Appl Immunol. 1990;91(2):198-203. doi: 10.1159/000235115. PMID: 1971264.

894: Bettelheim P, Valent P. Radioimmunometrische Histaminbestimmung bei myeloproliferativen Syndromen [Radioimmunometric determination of histamine in myeloproliferative syndromes]. Wien Klin Wochenschr. 1989 Oct 27;101(20):706-10. German. PMID: 2480027.

895: Valent P, Geissler K, Bettelheim P. Interleukin-3: Eine präklinische Studie [Interleukin-3: a preclinical study]. Wien Klin Wochenschr. 1989 Oct 13;101(19):652-63. German. PMID: 2482586.

896: Mayer P, Valent P, Schmidt G, Liehl E, Bettelheim P. The in vivo effects of recombinant human interleukin-3: demonstration of basophil differentiation factor, histamine-producing activity, and priming of GM-CSF-responsive progenitors in nonhuman primates. Blood. 1989 Aug 1;74(2):613-21. PMID: 2665851.

897: Valent P, Besemer J, Muhm M, Majdic O, Lechner K, Bettelheim P. Interleukin 3 activates human blood basophils via high-affinity binding sites. Proc Natl Acad Sci U S A. 1989 Jul;86(14):5542-6. doi: 10.1073/pnas.86.14.5542. PMID: 2473472; PMCID: PMC297659.

898: Valent P, Ashman LK, Hinterberger W, Eckersberger F, Majdic O, Lechner K, Bettelheim P. Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood. 1989 May 15;73(7):1778-85. PMID: 2469499.

899: Valent P, Schmidt G, Besemer J, Mayer P, Zenke G, Liehl E, Hinterberger W, Lechner K, Maurer D, Bettelheim P. Interleukin-3 is a differentiation factor for human basophils. Blood. 1989 May 15;73(7):1763-9. PMID: 2469498.

900: Valent P, Bartram CR, Radaszkiewicz T, Hinterberger W, Lechner K, Bettelheim P. T cell receptor alpha mRNA transcription in T-lymphoblastic transformation of chronic myelocytic leukemia. Leukemia. 1988 Mar;2(3):144-7. PMID: 3258050.